

- Anselmi M (see Agostoni et al). 2006;151:682-9
- Antman EM (see Januzzi Jr et al). 2006;151:360-6
- Antman EM (see Sabatine et al). 2006;151:25-31
- Anwaruddin S (see Baggish et al). 2006;151:48-54
- Apak I (see Iltumur et al). 2006;151:1115-22
- Apperson-Hansen C (see Klein et al). 2006;151:380-9
- APPROACH investigators (see Hubacek et al). 2006;151:308-15
- Aranda JM Jr (see Cooper-DeHoff et al). 2006;151:1072-9
- Arbogast PG (see Butler et al). 2006;151:643-53
- Arcement LM (see Hebert et al). 2006;151:478-83
- Arena R, Guazzi M, Myers J, Peberdy MA. Prognostic value of heart rate recovery in patients with heart failure. 2006;151:851.e7-851.e13
- Ariturk Z (see Iltumur et al). 2006;151:1115-22
- Armstrong PW, Mahaffey KW, Chang W-C, Weaver WD, Hochman JS, Theroux P, Rollins S, Todaro TG, Granger CB, COMMA Investigators. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. 2006;151:787-90
- Armstrong PW (see Al-Faleh et al). 2006;151:10-5
- Armstrong PW (see Fitchett et al). 2006;151:373-9
- Armstrong PW (see Galla et al). 2006;151:16-24
- Armstrong PW (see Kim et al). 2006;151:668-73
- Aronow WS (see Ahmed et al). 2006;151:444-50
- Aronson D (see Goldberg et al). 2006;151:1265-70
- Arruda ALM, Barretto RBM, Shub C, Chandrasekaran K, Pellikka PA. Prognostic significance of ST-segment elevation during dobutamine stress echocardiography. 2006;151:744.e1-744.e6
- Arsenault A (see D'Antonio et al). 2006;151:813-19
- Arsenic R (see Jeger et al). 2006;151:508-13
- Arthur HM (see Cortés and Arthur). 2006;151:249-56 (Curriculum cardiol.)
- Asawa K (see Hasegawa et al). 2006;151:332-7
- Asirvatham S (see Fountain et al). 2006;151:956-61 (Trial design)
- Aspelin P, Lundkvist J. Reply to Dr Fricke. 2006;151:(1)e3 (Letter reply)
- Aspelin P, Lundkvist J. Reply to Dr Hoher. 2006;151:(1)e7 (Letter reply)
- ASSENT 2 and 3 Investigators (see Al-Faleh et al). 2006;151:10-5
- Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. 2006;151:492-500
- Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis in Myocardial Infarction 16 (OPUS-TIMI 16) trial. 2006;151:976.e1-976.e6
- Aung M (see Yoshinaga et al). 2006;151:1324.e11-1324.e18
- Austin PC, Mamdani MM, Juurlink DN, Alter DA, Tu JV. Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality. 2006;151:969-75
- Avezum A (see Froehlich et al). 2006;151:1123-8
- Ayanian JZ (see Sequist et al). 2006;151:909-14
- Aybek T (see Doss et al). 2006;151:943.e1-943.e4
- Aylward PE (see Kauf et al). 2006;151:206-12
- Azadpour M (see Zagler et al). 2006;151:140-5
- Azar RR, Kassab R, Zoghbi A, Aboujaoudé S, El-Osta H, Ghorra P, Germanos M, Salame E. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. 2006;151:521.e1-521.e4
- Azzarello G (see Briguori et al). 2006;151:674-80

B

- B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. 2006;151:282-7 (Trial design)
- Baeza R (see Goyal et al). 2006;151:1156-72 (Meetings)
- Baggish AL, Siebert U, Lainchbury JG, Cameron R, Anwaruddin S, Chen A, Krauser DG, Tung R, Brown DF, Richards AM, Januzzi JL. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. 2006;151:48-54
- Bahit MC (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
- Bailleul C (see Boriani et al). 2006;151:1050-8
- Baillet R (see van Gilst et al). 2006;151:1240-6
- Bakris GL (see White et al). 2006;151:176-84
- Baldi JC (see Hammett et al). 2006;151:367.e7-367.e16
- Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II. 2006;151:975.e1-975.e9
- Balzi D, Barchielli A, Buiatti E, Franceschini C, Lavecchia R, Monami M, Santoro GM, Carrabba N, Margheri M, Olivetto I, Gensini GF, Marchionni N, AMI Florence Working Group. Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. 2006;151:1094-100
- Barasch E, Gottdiener JS, Larsen EKM, Chaves PHM, Newman AB, Manolio TA. Clinical significance of calcification of the fibrous skeleton of the heart and atherosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS). 2006;151:39-47
- Barazer I (see Berdagué et al). 2006;151:690-8
- Barbagelata A (see Perna et al). 2006;151:84-91
- Barbeau G (see Goodhart et al). 2006;151:529.e1-529.e6
- Barchielli A (see Balzi et al). 2006;151:1094-100
- Barnett P (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Barretto RBM (see Arruda et al). 2006;151:744.e1-744.e6
- Barrington W (see Hreybe et al). 2006;151:852-6
- Basorth D (see Kraleov et al). 2006;151:153-7
- Bassand J-P (see Schiele et al). 2006;151:661-7
- Bassanelli G (see Fragasso et al). 2006;151:1238.e1-1238.e8
- Baumgart D (see Eggebrecht et al). 2006;151:530-6
- Bax JJ (see Bountiokous et al). 2006;151:1323.e7-1323.e12
- Bax JJ (see Schuijff et al). 2006;151:404-11
- Bayol PA (see Perna et al). 2006;151:84-91
- Bazaz R (see Hreybe et al). 2006;151:852-6
- Beanlands RSB (see Yoshinaga et al). 2006;151:1324.e11-1324.e18
- Bechettille P (see Schiele et al). 2006;151:661-7
- Beck JD (see Elter et al). 2006;151:47.e1-47.e6
- Beck SR (see Burdon et al). 2006;151:706-11
- Becker E (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Becker RC (see Greenbaum et al). 2006;151:689.e1-689.e10
- Becker RC (see Patel et al). 2006;151:316-22
- Becker T (see Boriani et al). 2006;151:1050-8
- Bedi M (see Hreybe et al). 2006;151:852-6
- Bekercedjian R (see Korosoglou et al). 2006;151:131-8
- Beldekos DJ (see Zairis et al). 2006;151:892-7
- Bella JN (see Kizer et al). 2006;151:412-18
- Beller E (see Isbel et al). 2006;151:745-53
- Benamar A (see Remadi et al). 2006;151:198.e1-198.e7
- Bennett PH (see Jimenez-Corona et al). 2006;151:1080-6
- Bensimhon D (see Pruitt et al). 2006;151:628-32 (Meetings)

- Bensimhon DR, Kraus WE, Donahue MP. Obesity and physical activity: a review. 2006;151:598-603 (Meetings)
- Benson H, Dusek JA, Sherwood JB, Lam P, Bethea CF, Carpenter W, Levitsky S, Hill PC, Clem DW Jr, Jain MK, Drumel D, Kopeccky SL, Mueller PS, Marek D, Rollins S, Hibberd PL. Study of the Therapeutic Effects of Intercessory Prayer (STEP) in cardiac bypass patients: a multicenter randomized trial of uncertainty and certainty of receiving intercessory prayer. 2006;151:934-42
- Berdagué P, Caffin P-Y, Barazer I, Vergnes C, Sedighian S, Letrillard S, Pilosoff R, Goutorbe F, Piot C, Reny J-L. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. 2006;151:690-8
- Berger JS, Sanborn TA, Sherman W, Brown DL. Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention. 2006;151:1026-31
- Berger P (see Brodie et al). 2006;151:1231-8
- Bergstra A, Svilaas T, van den Heuvel AFM, van der Horst ICC, Zijlstra F. Glucose-insulin-potassium infusion in acute myocardial infarction: a hemodynamic study. 2006;151:345-51
- Berman DS (see Boden et al). 2006;151:1173-9 (Trial design)
- Berman DS (see Hecht et al). 2006;151:1139-46 (Curriculum cardi.)
- Berman DS (see Shellock et al). 2006;151:436-43
- Bernheim A (see Brunner-La Rocca et al). 2006;151:949-55 (Trial design)
- Berry C, Norrie J, Hogg K, Brett M, Stevenson K, McMurray JJV. The prevalence, nature, and importance of hematologic abnormalities in heart failure. 2006;151:1313-21
- Bertolami M (see Ballantyne et al). 2006;151:975.e1-975.e9
- Best LG (see Kizer et al). 2006;151:412-18
- Bethea CF (see Benson et al). 2006;151:934-42
- Bethencourt A (see Alfonso et al). 2006;151:681.e1-681.e9
- Betriu A (see Chacko et al). 2006;151:1032.e1-1032.e7
- Beyar R (see Goldberg et al). 2006;151:1265-70
- Bhalla MA (see Brenden et al). 2006;151:1006-11
- Bhalla V (see Brenden et al). 2006;151:1006-11
- Bhalla V (see Daniels et al). 2006;151:999-1005
- Bhalla V (see Fitzgerald et al). 2006;151:4e3 (Letter reply)
- Bhatt DL (see Chen et al). 2006;151:1260-4
- Bhatt DL (see Karha et al). 2006;151:976.e7-976.e11
- Bhatt DL (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
- Bhatt DL (see Serebruany et al). 2006;151:92-9
- Biffi M (see Boriani et al). 2006;151:1050-8
- Binder L (see Michalsen et al). 2006;151:870-7
- Biondi-Zoccai GGL (see Agostoni et al). 2006;151:682-9
- Birnbaum Y (see Atar et al). 2006;151:976.e1-976.e6
- Bittl JA (see Chacko et al). 2006;151:1032.e1-1032.e7
- Bittl JA (see Greenbaum et al). 2006;151:689.e1-689.e10
- Black IW (see Klein et al). 2006;151:380-9
- Blackburn G (see DeWald et al). 2006;151:604-24 (Meetings)
- Blackhouse G (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C, Mackie K, Chan C, Dzavik V. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. 2006;151:146-52
- Blackshear J (see Davidson et al). 2006;151:451-6
- Blair J (see Holper et al). 2006;151:69-75
- Blanchard BE (see Guidry et al). 2006;151:1322.e5-1322.e12
- Blaney M (see Bradley et al). 2006;151:1281-7
- Block P (see van Gilst et al). 2006;151:1240-6
- Bluemke DA (see Edvardsen et al). 2006;151:109-14
- Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GJB, Berman DS, Weintraub WS, COURAGE trial coprincipal investigators and study coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424. 2006;151:1173-9 (Trial design)
- Boden WE (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Boersma E (see Hernández et al). 2006;151:257-64 (Curriculum cardi.)
- Bollwein H (see Schühlen et al). 2006;151:1248-54
- Bonvicini M (see Giardini et al). 2006;151:922.e1-922.e5
- Borggreve M (see Kralek et al). 2006;151:153-7
- Boriani G, Müller CP, Seidl KH, Grove R, Vogt J, Danchel W, Schuchert A, Djiane P, Biffi M, Becker T, Baillet C, Trapp HJ, Resynchronization for the Hemodynamic Treatment for Heart Failure Management II (RHYTHM II) investigators. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy: the Resynchronization for the Hemodynamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study. 2006;151:1050-8
- Borm GF (see Elsmann et al). 2006;151:1239.e9-1239.12
- Borrelli G (see Macchia et al). 2006;151:754.e7-754.e17
- Bossone E (see Butera et al). 2006;151:228-34
- Botkin NF, Spencer FA, Goldberg RJ, Lessard D, Yarzebski J, Gore JM. Changing trends in the long-term prognosis of patients with acute myocardial infarction: a population-based perspective. 2006;151:199-205
- Bottcher M (see Kaltoft et al). 2006;151:1108-14
- Bountiokous M, Schinkel AFL, Bax JJ, Lampropoulos S, Poldermans D. The impact of hypertension on systolic and diastolic left ventricular function. A tissue Doppler echocardiographic study. 2006;151:1323.e7-1323.e12
- Bourassa MG (see Nigam et al). 2006;151:514-21
- Bowden DW (see Burdon et al). 2006;151:706-11
- Bowles KR (see Johnson et al). 2006;151:1012.e7-1012.e14
- Bowlin SJ, Stump TE, Sprecher DL, Tierney WM (see Koro et al). 2006;151:755.e1-755.e6
- Bowlin SJ (see Koro et al). 2006;151:755.e1-755.e6
- Bozbeyoglu E (see Uyarel et al). 2006;151:1239.e1-1239.e7
- Bozovich GE (see Goodman et al). 2006;151:791-7
- Bradley EH, Herrin J, Wang Y, McNamara RL, Radford MJ, Magid DJ, Canto JG, Blaney M, Krumholz HM. Door-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI). 2006;151:1281-7
- Bradshaw PJ, Jamrozik KD, Gilfillan IS, Thompson PL. Asymptomatic long-term survivors of coronary artery bypass surgery enjoy a quality of life equal to the general population. 2006;151:537-44
- Bragato R (see Mangiavacchi et al). 2006;151:477.e1-477.e6
- Braunwald E (see Januzzi Jr et al). 2006;151:360-6
- Braunwald E (see Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)
- Braunwald E (see Roe et al). 2006;151:1205-13
- Bregni M (see Briguori et al). 2006;151:674-80
- Breitbart Y (see Gurm et al). 2006;151:1031.e1-1031.e6
- Brenden CK, Hollander JE, Guss D, McCullough PA, Nowak R, Green G, Saltzberg M, Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R, Maisel AS, REDHOT Investigators. Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. 2006;151:1006-11

- Brener SJ. Insights into the pathophysiology of ST-elevation myocardial infarction. 2006;151:S4-10
- Brett M (see Berry et al). 2006;151:1313-21
- Briguori C, Reimers B, Sarais C, Napodano M, Pascotto P, Azzarello G, Bregni M, Porcellini A, Vinante O, Zanco P, Peschle C, Condorelli G, Colombo A. Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. 2006;151:674-80
- Brindis RG (see Roe et al). 2006;151:1205-13
- Brodala N (see Elter et al). 2006;151:47.e1-47.e6
- Brodie B (see Halkin et al). 2006;151:915.e1-915.e7
- Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, Berger P, Mehran R, McLaughlin M, Costantini C, Lansky AJ, Grines CL. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. 2006;151:1231-8
- Brouwer JA, Heeringa J, Geleijnse JM, Zock PL, Witteman JCM. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. 2006;151:857-62
- Brown DF (see Baggish et al). 2006;151:48-54
- Brown DL (see Berger et al). 2006;151:1026-31
- Brozovich F (see Johnson et al). 2006;151:1012.e7-1012.e14
- Brun S (see Chevalier et al). 2006;151:191.e1-191.e6
- Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M, TIME-CHF-Investigators. Management of elderly patients with congestive heart failure—design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). 2006;151:949-55 (Trial design)
- Brunner-La Rocca HP (see Mueller et al). 2006;151:845-50
- Budaj A (see Froehlich et al). 2006;151:1123-8
- Budaj A (see Goodman et al). 2006;151:654-60
- Budde T (see Michalsen et al). 2006;151:870-7
- Budoff MJ (see Hecht et al). 2006;151:1139-46 (Curriculum cardiol.)
- Buettner HJ (see Mueller et al). 2006;151:1214.e1-1214.e7
- Buiatti E (see Balzi et al). 2006;151:1094-100
- Buller CE (see Goodhart et al). 2006;151:529.e1-529.e6
- Burbank-Schmidt E (see Goldberg et al). 2006;151:501-7
- Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Variants of the *CD40* gene but not of the *CD40L* gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS). 2006;151:706-11
- Burelle D (see D'Antonio et al). 2006;151:813-19
- Burnett JC Jr (see Ammar et al). 2006;151:799-805
- Burri H (see Chevalier et al). 2006;151:191.e1-191.e6
- Burton JR (see Kim et al). 2006;151:668-73
- Buser PT (see Brunner-La Rocca et al). 2006;151:949-55 (Trial design)
- Butera G, Carminati M, Chessa M, Youssef R, Drago M, Giamberti A, Pomè G, Bossone E, Frigiola A. Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications. 2006;151:228-34
- Butler J, Speroff T, Arbogast PG, Newton M, Waitman LR, Stiles R, Müller RA, Ray W, Griffin MR. Improved compliance with quality measures at hospital discharge with a computerized physician order entry system. 2006;151:643-53
- Butler MK (see Hebert et al). 2006;151:478-83
- Butter C, Wellnhofer E, Seifert M, Schlegl M, Hoersch W, Goehring A, Fleck E. Time course of left ventricular volumes in severe congestive heart failure patients treated by optimized AV

- sequential left ventricular pacing alone—a 3-dimensional echocardiographic study. 2006;151:115-23
- Buturak A (see Uyarel et al). 2006;151:1239.e1-1239.e7

C

- CADILLAC Investigators (see Kandzari et al). 2006;151:1288-95
- Caffin P-Y (see Berdagué et al). 2006;151:690-8
- Cain VA (see Ballantyne et al). 2006;151:975.e1-975.e9
- Calciu C-D (see van Gilst et al). 2006;151:1240-6
- Califf RM (see Allen LaPointe et al). 2006;151:992-8
- Califf RM (see Galla et al). 2006;151:16-24
- Califf RM (see Kauf et al). 2006;151:206-12
- Califf RM (see O'Shea and Califf). 2006;151:962-8 (Meetings)
- Califf RM (see Patel et al). 2006;151:316-22, 633-42 (Meetings)
- Califf RM (see Roe et al). 2006;151:1205-13
- Calori G (see Fragasso et al). 2006;151:1238.e1-1238.e8
- Calviño R (see Peteiro et al). 2006;151:1324.e1-1324.e10
- Cam N (see Uyarel et al). 2006;151:1239.e1-1239.e7
- Camargo CA Jr (see Allen et al). 2006;151:1065-71
- Cambier PA (see Halkin et al). 2006;151:915.e1-915.e7
- Cameron R (see Baggish et al). 2006;151:48-54
- Cammarota G (see Pasceri et al). 2006;151:1215-22
- Campbell P (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
- Canadian Acute Coronary Syndromes (ACS) Registry Investigators (see Yan et al). 2006;151:352-9
- Cangiano JL (see Cooper-DeHoff et al). 2006;151:1072-9
- Cannon CP (see Atar et al). 2006;151:976.e1-976.e6
- Cannon CP (see Januzzi Jr et al). 2006;151:360-6
- Cannon CP (see Sabatine et al). 2006;151:25-31
- Cannon CP (see Smith et al). 2006;151:338-44
- Canto JG (see Bradley et al). 2006;151:1281-7
- Cantor WJ, Hall R, Tu JV. Do operator volumes relate to clinical outcomes after percutaneous coronary intervention in the Canadian health care system? 2006;151:902-8
- CAPTORS II Investigators (see Kim et al). 2006;151:668-73
- Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA, Mehran R, Stone GW (see Halkin et al). 2006;151:915.e1-915.e7
- Cardiovascular Outcomes Research Consortium (see Spertus et al). 2006;151:589-97 (Trial design)
- Carere RG (see Goodhart et al). 2006;151:529.e1-529.e6
- Carminati M (see Butera et al). 2006;151:228-34
- Caro J (see Mahoney et al). 2006;151:219-27
- Carpenter W (see Benson et al). 2006;151:934-42
- Carr JJ (see Burdon et al). 2006;151:706-11
- Carrabba N (see Balzi et al). 2006;151:1094-100
- Carroll S (see Healey et al). 2006;151:(6)e3 (Letter reply)
- Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group (see Krum et al). 2006;151:55-61
- Casabé JH (see Ferreiros et al). 2006;151:545-52
- Casey E (see Hughes et al). 2006;151:1122.e1-1122.e6
- Casolo G, Minneci S, Manta R, Sulla A, Del Meglio J, Rega L, Gensini G. Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement. 2006;151:101-8
- Casperson P (see Boden et al). 2006;151:1173-9 (Trial design)
- Casperson P (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Castro-Beiras A (see Peteiro et al). 2006;151:1324.e1-1324.e10
- Caughey M (see Elter et al). 2006;151:47.e1-47.e6
- Caulfield F (see Schiele et al). 2006;151:661-7
- Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality,

- cardiac mortality, and myocardial infarction. 2006;151:1101.e1-1101.e8
- Celestre M (see Rigo et al). 2006;151:124-30
- Cequier A (see Alfonso et al). 2006;151:681.e1-681.e9
- Cerise FP (see Hebert et al). 2006;151:478-83
- Cetin M (see Uyarel et al). 2006;151:1239.e1-1239.e7
- Cha JYM (see Yan et al). 2006;151:352-9
- Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. 2006;151:1032.e1-1032.e7
- Chaitman BR (see Boden et al). 2006;151:1173-9 (Trial design)
- Chan C (see Blackman et al). 2006;151:146-52
- Chan WL (see Ong et al). 2006;151:1323.e1-1323.e6
- Chandrasekaran K (see Arruda et al). 2006;151:744.e1-744.e6
- Chandrasekaran K (see Fountain et al). 2006;151:956-61 (Trial design)
- Chang W-C (see Armstrong et al). 2006;151:787-90
- Charbonneau L (see Raitt et al). 2006;151:390-6
- Chareonthaitawee P (see Sorajja et al). 2006;151:426-35
- CHARM Investigators (see McMurray et al). 2006;151:985-91
- Chaves PHM (see Barasch et al). 2006;151:39-47
- Chebotaev O (see Johnson et al). 2006;151:1012.e7-1012.e14
- Chen A (see Allen LaPointe et al). 2006;151:992-8
- Chen A (see Baggish et al). 2006;151:48-54
- Chen AY (see Roe et al). 2006;151:1205-13
- Chen J (see Lee et al). 2006;151:76-83
- Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. 2006;151:1260-4
- Chen R (see Mahoney et al). 2006;151:219-27
- Chen S (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Cheng TO. Is nesiritide really that good or that bad? 2006;151:(4)e1 (Letter)
- Chessa M (see Butera et al). 2006;151:228-34
- Chevalier P, Cottraux J, Mollard E, NanYao S, Brun S, Burri H, Restier L, Adeleine P. Prevention of implantable defibrillator shocks by cognitive behavioral therapy: a pilot trial. 2006;151:191.e1-191.e6
- Chew DP (see Chacko et al). 2006;151:1032.e1-1032.e7
- Chew DP (see Chen et al). 2006;151:1260-4
- Chin SP (see Ong et al). 2006;151:1323.e1-1323.e6
- Cho L (see Chacko et al). 2006;151:1032.e1-1032.e7
- Chocron S (see van Gilst et al). 2006;151:1240-6
- Chong A (see Alter et al). 2006;151:323-31
- Chopra V (see Cavusoglu et al). 2006;151:1101.e1-1101.e8
- Chou ET (see Minutello et al). 2006;151:164-7
- Chow C-M (see Yan et al). 2006;151:352-9
- Christ A (see Mueller et al). 2006;151:845-50
- Christenson RH (see Roe et al). 2006;151:1205-13
- Christian TF (see Ling et al). 2006;151:882-9
- Chu A (see Davidson et al). 2006;151:451-6
- Ciaglio L (see Pinto et al). 2006;151:S27-9
- Cimbaro Canella JP (see Perna et al). 2006;151:84-91
- Clark LT (see Cavusoglu et al). 2006;151:1101.e1-1101.e8
- Clegg J (see Greenbaum et al). 2006;151:689.e1-689.e10
- Clem DW Jr (see Benson et al). 2006;151:934-42
- Clinical Outcomes Assessment Program (COAP) (see Goss et al). 2006;151:1033-42
- Clopton P (see Brenden et al). 2006;151:1006-11
- Clopton P (see Daniels et al). 2006;151:999-1005
- Coady P (see Holper et al). 2006;151:69-75
- Coats JA (see Krum et al). 2006;151:55-61
- Cohen DJ (see Chacko et al). 2006;151:1032.e1-1032.e7
- Cohen DJ (see Lee et al). 2006;151:76-83
- Cohen M (see Goodman et al). 2006;151:791-7
- Cohn LH (see Gogbashian et al). 2006;151:1325-33
- Colivicchi F (see Mocini et al). 2006;151:192-7
- Colombo A (see Agostoni et al). 2006;151:682-9
- Colombo A (see Briguori et al). 2006;151:674-80
- COMMA Investigators (see Armstrong et al). 2006;151:787-90
- Condorelli G (see Briguori et al). 2006;151:674-80
- Connolly S (see Pritchett et al). 2006;151:1043-9
- Connolly SJ (see Healey et al). 2006;151:(6)e3 (Letter reply)
- Conti CR (see Cooper-DeHoff et al). 2006;151:1072-9
- Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ, INVEST Investigators. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST). 2006;151:1072-9
- Coresh J (see Astor et al). 2006;151:492-500
- Cortes C (see Ferreiros et al). 2006;151:545-52
- Cortés O, Arthur HM. Determinants of referral to cardiac rehabilitation programs in patients with coronary artery disease: a systematic review. 2006;151:249-56 (Curriculum cardiol.)
- Corti R (see Sudano et al). 2006;151:1147-55 (Curriculum cardiol.)
- Cortigiani L (see Rigo et al). 2006;151:124-30
- Costantini C (see Brodie et al). 2006;151:1231-8
- Costantini CO (see Kandzari et al). 2006;151:1288-95
- Cotter G (see Felker and Cotter). 2006;151:765-7 (Editorial)
- Cottraux J (see Chevalier et al). 2006;151:191.e1-191.e6
- COURAGE trial coprincipal investigators and study coordinators (see Boden et al). 2006;151:1173-9 (Trial design)
- Cox DA (see Brodie et al). 2006;151:1231-8
- Cox DA (see Halkin et al). 2006;151:915.e1-915.e7
- Cox DA (see Kandzari et al). 2006;151:1288-95
- Cox DA (see Nikolsky et al). 2006;151:168-75
- Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ. Acetylcysteine in Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. 2006;151:1032.e9-1032.e12
- Crater SW (see Krucoff et al). 2006;151:762-4 (Editorial)
- Crosslin DR (see Kauf et al). 2006;151:206-12
- Crystal E (see Healey et al). 2006;151:(6)e3 (Letter reply)
- Cui J (see Goldberg et al). 2006;151:1297-304
- Culler S (see Mahoney et al). 2006;151:219-27
- Culler S (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Culverhouse R (see Gage et al). 2006;151:713-19
- CURE Study Investigators (see Mahoney et al). 2006;151:219-27
- Cutaia V (see Rigo et al). 2006;151:124-30
- Czerny F (see Alter et al). 2006;151:829-36

D

- Dada M (see Boden et al). 2006;151:1173-9 (Trial design)
- Daimon M (see Kawata et al). 2006;151:798.e9-798.e15
- D'Aiuto F, Parkar M, Nibali L, Suvan J, Lessem J, Tonetti MS. Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized controlled clinical trial. 2006;151:977-84
- Dambrink J-H (see De Luca et al). 2006;151:1296.e1-1296.e6
- Dambrink J-H (see De Luca et al). 2006;151:1256-9
- Dambrink J-H (see Elsmann et al). 2006;151:1239.e9-1239.12
- Dambrink J-H (see van't Hof et al). 2006;151:1255.e1-1255.e5

- Dambrink JH (see Smit et al). 2006;151:1102-7
- Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storow AB, Abraham WT, Wu AHB, Steg PG, Westheim A, Knudson CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Maisel AS. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study. 2006;151:999-1005
- Danik HJS (see Magnani et al). 2006;151:463-70
- Danschel W (see Boriani et al). 2006;151:1050-8
- D'Antonio B, Dupuis G, Fortin C, Arseneault A, Burelle D. Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defects. 2006;151:813-19
- Das SR, Vaeth PAC, Stanek HG, de Lemos JA, Dobbins RL, McGuire DK. Increased cardiovascular risk associated with diabetes in Dallas County. 2006;151:1087-93
- DaSilva KGC Jr (see Korosoglou et al). 2006;151:131-8
- Daubert J-C (see Linde et al). 2006;151:288-94 (Trial design)
- Davidai G (see White et al). 2006;151:176-84
- Davidoff R (see Klein et al). 2006;151:380-9
- Davidson RM, McNeer JF, Logan L, Higginbotham MB, Anderson J, Blackshear J, Chu A, Hettelman B, McGrew F, Meece R, O'Connor C, Schneider R, Wagner GS, EXERDUCCS Investigators. A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. 2006;151:451-6
- Davies A (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
- Davies RF (see Yoshinaga et al). 2006;151:1324.e11-1324.e18
- de Belder MA (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
- de Boer MJ (see De Luca et al). 2006;151:1256-9, 1296.e1-1296.e6
- de Boer MJ (see Elmsan et al). 2006;151:1239.e9-1239.12
- de Boer MJ (see van't Hof et al). 2006;151:1255.e1-1255.e5
- de Boer MJ (see Smit et al). 2006;151:1102-7
- De Chiara F (see Mangiavacchi et al). 2006;151:477.e1-477.e6
- de Feyter PJ (see Rodriguez-Granillo et al). 2006;151:1020-4, 1025.e1-1025.e6
- de Groot E (see Vriend et al). 2006;151:242-7
- de Lemos JA (see Das et al). 2006;151:1087-93
- De Luca G, Ernst N, van't Hof AWJ, Ottervanger JP, Hoorntje JCA, Gosselink ATM, Dambrink J-H, de Boer MJ, Suryapranata H. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. 2006;151:1256-9
- De Luca G, Suryapranata H, van't Hof AWJ, Ottervanger JP, Hoorntje JCA, Dambrink J-H, Gosselink ATM, de Boer MJ. Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. 2006;151:1296.e1-1296.e6
- de Miguel R (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
- de Roos A (see Oosterhof et al). 2006;151:265-72 (Curriculum cardi.)
- de Roos A (see Schuijff et al). 2006;151:404-11
- de Waal TT (see Vriend et al). 2006;151:242-7
- Deaton C (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Dec GW Jr (see Magnani et al). 2006;151:463-70
- Decker C (see Spertus et al). 2006;151:589-97 (Trial design)
- DeFilippis AP, Sperling LS. Understanding omega-3's. 2006;151:564-70 (Curriculum cardi.)
- Deidda M (see Mercurio et al). 2006;151:923-7
- deKemp RA (see Yoshinaga et al). 2006;151:1324.e11-1324.e18
- Del Meglio J (see Casolo et al). 2006;151:101-8
- Dellborg M (see Svensson et al). 2006;151:798.e1-798.e7
- DeLong ER (see Allen LaPointe et al). 2006;151:992-8
- Denton M (see Tonkin et al). 2006;151:1305-12
- Detling N, Smith A, Nishimura R, Keller S, Martinez M, Young W, Holmes D. Psychophysiologic responses of invasive cardiologists in an academic catheterization laboratory. 2006;151:522-8
- Detre KM (see Holper et al). 2006;151:69-75
- Devereux RB (see Kizer et al). 2006;151:412-18
- DeWald T, Khadhiar L, Donahue MP, Blackburn G. Pharmacological and surgical treatments for obesity. 2006;151:604-24 (Meetings)
- Di Sciascio G (see Pasceri et al). 2006;151:1215-22
- Diaz R (see Kauf et al). 2006;151:206-12
- Dibra A, Schömig A, Kastrati A. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. 2006;151:(5)e7 (Letter reply)
- Dichtl W (see Alber et al). 2006;151:139.e1-139.e7
- Didier K (see Schiele et al). 2006;151:661-7
- Dietz R (see Taylor et al). 2006;151:891.e1-891.e7
- Dirschinger J (see Schühlen et al). 2006;151:1248-54
- DiSalvo TG (see Magnani et al). 2006;151:463-70
- Djane P (see Boriani et al). 2006;151:1050-8
- Dobbins RL (see Das et al). 2006;151:1087-93
- Dobos GJ (see Michalsen et al). 2006;151:870-7
- Doe VH (see Hughes et al). 2006;151:1122.e1-1122.e6
- Doerler J (see Alber et al). 2006;151:139.e1-139.e7
- Donahue M (see Patel et al). 2006;151:633-42 (Meetings)
- Donahue MP (see Bensimhon et al). 2006;151:598-603 (Meetings)
- Donahue MP (see DeWald et al). 2006;151:604-24 (Meetings)
- Dos Santos A (see Goodman et al). 2006;151:791-7
- Doss M, Aybek T, Wood JP, Martens S, Wimmer-Greinecker G, Moritz A. Left ventricular remodeling impacts the function of the Quattro stentless mitral valve bioprosthesis (a 4-year experience). 2006;151:943.e1-943.e4
- Dotzer F (see Schühlen et al). 2006;151:1248-54
- Drago M (see Butera et al). 2006;151:228-34
- Drumel D (see Benson et al). 2006;151:934-42
- Dubart A-E (see Korosoglou et al). 2006;151:131-8
- Dubourg O (see Mansencal et al). 2006;151:1129.e1-1129.e6
- Duc P (see Daniels et al). 2006;151:999-1005
- Ducas J (see Goodhart et al). 2006;151:529.e1-529.e6
- Ducloux D (see Schiele et al). 2006;151:661-7
- Duff H (see Goodhart et al). 2006;151:529.e1-529.e6
- Dunbar SB (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Dunlap ME (see McMurray et al). 2006;151:985-91
- Dupuis G (see D'Antonio et al). 2006;151:813-19
- Dusek JA (see Benson et al). 2006;151:934-42
- Dy S (see Hebert et al). 2006;151:478-83
- Dzavik V (see Blackman et al). 2006;151:146-52
- Dzavik V (see Goodhart et al). 2006;151:529.e1-529.e6
- Dzavik V (see Reynolds et al). 2006;151:890.e9-890.e15

E

- Eagle KA (see Froehlich et al). 2006;151:1123-8
- Eagle KA (see Goodman et al). 2006;151:654-60
- Earle S (see McMurray et al). 2006;151:985-91
- Eckermann S (see Tonkin et al). 2006;151:1305-12
- Edvardsen T, Rosen BD, Pan L, Jerosch-Herold M, Lai S, Hundley WG, Sinha S, Kronmal RA, Bluemke DA, Lima JAC. Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging—the Multi-Ethnic Study of Atherosclerosis (MESA). 2006;151:109-14

- Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) Study Group (see Goodman et al). 2006;151:791-7
- Eggebrecht H, Herold U, Schmermund A, Lind AY, Kuhnert O, Martini S, Kühl H, Kienbaum P, Peters J, Jakob H, Erbel R, Baumgart D. Endovascular stent-graft treatment of penetrating aortic ulcer: results over a median follow-up of 27 months. 2006;151:530-6
- Ehara S (see Hasegawa et al). 2006;151:332-7
- Ehrlich J (see Hecht et al). 2006;151:1139-46 (Curriculum cardiol.)
- EIRA-2 Investigators (see Ferreiros et al). 2006;151:545-52
- El-Osta H (see Azar et al). 2006;151:521.e1-521.e4
- Ellis SG (see Chen et al). 2006;151:1260-4
- Ellis SG (see Gurm et al). 2006;151:1031.e1-1031.e6
- Ellis SG (see Holmes Jr et al). 2006;151:779-85 (Curriculum cardiol.)
- Ellison SR (see Brenden et al). 2006;151:1006-11
- Elsmann P, van't Hof AWJ, de Boer MJ, Suryapranata H, Borm GF, Hoorntje JCA, Ottervanger JP, Gosselink ATM, Dambink J-HE, Zijlstra F. Impact of infarct location on left ventricular ejection fraction after correction for enzymatic infarct size in acute myocardial infarction treated with primary coronary intervention. 2006;151:1239.e9-1239.12
- Eltchaninoff H (see Meier et al). 2006;151:1019.e1-1019.e7
- Elter JR, Hinderliter AL, Offenbacher S, Beck JD, Caughey M, Brodala N, Madianos PN. The effects of periodontal therapy on vascular endothelial function: a pilot trial. 2006;151:47.e1-47.e6
- Emanuelsson H (see Greenbaum et al). 2006;151:689.e1-689.e10
- Eng C (see Cavusoglu et al). 2006;151:1101.e1-1101.e8
- Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-I hypertension: a double-blind, placebo-controlled pilot study. 2006;151:100.e1-100.e6
- Epstein LM (see Parkash et al). 2006;151:397-403
- Erbel R (see Eggebrecht et al). 2006;151:530-6
- Erbel R (see Klein et al). 2006;151:380-9
- Erdman RAM (see Pedersen et al). 2006;151:367.e1-367.e6
- Ernst N (see De Luca et al). 2006;151:1256-9
- Ernst N (see van't Hof et al). 2006;151:1255.e1-1255.e5
- Ernst NMSKJ (see Smit et al). 2006;151:1102-7
- Ervin FL (see Yan et al). 2006;151:352-9
- Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA_{1c} levels and mortality in patients with diabetes and advanced systolic heart failure. 2006;151:91.e1-91.e6
- Every NR (see Rumsfeld et al). 2006;151:32-8
- EXERDUCCS Investigators (see Davidson et al). 2006;151:451-6
- Ezzeddine R (see Hreybe et al). 2006;151:852-6
- F**
- Faivre R (see Schiele et al). 2006;151:661-7
- Faletra F (see Mangiavacchi et al). 2006;151:477.e1-477.e6
- Farcot J-C (see Mansencal et al). 2006;151:1129.e1-1129.e6
- Fathi R (see Gurm et al). 2006;151:1031.e1-1031.e6
- Faxon DP (see Holper et al). 2006;151:69-75
- Feild DQ (see Welinder et al). 2006;151:1059-64
- Felderhoff T (see Kaneda et al). 2006;151:726-9
- Feldman R (see Halkin et al). 2006;151:915.e1-915.e7
- Felker GM, Cotter G. Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. 2006;151:765-7 (Editorial)
- Felker GM, Shaw LK, Stough WG, O'Connor CM. Anemia in patients with heart failure and preserved systolic function. 2006;151:457-62
- Fendrick AM (see Stecker et al). 2006;151:820-8
- Feng Y (see Gong et al). 2006;151:62-8
- Ferketich AK (see Raman et al). 2006;151:736-44
- Fernández C (see Alfonso et al). 2006;151:681.e1-681.e9
- Ferreiros E, Nacinovich F, Casabé JH, Modenesi JC, Swieszkowski S, Cortes C, Hernan CA, Kazelian L, Varini S, EIRA-2 Investigators. Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina-2 (EIRA-2) Study. 2006;151:545-52
- Feske SK (see Smith et al). 2006;151:338-44
- Fieno DS (see Shellock et al). 2006;151:436-43
- Filipovic M (see Jeger et al). 2006;151:508-13
- Finsterer J (see Stöhlberger et al). 2006;151:(6)e1 (Letter)
- Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG, INTERACT Trial Long-Term Follow-Up Investigators. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. 2006;151:373-9
- Fitchett DH (see Yan et al). 2006;151:352-9
- Fitzgerald PJ (see Kaneda et al). 2006;151:726-9
- Fitzgerald RL, Maisel A, Bhalla V. Is nesiritide really that good or that bad? 2006;151:(4)e3 (Letter reply)
- Fleck E (see Butter et al). 2006;151:115-23
- Fleg JL (see Ahmed et al). 2006;151:444-50
- Fonarow GC (see Eshaghian et al). 2006;151:91.e1-91.e6
- Fong YYA (see Ong et al). 2006;151:1323.e1-1323.e6
- Forissier J-F (see Mansencal et al). 2006;151:1129.e1-1129.e6
- Formigari R (see Giardini et al). 2006;151:922.e1-922.e5
- Fortier A (see Nigam et al). 2006;151:514-21
- Fortin C (see D'Antonio et al). 2006;151:813-19
- Foster G. The behavioral approach for treating obesity. 2006;151:625-7 (Meetings)
- Fountain RB, Holmes DR, Chandrasekaran K, Packer D, Asirvatham S, Van Tassel R, Turi Z. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTION in Patients with Atrial Fibrillation) Trial. 2006;151:956-61 (Trial design)
- Foussas SG (see Zairis et al). 2006;151:892-7
- Fowler MB (see Krum et al). 2006;151:55-61
- Fox JM (see Reynolds et al). 2006;151:890.e9-890.e15
- Fox KAA (see Goodman et al). 2006;151:654-60
- Fragasso G, Montano C, Perseghin G, Palloschi A, Calori G, Lattuada G, Oggionni S, Bassanelli G, Locatelli M, Lopaschuk G, Margonato A. The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition. 2006;151:1238.e1-1238.e8
- Frana B (see Mueller et al). 2006;151:471-7
- Franceschini C (see Balzi et al). 2006;151:1094-100
- Franzosi MG (see Macchia et al). 2006;151:754.e7-754.e17
- Freedman BI (see Burdon et al). 2006;151:706-11
- French JK (see Hammett et al). 2006;151:367.e7-367.e16
- Frick M (see Alber et al). 2006;151:139.e1-139.e7
- Fricke F-U. To the Editor. 2006;151:(1)e1 (Letter)
- Friedlander D (see Tonkin et al). 2006;151:1305-12
- Friedrich MG (see Taylor et al). 2006;151:891.e1-891.e7
- Frigiola A (see Butera et al). 2006;151:228-34
- Froehlich JB, Mukherjee D, Avezum A, Budaj A, Kline-Rogers EM, López-Sendón J, Allegrone J, Eagle KA, Mehta RH, Goldberg RJ, GRACE Investigators. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The

Global Registry of Acute Coronary Events (GRACE).
2006;151:1123-8

Froelicher V (see McAuley et al). 2006;151:890.e1-890.e7

Fu Y (see Al-Faleh et al). 2006;151:10-5

Fu Y (see Kim et al). 2006;151:668-73

G

Gabay JM (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7

Gabriel C (see Steinwender et al). 2006;151:1296.e7-1296.e13

Gabriel S (see Mahoney et al). 2006;151:219-27

Gaddi O (see Giardini et al). 2006;151:922.e1-922.e5

Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). 2006;151:713-19

Galbraith PD (see Hubacek et al). 2006;151:308-15

Galimberti P (see Mangiacavalli et al). 2006;151:477.e1-477.e6

Galin ID, Smith DA. To the Editor. 2006;151(5):e1 (Letter)

Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, Ohman EM, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. 2006;151:16-24

Galloway JM (see Sequist et al). 2006;151:909-14

Galpechian V (see Lipshultz et al). 2006;151:916-22

Ganz LI (see Hrybe et al). 2006;151:852-6

Gao M (see Hubacek et al). 2006;151:308-15

Gao Y (see Gong et al). 2006;151:62-8

Garcia A (see Raman et al). 2006;151:736-44

Garcia-Barreto D (see Cooper-DeHoff et al). 2006;151:1072-9

Garcia Ben M (see Perna et al). 2006;151:84-91

Garcia E (see Kandzari et al). 2006;151:1288-95

Garcia E (see Nikolsky et al). 2006;151:168-75

Garcia Garcia HM (see Agostoni et al). 2006;151:682-9

Garcia-Garcia HM (see Rodriguez-Granillo et al). 2006;151:1025.e1-1025.e6

Garcia MJ (see Schoenhagen et al). 2006;151:945-8 (Editorial)

Gasparini M (see Mangiacavalli et al). 2006;151:477.e1-477.e6

Gavora P (see Masura et al). 2006;151:755.e7-755.e10

Gaxiola E (see Cooper-DeHoff et al). 2006;151:1072-9

Gazer B (see Engelhard et al). 2006;151:100.e1-100.e6

Geleijnse JM (see Brouwer et al). 2006;151:857-62

Genovese L (see Mangiacavalli et al). 2006;151:477.e1-477.e6

Gensini G (see Casolo et al). 2006;151:101-8

Gensini GF (see Balzi et al). 2006;151:1094-100

Germanos M (see Azar et al). 2006;151:521.e1-521.e4

Gersh BJ (see Henkel et al). 2006;151:806-12

Gersh BJ (see Holmes Jr et al). 2006;151:779-85

(Curriculum cardiol.)

Gersh BJ (see Kandzari et al). 2006;151:1288-95

Gersh BJ (see Moller et al). 2006;151:419-25

Gerstenblith G (see Spaeder et al). 2006;151:844.e1-844.e10

Ghali WA (see Hubacek et al). 2006;151:308-15

Ghorra P (see Azar et al). 2006;151:521.e1-521.e4

Giamberti A (see Butera et al). 2006;151:228-34

Giannantonio P (see Mocini et al). 2006;151:192-7

Giardini A, Denti A, Formigari R, Salomone L, Prandstraller D, Bonvicini M, Palareti G, Guidetti D, Gaddi O, Picchio FM. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. 2006;151:922.e1-922.e5

Giazitzoglou E (see Katrisis et al). 2006;151:1107.e1-1107.e7

Gibbons RJ (see Sorajja et al). 2006;151:426-35

Gibler WB (see Roe et al). 2006;151:1205-13

Gibson CM (see Pinto et al). 2006;151:S27-9

Gibson CM (see Sabatine et al). 2006;151:25-31

Gibson CM (see Svensson et al). 2006;151:798.e1-798.e7

Gilchrist IC (see Greenbaum et al). 2006;151:689.e1-689.e10

Giles T (see White et al). 2006;151:176-84

Gilfillan IS (see Bradshaw et al). 2006;151:537-44

Gilkeson R (see Johnson et al). 2006;151:1012.e7-1012.e14

Gin K (see Reynolds et al). 2006;151:890.e9-890.e15

Ginsberg JS (see Natarajan et al). 2006;151:175.e1-175.e6

Girotra S (see Mukamal et al). 2006;151:368-72

Giugliano RP (see Allen et al). 2006;151:1065-71

Glasziou P (see Tonkin et al). 2006;151:1305-12

Glatfelter K (see Goldberg et al). 2006;151:501-7

Glyptis MP (see Zairis et al). 2006;151:892-7

Goehring A (see Butter et al). 2006;151:115-23

Goeree R (see Weintraub et al). 2006;151:1180-5 (Trial design)

Gogbashian A, Sepic J, Soltesz EG, Nascimben L, Cohn LH.

Operative and long-term survival of elderly is significantly improved by mitral valve repair. 2006;151:1325-33

Gold M (see Linde et al). 2006;151:288-94 (Trial design)

Goldberg A, Gruberg L, Roguin A, Petcherski S, Rimer D, Markiewicz W, Beyar R, Aronson D. Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina. 2006;151:1265-70

Goldberg RJ, Cui J, Olendzki B, Spencer F, Yarzebski J, Lessard D, Gore J. Excess body weight, clinical profile, management practices, and hospital prognosis in men and women after acute myocardial infarction. 2006;151:1297-304

Goldberg RJ, Glatfelter K, Burbank-Schmidt E, Lessard D, Gore JM. Trends in community mortality due to coronary heart disease. 2006;151:501-7

Goldberg RJ (see Botkin et al). 2006;151:199-205

Goldberg RJ (see Froehlich et al). 2006;151:1123-8

Gómez-Reico M (see Alfonso et al). 2006;151:681.e1-681.e9

Gong K, Zhang Z, Song G. What mediated the beneficial roles of methotrexate in chronic heart failure? 2006;151(5):e11-e12 (Letter reply)

Gong K, Zhang Z, Sun X, Zhang X, Li A, Yan J, Luo Q, Gao Y, Feng Y. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. 2006;151:62-8

Goodhart DM, Hubacek J, Anderson TJ, Duff H, Barbeau G, Ducas J, Carere RG, Lazzam C, Dzavik V, Buller CE, Trabelsi M. Effect of percutaneous coronary intervention of nonacute total coronary artery occlusions on QT dispersion. 2006;151:529.e1-529.e6

Goodhart DM (see Natarajan et al). 2006;151:175.e1-175.e6

Goodman S (see Al-Faleh et al). 2006;151:10-5

Goodman SG, Bozovich GE, Tan M, Dos Santos A, Gurfinkel EP, Cohen M, Langer A. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Study Group. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy. 2006;151:791-7

Goodman SG, Steg PG, Eagle KA, Fox KAA, López-Sendón J, Montalescot G, Budaj A, Kienly BM, Gore JM, Algrone J, Granger CB, Gurfinkel EP, GRACE Investigators. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). 2006;151:654-60

- Goodman SG (see Fitchett et al). 2006;151:373-9
 Goodman SG (see Yan et al). 2006;151:352-9
 Gore J (see Goldberg et al). 2006;151:1297-304
 Gore JM (see Botkin et al). 2006;151:199-205
 Gore JM (see Goldberg et al). 2006;151:501-7
 Gore JM (see Goodman et al). 2006;151:654-60
 Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Huestis MA. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. 2006;151:754.e1-754.e5
 Goss JR, Maynard C, Aldea GS, Marcus-Smith M, Whitten RW, Johnston G, Phillips RC, Reisman M, Kelley A, Anderson RP, Clinical Outcomes Assessment Program (COAP). Effects of a statewide physician-led quality-improvement program on the quality of cardiac care. 2006;151:1033-42
 Gosselink ATM (see De Luca et al). 2006;151:1256-9, 1296.e1-1296.e6
 Gosselink ATM (see Elsmann et al). 2006;151:1239.e9-1239.12
 Gosselink ATM (see Smit et al). 2006;151:1102-7
 Gosselink M (see van't Hof et al). 2006;151:1255.e1-1255.e5
 Goto S (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
 Gottdiener JS (see Barasch et al). 2006;151:39-47
 Gottlieb SH (see Spaeder et al). 2006;151:844.e1-844.e10
 Goutorbe F (see Berdague et al). 2006;151:690-8
 Goyal A, Mills JS, Tricoci P, Thomas KL, Baeza R, Adams GL, Melloni C. Highlights from the 55th Annual Scientific Sessions of the American College of Cardiology: March 11 to 14, 2006, Atlanta, Georgia. 2006;151:1156-72 (Meetings)
 Goyal A, Tricoci P, Melloni C, Mills JS, Thomas KL, Adams GL, Mitchell RG, Turer AT. Highlights from the American Heart Association Scientific Sessions, November 13 to 16, 2005, Dallas, TX. 2006;151:295-307 (Meetings)
 GRACE Investigators (see Froehlich et al). 2006;151:1123-8
 GRACE Investigators (see Goodman et al). 2006;151:654-60
 Graham MM (see Hubacek et al). 2006;151:308-15
 Granger C (see Al-Faleh et al). 2006;151:10-5
 Granger CB (see Armstrong et al). 2006;151:787-90
 Granger CB (see Galla et al). 2006;151:16-24
 Granger CB (see Goodman et al). 2006;151:654-60
 Granger CB (see Kauf et al). 2006;151:206-12
 Granger CB (see McMurray et al). 2006;151:985-91
 Granger CB (see Patel et al). 2006;151:316-22
 Green G (see Brenden et al). 2006;151:1006-11
 Green MS (see Parkash and Green). 2006;151:(2)e3 (Letter reply)
 Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD. Initial experience with an intravenous P2Y₁₂ platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. 2006;151:689.e1-689.e10
 Greenspon AJ (see Lewis et al). 2006;151:699-705
 Gregory D, Kimmelstiel C, Perry K, Parikh A, Konstam V, Konstam MA. Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial. 2006;151:1013-19
 Grenadier E (see Meier et al). 2006;151:1019.e1-1019.e7
 Griffin J (see Patel et al). 2006;151:316-22
 Griffin JJ (see Nikolsky et al). 2006;151:168-75
 Griffin MR (see Butler et al). 2006;151:643-53
 Grimm RA (see Klein et al). 2006;151:380-9
 Grimm W (see Alter et al). 2006;151:829-36
 Grines CL (see Brodie et al). 2006;151:1231-8
 Grines CL (see Greenbaum et al). 2006;151:689.e1-689.e10
 Grines CL (see Kandzari et al). 2006;151:1288-95
 Grines CL (see Nikolsky et al). 2006;151:168-75
 Grinfeld L (see Perna et al). 2006;151:84-91
 Grip L (see Svensson et al). 2006;151:798.e1-798.e7
 Grogan DR (see Greenbaum et al). 2006;151:689.e1-689.e10
 Gronda E (see Mangiavacchi et al). 2006;151:477.e1-477.e6
 Gronning B (see Kragelund et al). 2006;151:712.e1-712.e7
 Gross M (see Taylor et al). 2006;151:891.e1-891.e7
 Grossman P (see Michalsen et al). 2006;151:870-7
 Grove R (see Boriani et al). 2006;151:1050-8
 Grover A (see Singh et al). 2006;151:851.e1-851.e5
 Grube E (see Kaneda et al). 2006;151:726-9
 Gruberg L (see Goldberg et al). 2006;151:1265-70
 Grunkemeier GL (see Wu et al). 2006;151:1276-80
 Grunwald GK (see Rumsfeld et al). 2006;151:32-8
 Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione Investigators (see Macchia et al). 2006;151:754.e7-754.e17
 Guagliumi G (see Meier et al). 2006;151:1019.e1-1019.e7
 Guagliumi G (see Nikolsky et al). 2006;151:168-75
 Guazzi M (see Arena et al). 2006;151:851.e7-851.e13
 Guertin M-C (see Nigam et al). 2006;151:514-21
 Guidetti D (see Giardini et al). 2006;151:922.e1-922.e5
 Guidry MA, Blanchard BE, Thompson PD, Maresh CM, Seip RL, Taylor AL, Pescatello LS. The influence of short and long duration on the blood pressure response to an acute bout of dynamic exercise. 2006;151:1322.e5-1322.e12
 Gurfinkel EP (see Goodman et al). 2006;151:654-60, 791-7
 Gurm HS, Breitbart Y, Vivekanathan D, Yen MH, Fathi R, Ziada KM, Whitlow PL, Ellis SG. Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy—a propensity-adjusted analysis. 2006;151:1031.e1-1031.e6
 Guss D (see Brenden et al). 2006;151:1006-11
 Guzman L (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
 Györfy B (see Vannay et al). 2006;151:878-81
- ## H
- Haase KK (see Kralek et al). 2006;151:153-7
 Habbema JDF (see Hernández et al). 2006;151:257-64 (Curriculum cardiol.)
 Haber RH (see Halkin et al). 2006;151:915.e1-915.e7
 Haghi D (see Kralek et al). 2006;151:153-7
 Hainer J (see McMurray et al). 2006;151:985-91
 Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, Haber RH, Cambier PA, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA, Mehran R, Stone GW. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. 2006;151:915.e1-915.e7
 Hall JA (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
 Hall P (see Halkin et al). 2006;151:915.e1-915.e7
 Hall R (see Cantor et al). 2006;151:902-8
 Halliburton SS (see Schoenhagen et al). 2006;151:945-8 (Editorial)
 Halperin JL (see Klein et al). 2006;151:380-9
 Haluska B (see Isbel et al). 2006;151:745-53
 Hammett CJK, Prapavessis H, Baldi JC, Varo N, Schoenbeck U, Ameratunga R, French JK, White HD, Stewart RAH. Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk. 2006;151:367.e7-367.e16
 Hammill BG (see Allen LaPointe et al). 2006;151:992-8
 Han KH (see Lee et al). 2006;151:158-63

- Hansen A (see Korosoglou et al). 2006;151:131-8
- Hanson RL (see Jimenez-Corona et al). 2006;151:1080-6
- Harcombe AA (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
- Hardt S (see Korosoglou et al). 2006;151:131-8
- Harkness S (see Reynolds et al). 2006;151:890.e9-890.e15
- Harrington RA (see Galla et al). 2006;151:16-24
- Harrington RA (see Greenbaum et al). 2006;151:689.e1-689.e10
- Harrington RA (see Patel et al). 2006;151:316-22
- Harrington RA (see Roe et al). 2006;151:1205-13
- Harris CL (see Boden et al). 2006;151:1173-9 (Trial design)
- Hartigan P (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Hartigan PM (see Boden et al). 2006;151:1173-9 (Trial design)
- Hasegawa R (see Kawata et al). 2006;151:798.e9-798.e15
- Hasegawa T, Ehara S, Kobayashi Y, Kataoka T, Yamashita H, Nishioka H, Asawa K, Yamagishi H, Yoshiyama M, Takeuchi K, Yoshikawa J, Ueda M. Acute myocardial infarction: clinical characteristics and plaque morphology between expansive remodeling and constrictive remodeling by intravascular ultrasound. 2006;151:332-7
- Hauptman PJ, Rector TS, Wentworth D, Kubo S. Quality of life in advanced heart failure: role of mitral regurgitation. 2006;151:213-18
- Hauser MF (see Ling et al). 2006;151:882-9
- Hausleiter J (see Schühlen et al). 2006;151:1248-54
- Hawley C (see Isbel et al). 2006;151:745-53
- Healey JS, Carroll S, Connolly SJ, Crystal E. Benefits of left atrial appendage occlusion. 2006;151:6e3 (Letter reply)
- Hebert KA, Horswell RL, Dy S, Key JJ Jr, Butler MK, Cerise FP, Arcement LM. Mortality benefit of a comprehensive heart failure disease management program in indigent patients. 2006;151:478-83
- Hecht HS, Budoff MJ, Berman DS, Ehrlich J, Rumberger JA. Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment. 2006;151:1139-46 (Curriculum cardiol.)
- Heeringa J (see Brouwer et al). 2006;151:857-62
- Hefter G (see Spaeder et al). 2006;151:844.e1-844.e10
- Heidenreich PA (see Nath et al). 2006;151:730-5
- Heishman SJ (see Gorelick et al). 2006;151:754.e1-754.e5
- Heiss G (see Astor et al). 2006;151:492-500
- Heiss G (see Kulkarni et al). 2006;151:185-91
- Hellkamp AS (see Lewis et al). 2006;151:699-705
- Henkel DM, Witt BJ, Gersh BJ, Jacobsen SJ, Weston SA, Meverden RA, Roger VL. Ventricular arrhythmias after acute myocardial infarction: a 20-year community study. 2006;151:806-12
- Hennekens CH (see Serebruany et al). 2006;151:92-9
- Hennekens CH (see Zagler et al). 2006;151:140-5
- Henry T. Contemporary challenges in the management of acute myocardial infarction: ST-elevation myocardial infarction guidelines and the real world. 2006;151:S11-6
- Henry TD (see Herrmann and Henry). 2006;151:S1-2
- Herlitz J (see Svensson et al). 2006;151:798.e1-798.e7
- Hermiller J (see Halkin et al). 2006;151:915.e1-915.e7
- Hernan CA (see Ferreiros et al). 2006;151:545-52
- Hernández AV, Boersma E, Murray GD, Habbema JDF, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? 2006;151:257-64 (Curriculum cardiol.)
- Hernandez Garcia HR (see Ballantyne et al). 2006;151:975.e1-975.e9
- Herold U (see Eggebrecht et al). 2006;151:530-6
- Herrin J (see Bradley et al). 2006;151:1281-7
- Herrington D (see Burdon et al). 2006;151:706-11
- Herrmann HC, Henry TD. Optimizing reperfusion outcomes in ST-elevation myocardial infarction. 2006;151:S1-2
- Herrmann HC. Introduction. 2006;151:S3
- Herrmann HC. Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation. 2006;151:S30-9
- Herrmann HC (see Daniels et al). 2006;151:999-1005
- Herrmann HC (see Halkin et al). 2006;151:915.e1-915.e7
- Hettleman B (see Davidson et al). 2006;151:451-6
- Heusch G (see Michalsen et al). 2006;151:870-7
- Hewkin A (see Cooper-DeHoff et al). 2006;151:1072-9
- Hibberd PL (see Benson et al). 2006;151:934-42
- Higginbotham MB (see Davidson et al). 2006;151:451-6
- Hildebrandt P (see Kragelund et al). 2006;151:712.e1-712.e7
- Hill PC (see Benson et al). 2006;151:934-42
- Hillege HL (see Hogenhuis et al). 2006;151:1012.e1-1012.e5
- Hillis GS (see Moller et al). 2006;151:419-25
- Himi T (see Kawata et al). 2006;151:798.e9-798.e15
- Hinderliter AL (see Elter et al). 2006;151:47.e1-47.e6
- Hirakawa Y, Masuda Y, Uemura K, Kuzuya M, Kimata T, Iguchi A. Differences in inhospital mortality between men and women with acute myocardial infarction undergoing percutaneous coronary intervention in Japan: Tokai Acute Myocardial Infarction Study (TAMIS). 2006;151:1271-5
- Hirsch AT (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
- Hocher B. To the Editor. 2006;151:(1)e5 (Letter)
- Hochholzer W (see Mueller et al). 2006;151:1214.e1-1214.e7
- Hochman JS (see Armstrong et al). 2006;151:787-90
- Hochman JS (see Reynolds et al). 2006;151:890.e9-890.e15
- Hodge DO (see Sorajja et al). 2006;151:426-35
- Hoersch W (see Butter et al). 2006;151:115-23
- Hoes AW (see Hogenhuis et al). 2006;151:1012.e1-1012.e5
- Hofmann R (see Steinwender et al). 2006;151:1296.e7-1296.e13
- Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Hoes AW, van Veldhuisen DJ. Low prevalence of B-type natriuretic peptide levels <100 pg/mL in patients with heart failure at hospital discharge. 2006;151:1012.e1-1012.e5
- Hogg K (see Berry et al). 2006;151:1313-21
- Hoit BD (see Johnson et al). 2006;151:1012.e7-1012.e14
- Hollander JE (see Brenden et al). 2006;151:1006-11
- Hollander JE (see Daniels et al). 2006;151:999-1005
- Holmes D (see Detling et al). 2006;151:522-8
- Holmes DR Jr, Gersh BJ, Ellis SG. Rescue percutaneous coronary intervention after failed fibrinolytic therapy: Have expectations been met? 2006;151:779-85 (Curriculum cardiol.)
- Holmes DR Jr (see Ong et al). 2006;151:1194-204 (Trial design)
- Holmes DR (see Fountain et al). 2006;151:956-61 (Trial design)
- Holper EM, Blair J, Selzer F, Detre KM, Jacobs AK, Williams DO, Vlachos H, Wilensky RL, Coady P, Faxon DP. Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry Investigators. The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry. 2006;151:69-75
- Honda Y (see Kaneda et al). 2006;151:726-9
- Hong M-K (see Lee et al). 2006;151:158-63
- Hong MK (see Minutello et al). 2006;151:164-7
- Hoorntje JCA (see De Luca et al). 2006;151:1256-9, 1296.e1-1296.e6
- Hoorntje JCA (see Elsmann et al). 2006;151:1239.e9-1239.12
- Hoorntje JCA (see Smit et al). 2006;151:1102-7
- Hoorntje JCA (see van't Hof et al). 2006;151:1255.e1-1255.e5

- Horswell RL (see Hebert et al). 2006;151:478-83
- Horwich TB (see Eshaghian et al). 2006;151:91.e1-91.e6
- Hreybe H, Ezzeddine R, Bedi M, Barrington W, Bazaz R, Ganz JJ, Jain S, Ngwu O, London B, Saba S. Renal insufficiency predicts the time to first appropriate defibrillator shock. 2006;151:852-6
- Hsueh C-W (see Liu et al). 2006;151:235-41
- Huang J-L (see Liu et al). 2006;151:235-41
- Hubacek J, Galbraith PD, Gao M, Humphries K, Graham MM, Knudtson ML, Ghali WA, APPROACH investigators. External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes. 2006;151:308-15
- Hubacek J (see Goodhart et al). 2006;151:529.e1-529.e6
- Huestis MA (see Gorelick et al). 2006;151:754.e1-754.e5
- Hughes JW, Casey E, Luyster F, Doe VH, Waechter D, Rosneck J, Josephson R. Depression symptoms predict heart rate recovery after treadmill stress testing. 2006;151:1122.e1-1122.e6
- Humphries K (see Hubacek et al). 2006;151:308-15
- Hundley WG (see Edvardson et al). 2006;151:109-14
- Hunt D (see Tonkin et al). 2006;151:1305-12
- I**
- IEPR Investigators (see McCullough et al). 2006;151:139.e9-139.e13
- Iguchi A (see Hirakawa et al). 2006;151:1271-5
- Ilumur K, Karabulut A, Apak I, Aluculu U, Ariturk Z, Toprak N. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. 2006;151:1115-22
- IMAGINE Investigators (see van Gilst et al). 2006;151:1240-6
- Ing D (see Blackman et al). 2006;151:146-52
- INTERACT Trial Long-Term Follow-Up Investigators (see Fitchett et al). 2006;151:373-9
- INVEST Investigators (see Cooper-DeHoff et al). 2006;151:1072-9
- Isbel NM, Haluska B, Johnson DW, Beller E, Hawley C, Marwick TH. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. 2006;151:745-53
- Iversen S (see Kaneda et al). 2006;151:726-9
- J**
- Jaarsma T (see Hogenhuis et al). 2006;151:1012.e1-1012.e5
- Jääskeläinen P (see Poutanen et al). 2006;151:725.e1-725.e9
- Jackevicius C (see Blackman et al). 2006;151:146-52
- Jackson J (see Mahoney et al). 2006;151:219-27
- Jacobs AK (see Holper et al). 2006;151:69-75
- Jacobs DR Jr (see Lee et al). 2006;151:1247.e1-1247.e7
- Jacobsen SJ (see Henkel et al). 2006;151:806-12
- Jacobson J (see Latson et al). 2006;151:1129.e7-1129.e11
- Jain MK (see Benson et al). 2006;151:934-42
- Jain S (see Hreybe et al). 2006;151:852-6
- Jakob H (see Eggebrecht et al). 2006;151:530-6
- Jamrozik KD (see Bradshaw et al). 2006;151:537-44
- Jang I-K (see Yeh and Jang). 2006;151:1131-8 (Curriculum cardiol.)
- Januzzi JL Jr, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, Ohman EM, Cannon CP, Braunwald E. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. 2006;151:360-6
- Januzzi JL (see Baggish et al). 2006;151:48-54
- Jasper SE (see Klein et al). 2006;151:380-9
- Jeger RV, Probst C, Arsenic R, Lippuner T, Pfisterer ME, Seeberger MD, Filipovic M. Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease. 2006;151:508-13
- Jerosch-Herold M (see Edvardson et al). 2006;151:109-14
- Jeschke RE (see Coyle et al). 2006;151:1032.e9-1032.e12
- Jesse R (see Brenden et al). 2006;151:1006-11
- Jimenez-Corona A, Nelson RG, Sievers ML, Knowler WC, Hanson RL, Bennett PH. Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes. 2006;151:1080-6
- Jin R (see Wu et al). 2006;151:1276-80
- Jo S-H (see Park et al). 2006;151:864-9
- John JM (see Chen et al). 2006;151:1260-4
- Johnson DW (see Isbel et al). 2006;151:745-53
- Johnson KM (see Pires et al). 2006;151:837-43
- Johnson MT, Zhang S, Gilkeson R, Ameduri R, Chebotarev O, Kenton AB, Bowles KR, Towbin JA, Robin NH, Brozovich F, Hoit BD. Intrafamilial variability of noncompaction of the ventricular myocardium. 2006;151:1012.e7-1012.e14
- Johnston G (see Goss et al). 2006;151:1033-42
- Johnstone D (see van Gilst et al). 2006;151:1240-6
- Jokinen E (see Poutanen et al). 2006;151:725.e1-725.e9
- Jonas N (see Staub et al). 2006;151:1223-30
- Jones PG (see Spertus et al). 2006;151:589-97 (Trial design)
- Jones TK (see Latson et al). 2006;151:1129.e7-1129.e11
- Joseph T (see Mansencal et al). 2006;151:1129.e1-1129.e6
- Josephson R (see Hughes et al). 2006;151:1122.e1-1122.e6
- Juurink DN (see Austin et al). 2006;151:969-75
- K**
- Kaltoft A, Bottcher M, Sand NP, Rehling M, Andersen NT, Zijlstra F, Nielsen TT. Sestamibi single photon emission computed tomography immediately after primary percutaneous coronary intervention identifies patients at risk for large infarcts. 2006;151:1108-14
- Kammler J (see Steinwender et al). 2006;151:1296.e7-1296.e13
- Kandzari DE, Tchong JE, Gersh BJ, Cox DA, Stuckey T, Turco M, Mehran R, Garcia E, Zimetbaum P, McGlaughlin MG, Lansky AJ, Costantini CO, Grines CL, Stone GW, CADILLAC Investigators. Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. 2006;151:1288-95
- Kaneda H, Terashima M, Takahashi T, Iversen S, Felderhoff T, Grube E, Yock PG, Honda Y, Fitzgerald PJ. Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: an intravascular ultrasound study. 2006;151:726-9
- Kappetein AP (see Ong et al). 2006;151:1194-204 (Trial design)
- Karabinos I (see Katrasis et al). 2006;151:1107.e1-1107.e7
- Karabulut A (see Ilumur et al). 2006;151:1115-22
- Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. 2006;151:976.e7-976.e11
- Karlsson T (see Svensson et al). 2006;151:798.e1-798.e7
- Karvouni E (see Katrasis et al). 2006;151:1107.e1-1107.e7
- Karwatowska-Prokopczuk E (see Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)
- Kasikcioglu H (see Uyarel et al). 2006;151:1239.e1-1239.e7
- Kasper EK (see Spaeder et al). 2006;151:844.e1-844.e10
- Kassab R (see Azar et al). 2006;151:521.e1-521.e4

- Kastelein JJP (see Vriend et al). 2006;151:242-7
- Kastrati A (see Dibra et al). 2006;151:5:e7 (Letter reply)
- Kastrati A (see Schühlen et al). 2006;151:1248-54
- Kataoka T (see Hasegawa et al). 2006;151:332-7
- Katritsis DG, Korovesis S, Karvouni E, Giazitzoglou E, Karabinos I, Tzanalaridou E, Panagiotakos D, Webb-Peploe MM. Handgrip-enhanced myocardial fractional flow reserve for assessment of coronary artery stenoses. 2006;151:1107.e1-1107.e7
- Katus HA (see Korosoglou et al). 2006;151:131-8
- Katus HA (see Krum et al). 2006;151:55-61
- Kauf TL, Velazquez EJ, Crosslin DR, Weaver WD, Diaz R, Granger CB, McMurray JJV, Rouleau J-L, Aylward PE, White HD, Califf RM, Schulman KA. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. 2006;151:206-12
- Kaufman S (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Kawata T, Daimon M, Hasegawa R, Teramoto K, Toyoda T, Sekine T, Yamamoto K, Uchida D, Himi T, Yoshida K, Komuro I. Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist. 2006;151:798.e9-798.e15
- Kazanegra R (see Daniels et al). 2006;151:999-1005
- Kazelian L (see Ferreiros et al). 2006;151:545-52
- Keller S (see Dettling et al). 2006;151:522-8
- Kelley A (see Goss et al). 2006;151:1033-42
- Kelsey SF (see McCullough et al). 2006;151:139.e9-139.e13
- Kennard ED (see McCullough et al). 2006;151:139.e9-139.e13
- Kennelly BM (see Goodman et al). 2006;151:654-60
- Kenton AB (see Johnson et al). 2006;151:1012.e7-1012.e14
- Kerciakes DJ (see Greenbaum et al). 2006;151:689.e1-689.e10
- Kerkhoff G (see Michalsen et al). 2006;151:870-7
- Kern L (see Spaeder et al). 2006;151:844.e1-844.e10
- Kerr C (see Pritchett et al). 2006;151:1043-9
- Kerr D (see Raitt et al). 2006;151:390-6
- Key JJ Jr (see Hebert et al). 2006;151:478-83
- Khaodhiar L (see DeWald et al). 2006;151:604-24 (Meetings)
- Kienbaum P (see Eggebrecht et al). 2006;151:530-6
- Kim DH, Burton JR, Fu Y, Lindholm L, Van de Werf F, Armstrong PW, CAPTORS II Investigators. What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? 2006;151:668-73
- Kim H-S (see Park et al). 2006;151:864-9
- Kim J-J (see Lee et al). 2006;151:158-63
- Kim J (see Lee et al). 2006;151:158-63
- Kim S-W (see Pregowski et al). 2006;151:898-901
- Kim Y-H (see Lee et al). 2006;151:158-63
- Kimata T (see Hirakawa et al). 2006;151:1271-5
- Kimmelstiel C (see Gregory et al). 2006;151:1013-19
- Kirby A (see Tonkin et al). 2006;151:1305-12
- Kirtane A (see Svensson et al). 2006;151:798.e1-798.e7
- Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET, Roman MJ, Devereux RB. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). 2006;151:412-18
- Klarich KW (see Ling et al). 2006;151:882-9
- Kleijne J (see Ong et al). 2006;151:1194-204 (Trial design)
- Klein AL, Grimm RA, Jasper SE, Murray RD, Apperson-Hansen C, Lieber EA, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF. ACUTE Steering and Publications Committee for the ACUTE Investigators. Efficacy of trans-esophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial. 2006;151:380-9
- Klersy C (see Mangiacavacchi et al). 2006;151:477.e1-477.e6
- Kline-Rogers EM (see Froehlich et al). 2006;151:1123-8
- Knight BP (see Stecker et al). 2006;151:820-8
- Knoblauch NTM (see Michalsen et al). 2006;151:870-7
- Knowler WC (see Jimenez-Corona et al). 2006;151:1080-6
- Knudson CW (see Daniels et al). 2006;151:999-1005
- Knudtson M (see Boden et al). 2006;151:1173-9 (Trial design)
- Knudtson ML (see Hubacck et al). 2006;151:308-15
- Kobayashi Y (see Hasegawa et al). 2006;151:332-7
- Kober L (see Kragelund et al). 2006;151:712.e1-712.e7
- Koglin J (see Ong et al). 2006;151:1194-204 (Trial design)
- Kolkman JJE (see Smit et al). 2006;151:1102-7
- Kolm P (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Komuro I (see Kawata et al). 2006;151:798.e9-798.e15
- Konstam MA (see Gregory et al). 2006;151:1013-19
- Konstam V (see Gregory et al). 2006;151:1013-19
- Konstantinides S (see Michalsen et al). 2006;151:870-7
- Kopecky SL (see Benson et al). 2006;151:934-42
- Környei M (see Vannay et al). 2006;151:878-81
- Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. 2006;151:755.e1-755.e6
- Korosoglou G, Dubart A-E, DaSilva KGC Jr, Labadze N, Hardt S, Hansen A, Bekerredjian R, Zugck C, Zehelein J, Katus HA, Kuecherer H. Real-time myocardial perfusion imaging for pharmacologic stress testing: added value to single photon emission computed tomography. 2006;151:131-8
- Korovesis S (see Katritsis et al). 2006;151:1107.e1-1107.e7
- Kors JA (see Ammar et al). 2006;151:799-805
- Kostuk W (see Boden et al). 2006;151:1173-9 (Trial design)
- Kottke-Marchant K (see Karha et al). 2006;151:976.e7-976.e11
- Kovach R (see Halkin et al). 2006;151:915.e1-915.e7
- Kowey P (see Pritchett et al). 2006;151:1043-9
- Kozma G (see Vannay et al). 2006;151:878-81
- Kragelund C, Gronning B, Omland T, Kober L, Strande S, Steffensen R, Hildebrandt P. Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? 2006;151:712.e1-712.e7
- Krakov S, Poerner TC, Basorth D, Lang S, Wolpert C, Haghi D, Borggreffe M, Haase KK, Sülsebeck T. Side branch occlusion after coronary stent implantation in patients presenting with ST-elevation myocardial infarction: clinical impact and angiographic predictors. 2006;151:153-7
- Kramer JM (see Allen LaPointe et al). 2006;151:992-8
- Kraus WE (see Bensimhon et al). 2006;151:598-603 (Meetings)
- Kraus WE (see Pruitt et al). 2006;151:628-32 (Meetings)
- Krauser DG (see Baggish et al). 2006;151:48-54
- Krishnaswamy P (see Daniels et al). 2006;151:999-1005
- Kronmal RA (see Edwards et al). 2006;151:109-14
- Krucoff MW, Crater SW, Lee KL. From efficacy to safety concerns: a STEP forward or a step back for clinical research and intercessory prayer?: the Study of Therapeutic Effects of Intercessory Prayer (STEP). 2006;151:762-4 (Editorial)
- Kruk M (see Pregowski et al). 2006;151:898-901
- Krum H, Mohacsi P, Katus HA, Tendra M, Rouleau J-L, Fowler MB, Coats JA, Roecker EB, Packer M, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Are β -blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. 2006;151:55-61

- Krumholz H (see Spertus et al). 2006;151:589-97 (Trial design)
 Krumholz HM (see Bradley et al). 2006;151:1281-7
 Krumholz HM (see Sedrakyan et al). 2006;151:720-5
 Kubo S (see Hauptman et al). 2006;151:213-18
 Kuecherer H (see Korosoglou et al). 2006;151:131-8
 Kühl H (see Eggebrecht et al). 2006;151:530-6
 Kuhnt O (see Eggebrecht et al). 2006;151:530-6
 Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. 2006;151:185-91
 Kuntz RE (see Halkin et al). 2006;151:915.e1-915.e7
 Kuusisto J (see Poutanen et al). 2006;151:725.e1-725.e9
 Kuzuya M (see Hirakawa et al). 2006;151:1271-5
 Kypta A (see Steinwender et al). 2006;151:1296.e7-1296.e13

L

- Laakso M (see Poutanen et al). 2006;151:725.e1-725.e9
 Labadze N (see Korosoglou et al). 2006;151:131-8
 Lacombe P (see Mansencal et al). 2006;151:1129.e1-1129.e6
 Lai H-C (see Liu et al). 2006;151:235-41
 Lai S (see Edvardson et al). 2006;151:109-14
 Lainchbury JG (see Baggish et al). 2006;151:48-54
 Lam P (see Benson et al). 2006;151:934-42
 Lamas GA (see Lewis et al). 2006;151:699-705
 Lamb HJ (see Schuijff et al). 2006;151:404-11
 Lampropoulos S (see Bountiokos et al). 2006;151:1323.e7-1323.e12
 Lamy A (see Mahoney et al). 2006;151:219-27
 Lang S (see Kravet et al). 2006;151:153-7
 Langefeld CD (see Burdon et al). 2006;151:706-11
 Langer A (see Fitchett et al). 2006;151:373-9
 Langer A (see Goodman et al). 2006;151:791-7
 Langer A (see Yan et al). 2006;151:352-9
 Lansky AJ (see Brodie et al). 2006;151:1231-8
 Lansky AJ (see Chacko et al). 2006;151:1032.e1-1032.e7
 Lansky AJ (see Kandzari et al). 2006;151:1288-95
 Lansky AJ (see Nikolsky et al). 2006;151:168-75
 Larsen EKM (see Barasch et al). 2006;151:39-47
 Laskey WK, Maisel WH. Cardiac resynchronization therapy: a regulatory perspective. 2006;151:757-61 (Editorial)
 Latson LA, Jones TK, Jacobson J, Zahn E, Rhodes JF. Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder. 2006;151:1129.e7-1129.e11
 Lattuada G (see Fragasso et al). 2006;151:1238.e1-1238.e8
 Laule-Kilian K (see Mueller et al). 2006;151:471-7, 845-50
 Lavecchia R (see Balzi et al). 2006;151:1094-100
 Lazzam C (see Goodhart et al). 2006;151:529.e1-529.e6
 Lee CW (see Lee et al). 2006;151:158-63
 Lee D-H, Zacharski LR, Jacobs DR Jr. Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes. 2006;151:1247.e1-1247.e7
 Lee DS (see Chen et al). 2006;151:1260-4
 Lee ET (see Kizer et al). 2006;151:412-18
 Lee KL (see Krucoff et al). 2006;151:762-4 (Editorial)
 Lee KL (see Lewis et al). 2006;151:699-705
 Lee S-W, Park S-W, Hong M-K, Kim Y-H, Han KH, Kim J, Park J-H, Oh S-J, Moon DH, Oh SJ, Lee CW, Kim JJ, Park S-J. Incidence and predictors of late recurrence after β -radiation therapy with a ^{188}Re -MAG₃-filled balloon for diffuse in-stent restenosis. 2006;151:158-63
 Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. 2006;151:76-83
 Lee W-L (see Liu et al). 2006;151:235-41
 Legall P (see Schiele et al). 2006;151:661-7
 Lehmann N (see Michalsen et al). 2006;151:870-7
 Leisch F (see Steinwender et al). 2006;151:1296.e7-1296.e13
 Lemler MS, Ramaciotti C, Stromberg D, Scott WA, Leonard SR. The extracardiac lateral tunnel Fontan, constructed with bovine pericardium: comparison with the extracardiac conduit Fontan. 2006;151:928-33
 Leonard SR (see Lemler et al). 2006;151:928-33
 Lepère C (see Mansencal et al). 2006;151:1129.e1-1129.e6
 Lessard D (see Botkin et al). 2006;151:199-205
 Lessard D (see Goldberg et al). 2006;151:501-7, 1297-304
 Lessem J (see D'Aiuto et al). 2006;151:977-84
 Letrillard S (see Berdagué et al). 2006;151:690-8
 Levantesi G (see Macchia et al). 2006;151:754.e7-754.e17
 Levitsky S (see Benson et al). 2006;151:934-42
 Lewis C (see Weintraub et al). 2006;151:1180-5 (Trial design)
 Lewis EF, Hellkamp AS, Pfeffer MA, Greenspon AJ, Machado C, Singh S, Schron E, Lee KL, Lamas GA. The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST). 2006;151:699-705
 Li A (see Gong et al). 2006;151:62-8
 Li G-P (see Liu and Li). 2006;151:(2)e1 (Letter)
 Li L (see Park et al). 2006;151:864-9
 Liao C-S (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
 Lieber EA (see Klein et al). 2006;151:380-9
 Liebman J (see Welinder et al). 2006;151:1059-64
 Liew CK (see Ong et al). 2006;151:1323.e1-1323.e6
 Liew hB (see Ong et al). 2006;151:1323.e1-1323.e6
 Lima JAC (see Edvardson et al). 2006;151:109-14
 Lincoff AM (see Chacko et al). 2006;151:1032.e1-1032.e7
 Lind AY (see Eggebrecht et al). 2006;151:530-6
 Lindblad L (see Patel et al). 2006;151:316-22
 Linde C, Gold M, Abraham WT, Daubert J-C, REVERSE Study Group. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure—the REsynchronization REVerses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. 2006;151:288-94 (Trial design)
 Lindholm L (see Kim et al). 2006;151:668-73
 Lindvall B (see Meier et al). 2006;151:1019.e1-1019.e7
 Ling LH, Christian TF, Mulvagh SL, Klarich KW, Hauser MF, Nishimura RA, Pellikka PA. Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 210 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography. 2006;151:882-9
 Linker NJ (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
 LIPID Study Group (see Tonkin et al). 2006;151:1305-12
 Lippuner T (see Jeger et al). 2006;151:508-13
 Lipshultz SE, Wong JCL, Lipsitz SR, Simbre VC II, Zareba KM, Galpechian V, Rifai N. Frequency of clinically unsuspected myocardial injury at a children's hospital. 2006;151:916-22
 Lipsitz SR (see Lipshultz et al). 2006;151:916-22
 Liu JE (see Kizer et al). 2006;151:412-18
 Liu T, Li G-P. Potential mechanisms between atrial dilatation and atrial fibrillation. 2006;151:(2)e1 (Letter)

- Liu T-J, Lai H-C, Lee W-L, Wang K-Y, Wu T-J, Huang J-L, Hsueh C-W, Ting C-T. Immediate and late outcomes of patients undergoing transeptal left-sided heart catheterization for symptomatic valvular and arrhythmic diseases. 2006;151:235-41
- Lloyd-Jones DM (see Allen et al). 2006;151:1065-71
- Locatelli M (see Fragasso et al). 2006;151:1238.e1-1238.e8
- Logan L (see Davidson et al). 2006;151:451-6
- London B (see Hreybe et al). 2006;151:852-6
- Lopaschuk G (see Fragasso et al). 2006;151:1238.e1-1238.e8
- López-Minguez JR (see Alfonso et al). 2006;151:681.e1-681.e9
- López-Sendón J (see Froehlich et al). 2006;151:1123-8
- López-Sendón J (see Goodman et al). 2006;151:654-60
- Lortie M (see Yoshinaga et al). 2006;151:1324.e11-1324.e18
- Lundkvist J (see Asplén and Lundkvist). 2006;151:(1)e3 (Letter reply). (1)e7 (Letter reply)
- Luo Q (see Gong et al). 2006;151:62-8
- Lüscher TF (see Sudano et al). 2006;151:1147-55 (Curriculum cardiol.)
- Luyster F (see Hughes et al). 2006;151:1122.e1-1122.e6
- Lytle B (see Kulkarni et al). 2006;151:185-91
- Lytle BW (see Schoenhagen et al). 2006;151:945-8 (Editorial)

M

- Macaya C (see Alfonso et al). 2006;151:681.e1-681.e9
- Macchia A, Levantesi G, Borrelli G, Franzosi MG, Maggioni AP, Marfisi R, Scarano M, Tavazzi L, Tognoni G, Valagussa F, Marchioli R, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione Investigators. A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring. 2006;151:754.e7-754.e17
- Machado C (see Lewis et al). 2006;151:699-705
- Mack MJ (see Ong et al). 2006;151:1194-204 (Trial design)
- Mackie K (see Blackman et al). 2006;151:146-52
- Mackin P, McAllister-Williams H. Schizophrenia and increased risk of cardiovascular disease. 2006;151:(5)e13 (Letter)
- Madianos PN (see Elter et al). 2006;151:47.e1-47.e6
- Machara A (see Pregowski et al). 2006;151:898-901
- Maggioni AP (see Macchia et al). 2006;151:754.e7-754.e17
- Magid DJ (see Bradley et al). 2006;151:1281-7
- Magid DJ (see Rumsfeld et al). 2006;151:32-8
- Magnani JW, Danik HJS, Dec GW Jr, DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. 2006;151:463-70
- Magnin D (see Schiele et al). 2006;151:661-7
- Magnus P (see Tonkin et al). 2006;151:1305-12
- Mahaffey KW (see Armstrong et al). 2006;151:787-90
- Mahaffey KW (see Galla et al). 2006;151:16-24
- Mahoney EM, Mehta S, Yuan Y, Jackson J, Chen R, Gabriel S, Lamy A, Culler S, Caro J, Yusuf S, Weintraub WS, CURE Study Investigators. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. 2006;151:219-27
- Mahoney EM (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Maisch B (see Alter et al). 2006;151:829-36
- Maisel A (see Fitzgerald et al). 2006;151:(4)e3 (Letter reply)
- Maisel AS (see Brenden et al). 2006;151:1006-11
- Maisel AS (see Daniels et al). 2006;151:999-1005
- Maisel WH (see Laskey and Maisel). 2006;151:757-61 (Editorial)
- Maisel WH (see Parkash et al). 2006;151:397-403
- Makrygiannis SS (see Zairis et al). 2006;151:892-7
- Makwana R (see Ammar et al). 2006;151:799-805
- Malhotra S (see Singh et al). 2006;151:851.e1-851.e5
- Malinin AI (see Serebruany et al). 2006;151:92-9
- Mamdani MM (see Austin et al). 2006;151:969-75
- Mancini GBJ (see Boden et al). 2006;151:1173-9 (Trial design)
- Mangiavacchi M, Gasparini M, Faletta F, Klersy C, Morenghi E, Galimberti P, Genovese L, Regoli F, De Chiara F, Bragato R, Andreuzzi B, Pini D, Gronda E. Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure. 2006;151:477.e1-477.e6
- Manolio TA (see Barasch et al). 2006;151:39-47
- Manousakis SJ (see Zairis et al). 2006;151:892-7
- Mansencal N, Mitry E, Forissier J-F, Martin F, Redheuil A, Lepère C, Farcot J-C, Joseph T, Lacombe P, Rougier P, Dubourg O. Assessment of patent foramen ovale in carcinoid heart disease. 2006;151:1129.e1-1129.e6
- Manta R (see Casolo et al). 2006;151:101-8
- Mantilla R (see Alfonso et al). 2006;151:681.e1-681.e9
- Marchioli R (see Macchia et al). 2006;151:754.e7-754.e17
- Marchionni N (see Balzi et al). 2006;151:1094-100
- Marcus-Smith M (see Goss et al). 2006;151:1033-42
- Marek D (see Benson et al). 2006;151:934-42
- Maresh CM (see Guidry et al). 2006;151:1322.e5-1322.e12
- Marfisi R (see Macchia et al). 2006;151:754.e7-754.e17
- Margheri M (see Balzi et al). 2006;151:1094-100
- Margonato A (see Fragasso et al). 2006;151:1238.e1-1238.e8
- Mariñas J (see Peteiro et al). 2006;151:1324.e1-1324.e10
- Markiewicz W (see Goldberg et al). 2006;151:1265-70
- Marmur JD (see Cavusoglu et al). 2006;151:1101.e1-1101.e8
- Maron DJ (see Boden et al). 2006;151:1173-9 (Trial design)
- Marshall DA, Vernalis MN, Remaley AT, Walizer EM, Scally JP, Taylor AJ. The role of exercise in modulating the impact of an ultralow-fat diet on serum lipids and apolipoproteins in patients with or at risk for coronary artery disease. 2006;151:484-91
- Martens S (see Doss et al). 2006;151:943.e1-943.e4
- Marti V (see Alfonso et al). 2006;151:681.e1-681.e9
- Marticho P (see Remadi et al). 2006;151:198.e1-198.e7
- Martin F (see Mansencal et al). 2006;151:1129.e1-1129.e6
- Martinez M (see Detling et al). 2006;151:522-8
- Martini S (see Eggebrecht et al). 2006;151:530-6
- Marwick TH (see Isbel et al). 2006;151:745-53
- Mas J-L (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
- Maschek W (see Steinwender et al). 2006;151:1296.e7-1296.e13
- Masud AZ (see Halkin et al). 2006;151:915.e1-915.e7
- Masuda Y (see Hirakawa et al). 2006;151:1271-5
- Masura J, Tittel P, Gavora P, Podnar T. Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders. 2006;151:755.e7-755.e10
- Maynard C (see Goss et al). 2006;151:1033-42
- Maynard C (see Welinder et al). 2006;151:1059-64
- Mc Fadden EP (see Rodriguez-Granillo et al). 2006;151:1020-4
- McAllister-Williams H (see Mackin and McAllister-Williams). 2006;151:(5)e13 (Letter)
- McAuley P, Myers J, Abella J, Froelicher V. Evaluation of a specific activity questionnaire to predict mortality in men referred for exercise testing. 2006;151:890.e1-890.e7
- McCabe CH (see Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)
- McCabe CH (see Sabatine et al). 2006;151:25-31

- McCarthy B (see Raman et al). 2006;151:736-44
- McCord J (see Daniels et al). 2006;151:999-1005
- McCullough PA, Silver MA, Kennard ED, Kelsey SF, Michaels AD, IEPR Investigators. Impact of body mass index on outcomes of enhanced external counterpulsation therapy. 2006;151:139.e9-139.e13
- McCullough PA (see Brenden et al). 2006;151:1006-11
- McCullough PA (see Daniels et al). 2006;151:999-1005
- McFadden EP (see Agostoni et al). 2006;151:682-9
- McLaughlin MG (see Kandzari et al). 2006;151:1288-95
- McGrew F (see Davidson et al). 2006;151:451-6
- McGuire DK (see Das et al). 2006;151:1087-93
- McKelvie R (see Yoshinaga et al). 2006;151:1324.e11-1324.e18
- McLaughlin M (see Brodie et al). 2006;151:1231-8
- McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Östergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 2006;151:985-91
- McMurray JJV (see Berry et al). 2006;151:1313-21
- McMurray JJV (see Kauf et al). 2006;151:206-12
- McNamara RL (see Bradley et al). 2006;151:1281-7
- McNeer JF (see Davidson et al). 2006;151:451-6
- Meesse R (see Davidson et al). 2006;151:451-6
- Mehilli J (see Schühlen et al). 2006;151:1248-54
- Mehra MR. Optimizing outcomes in the patient with acute decompensated heart failure. 2006;151:571-9 (Curriculum cardiol.)
- Mehran R (see Brodie et al). 2006;151:1231-8
- Mehran R (see Halkin et al). 2006;151:915.e1-915.e7
- Mehran R (see Kandzari et al). 2006;151:1288-95
- Mehran R (see Nikolsky et al). 2006;151:168-75
- Mehta RH (see Froehlich et al). 2006;151:1123-8
- Mehta S (see Mahoney et al). 2006;151:219-27
- Mehta SR (see Natarajan et al). 2006;151:175.e1-175.e6
- Meier B, Sousa E, Guagliumi G, Van den Branden F, Grenadier E, Windecker S, te Riele H, Voudris V, Eltchaninoff H, Lindvall B, Sneed D, Talen A, SVELTE Study Group. Sirolimus-eluting coronary stents in small vessels. 2006;151:1019.e1-1019.e7
- Meine TJ (see Patel et al). 2006;151:316-22
- Mele L (see Mocini et al). 2006;151:192-7
- Melloni C (see Goyal et al). 2006;151:295-307 (Meetings), 1156-72 (Meetings)
- Mendelsohn A (see Fitchett et al). 2006;151:373-9
- Meneveau N (see Schiele et al). 2006;151:661-7
- Menichella G (see Mocini et al). 2006;151:192-7
- Mercado C (see Zagler et al). 2006;151:140-5
- Mercuro G, Saiu F, Deidda M, Mercuro S, Vitale C, Rosano GMC. Impairment of physical exercise capacity in healthy postmenopausal women. 2006;151:923-7
- Mercuro S (see Mercuro et al). 2006;151:923-7
- MERLIN-TIMI 36 Investigators (see Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)
- Messroghli DR (see Taylor et al). 2006;151:891.e1-891.e7
- Meverden RA (see Henkel et al). 2006;151:806-12
- Michaels AD (see McCullough et al). 2006;151:139.e9-139.e13
- Michalsen A, Knoblauch NTM, Lehmann N, Grossman P, Kerkhoff G, Wilhelm FH, Moebus S, Konstantinides S, Binder L, Heusch G, Siffert W, Budde T, Dobos GJ. Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina—the role of GNB3 C825T polymorphism. 2006;151:870-7
- Michelson EL (see McMurray et al). 2006;151:985-91
- Miller RA (see Butler et al). 2006;151:643-53
- Miller TD (see Sorajja et al). 2006;151:426-35
- Milligan PE (see Gage et al). 2006;151:713-19
- Mills JS (see Goyal et al). 2006;151:295-307 (Meetings), 1156-72 (Meetings)
- Minneci S (see Casolo et al). 2006;151:101-8
- Mintz GS (see Pregowski et al). 2006;151:898-901
- Minutello RM, Chou ET, Hong MK, Wong SC. Impact of race and ethnicity on in-hospital outcomes after percutaneous coronary intervention (report from the 2000-2001 New York State Angioplasty Registry). 2006;151:164-7
- MIRACLE and MIRACLE-ICD Investigators (see Pires et al). 2006;151:837-43
- Mitchell RG (see Goyal et al). 2006;151:295-307 (Meetings)
- Mitry E (see Mansencal et al). 2006;151:1129.e1-1129.e6
- Mittleman MA (see Mukamal et al). 2006;151:368-72
- Mocini D, Staibano M, Mele L, Giannantonio P, Menichella G, Colivicchi F, Sordini P, Salera P, Tubaro M, Santini M. Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting. 2006;151:192-7
- Modenesi JC (see Ferreiros et al). 2006;151:545-52
- Modic MT (see Schoenhagen et al). 2006;151:945-8 (Editorial)
- Moebus S (see Michalsen et al). 2006;151:870-7
- Mohacsi P (see Krum et al). 2006;151:55-61
- Mohr FW (see Ong et al). 2006;151:1194-204 (Trial design)
- Mollard E (see Chevalier et al). 2006;151:191.e1-191.e6
- Moller JE, Hillis GS, Oh JK, Reeder GS, Gersh BJ, Pellikka PA. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. 2006;151:419-25
- Monami M (see Balzi et al). 2006;151:1094-100
- Monserrat L (see Peteiro et al). 2006;151:1324.e1-1324.e10
- Montalescot G (see Goodman et al). 2006;151:654-60
- Montano C (see Fragasso et al). 2006;151:1238.e1-1238.e8
- Moolchan ET (see Gorelick et al). 2006;151:754.e1-754.e5
- Moon DH (see Lee et al). 2006;151:158-63
- Morel M-A (see Ong et al). 2006;151:1194-204 (Trial design)
- Morenghi E (see Mangiacavalli et al). 2006;151:477.e1-477.e6
- Morice M-C (see Ong et al). 2006;151:1194-204 (Trial design)
- Morin J (see Yoshinaga et al). 2006;151:1324.e11-1324.e18
- Moris C (see Alfonso et al). 2006;151:681.e1-681.e9
- Moritz A (see Doss et al). 2006;151:943.e1-943.e4
- Morrow DA, Scirica BM, Karwowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E, MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. 2006;151:1186.e1-1186.e9 (Trial design)
- Morrow DA (see Januzzi Jr et al). 2006;151:360-6
- Morrow DA (see Sabatine et al). 2006;151:25-31
- Mueller-Brand J (see Staub et al). 2006;151:1223-30
- Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. Inflammation and long-term mortality in acute congestive heart failure. 2006;151:845-50
- Mueller C, Laule-Kilian K, Frana B, Rodriguez D, Scholer A, Schindler C, Perruchoud AP. Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. 2006;151:471-7
- Mueller C, Neumann FJ, Hochholzer W, Trenk D, Zeller T, Perruchoud AP, Buettner HJ. The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction. 2006;151:1214.e1-1214.e7

- Mueller C (see Staub et al). 2006;151:1223-30
Mueller PS (see Benson et al). 2006;151:934-42
Muhlbaier (see Allen LaPointe et al). 2006;151:992-8
Mukamal KJ, Girotra S, Mittleman MA. Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts. 2006;151:368-72
Mukherjee D (see Froehlich et al). 2006;151:1123-8
Mulder BJM (see Oosterhof et al). 2006;151:265-72 (Curriculum cardiol.)
Mulder BJM (see Vriend et al). 2006;151:242-7
Müller CP (see Boriani et al). 2006;151:1050-8
Mulray S (see Tonkin et al). 2006;151:1305-12
Mulvagh SL (see Ling et al). 2006;151:882-9
Murphy S (see Smith et al). 2006;151:338-44
Murphy SA (see Atar et al). 2006;151:976.e1-976.e6
Murphy SA (see Januzzi Jr et al). 2006;151:360-6
Murray GD (see Hernández et al). 2006;151:257-64 (Curriculum cardiol.)
Murray RD (see Klein et al). 2006;151:380-9
Myers J (see Arena et al). 2006;151:851.e7-851.e13
Myers J (see McAuley et al). 2006;151:890.e1-890.e7
Myers MG (see van Gilst et al). 2006;151:1240-6

N

- Nacinovich F (see Ferreiros et al). 2006;151:545-52
Najjar SS (see Spaeder et al). 2006;151:844.e1-844.e10
NanYao S (see Chevalier et al). 2006;151:191.e1-191.e6
Napodano M (see Briguori et al). 2006;151:674-80
Nascimben L (see Gogbashian et al). 2006;151:1325-33
Natarajan MK, Velianou JL, Turpie AGG, Mehta SR, Raco D, Goodhart DM, Afzal R, Ginsberg JS. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. 2006;151:175.e1-175.e6
Nath J, Vacek JL, Heidenreich PA. A dilated inferior vena cava is a marker of poor survival. 2006;151:730-5
Navarro Estrada JL, Rubinstein F, Bahit MC, Rolandi F, Perez de Arenaza D, Gabay JM, Alvarez J, Sarmiento R, Rojas Matas C, Szejfman C, Tettamanzi A, de Miguel R, Guzman L, PACS Investigators. NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes. 2006;151:1093.e1-1093.e7
Naylor CD (see Parker and Naylor). 2006;151:580-8 (Curriculum cardiol.)
Nease R (see Weintraub et al). 2006;151:1180-5 (Trial design)
Negoiu M (see Nikolsky et al). 2006;151:168-75
Nelson RA (see Gorelick et al). 2006;151:754.e1-754.e5
Nelson RG (see Jimenez-Corona et al). 2006;151:1080-6
Neumann FJ (see Mueller et al). 2006;151:1214.e1-1214.e7
Neutel JM (see White et al). 2006;151:176-84
Newby LK (see Galla et al). 2006;151:16-24
Newby LK (see Januzzi Jr et al). 2006;151:360-6
Newby LK (see Roe et al). 2006;151:1205-13
Newman AB (see Barasch et al). 2006;151:39-47
Newton M (see Butler et al). 2006;151:643-53
Ngwu O (see Hreybe et al). 2006;151:852-6
Nibali L (see D'Aiuto et al). 2006;151:977-84
Nielsen TT (see Kaltoft et al). 2006;151:1108-14
Nigam A, Bourassa MG, Fortier A, Guertin M-C, Tardif J-C. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. 2006;151:514-21

- Nikolsky E, Stone GW, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, Lansky AJ, Mehran R. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. 2006;151:168-75
Nishimura R (see Detling et al). 2006;151:522-8
Nishimura RA (see Ling et al). 2006;151:882-9
Nishioka H (see Hasegawa et al). 2006;151:332-7
Nissen SE (see Schoenhagen et al). 2006;151:945-8 (Editorial)
Noll G (see Sudano et al). 2006;151:1147-55 (Curriculum cardiol.)
Norrie J (see Berry et al). 2006;151:1313-21
Nowak R (see Brenden et al). 2006;151:1006-11
Nowak RM (see Daniels et al). 2006;151:999-1005
Nul D (see Ballantyne et al). 2006;151:975.e1-975.e9
Nusbaumer C (see Staub et al). 2006;151:1223-30

O

- O'Brien B (see Weintraub et al). 2006;151:1180-5 (Trial design)
O'Connor C (see Davidson et al). 2006;151:451-6
O'Connor C (see Serebrany et al). 2006;151:92-9
O'Connor CM (see Felker et al). 2006;151:457-62
O'Donnell CJ (see Allen et al). 2006;151:1065-71
Offenbacher S (see Elter et al). 2006;151:47.e1-47.e6
Oggionni S (see Fragasso et al). 2006;151:1238.e1-1238.e8
Oh B-H (see Park et al). 2006;151:864-9
Oh JK (see Moller et al). 2006;151:419-25
Oh S-J (see Lee et al). 2006;151:158-63
Oh SJ (see Lee et al). 2006;151:158-63
O'Hara GE (see Raitt et al). 2006;151:390-6
Ohlsson A (see Svensson et al). 2006;151:798.e1-798.e7
Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liao C-S, Mas J-L, Richard A-J, Röther J, Wilson PWF, REACH Registry Investigators. The REDuction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. 2006;151:786.e1-786.e10 (Trial design)
Ohman EM (see Galla et al). 2006;151:16-24
Ohman EM (see Januzzi Jr et al). 2006;151:360-6
Ohman EM (see Roe et al). 2006;151:1205-13
Okmen E (see Uyarel et al). 2006;151:1239.e1-1239.e7
Olendzki B (see Goldberg et al). 2006;151:1297-304
Olivetto I (see Balzi et al). 2006;151:1094-100
Olofsson B (see McMurray et al). 2006;151:985-91
Olympios CD (see Zairis et al). 2006;151:892-7
Omland T (see Daniels et al). 2006;151:999-1005
Omland T (see Kragelund et al). 2006;151:712.e1-712.e7
Ommen SR (see Sorajja et al). 2006;151:426-35
On-TIME study group (see Smit et al). 2006;151:1102-7
On-TIME study group (see van't Hof et al). 2006;151:1255.e1-1255.e5
Ong ATL, Serruys PW, Mohr FW, Morice M-C, Kappetein AP, Holmes DR Jr, Mack MJ, van den Brand M, Morel M-A, van Es G-A, Kleijne J, Koglin J, Russell ME. The SYNergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. 2006;151:1194-204 (Trial design)
Ong ATL (see Pedersen et al). 2006;151:367.e1-367.e6
Ong TK, Chin SP, Liew CK, Chan WL, Seyfarth MT, Liew HB, Rapae A, Fong YYA, Ang CK, Sim KH. Accuracy of 64-row multidetector computed tomography in detecting coronary artery disease in 134 symptomatic patients: influence of calcification. 2006;151:1323.e1-1323.e6

- Oosterhof T, Mulder BJM, Vliegen HW, de Roos A. Cardiovascular magnetic resonance in the follow-up of patients with corrected tetralogy of Fallot: a review. 2006;151:265-72 (Curriculum cardiol.)
- O'Rourke R (see Weintraub et al). 2006;151:1180-5 (Trial design)
- O'Rourke RA (see Boden et al). 2006;151:1173-9 (Trial design)
- Orsinelli DA (see Klein et al). 2006;151:380-9
- O'Shea JC, Califf RM. 24-hour ambulatory blood pressure monitoring. 2006;151:962-8 (Meetings)
- Östergren J (see McMurray et al). 2006;151:985-91
- Ottavanger JP (see De Luca et al). 2006;151:1256-9, 1296.e1-1296.e6
- Ottavanger JP (see Elsmann et al). 2006;151:1239.e9-1239.12
- Ottavanger JP (see Smit et al). 2006;151:1102-7
- Ottavanger JP (see van't Hof et al). 2006;151:1255.e1-1255.e5
- Owen A. Life expectancy of elderly and very elderly patients with chronic heart failure. 2006;151:1322.e1-1322.e4

P

- Pachinger O (see Alber et al). 2006;151:139.e1-139.e7
- Packer D (see Fountain et al). 2006;151:956-61 (Trial design)
- Packer M (see Krum et al). 2006;151:55-61
- PACS Investigators (see Estrada et al). 2006;151:1093.e1-1093.e7
- Padder FA (see Raitt et al). 2006;151:390-6
- Page RL (see Pritchett et al). 2006;151:1043-9
- Pahlm O (see Welinder et al). 2006;151:1059-64
- Palareti G (see Giardini et al). 2006;151:922.e1-922.e5
- Pallosi A (see Fragasso et al). 2006;151:1238.e1-1238.e8
- Palmer JG (see Spaeder et al). 2006;151:844.e1-844.e10
- Palmieri V (see Kizer et al). 2006;151:412-18
- Pan L (see Edvardsen et al). 2006;151:109-14
- Panagiotakos D (see Katrakis et al). 2006;151:1107.e1-1107.e7
- Paran E (see Engelhard et al). 2006;151:100.e1-100.e6
- Parikh A (see Gregory et al). 2006;151:1013-19
- Park J-H (see Lee et al). 2006;151:158-63
- Park J-S, Zhang S-Y, Jo S-H, Seo J-B, Li L, Park K-W, Oh B-H, Park Y-B, Kim H-S. Common adrenergic receptor polymorphisms as novel risk factors for vasospastic angina. 2006;151:864-9
- Park K-W (see Park et al). 2006;151:864-9
- Park S-J (see Lee et al). 2006;151:158-63
- Park S-W (see Lee et al). 2006;151:158-63
- Park Y-B (see Park et al). 2006;151:864-9
- Parkar M (see D'Aiuto et al). 2006;151:977-84
- Parkash R, Green MS. Potential mechanisms between atrial dilatation and atrial fibrillation. 2006;151(2):e3 (Letter reply)
- Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. 2006;151:397-403
- Parker AB, Naylor CD. Interpretation of subgroup results in clinical trial publications: insights from a survey of medical specialists in Ontario, Canada. 2006;151:580-8 (Curriculum cardiol.)
- Pasanisi E (see Rigo et al). 2006;151:124-30
- Pasceri V, Patti G, Cammarota G, Pristipino C, Richichi G, Di Sciacio G. Virulent strains of *Helicobacter pylori* and vascular diseases: a meta-analysis. 2006;151:1215-22
- Pascotto P (see Briguori et al). 2006;151:674-80
- Patel MR, Donahue M, Wilson PWF, Califf RM. Clinical trial issues in weight-loss therapy. 2006;151:633-42 (Meetings)
- Patel MR, Meine TJ, Lindblad L, Griffin J, Granger CB, Becker RC, Van de Werf F, White H, Califf RM, Harrington RA. Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. 2006;151:316-22
- Patsourakos NG (see Zairis et al). 2006;151:892-7
- Patterson C. A salty salute: progenitor cell therapies and no-option heart disease. 2006;151:553-5 (Editorial)
- Patti G (see Pasceri et al). 2006;151:1215-22
- Pawar R (see Rodriguez-Granillo et al). 2006;151:1025.e1-1025.e6
- Payton OD (see Riddle and Payton). 2006;151(6):e5 (Letter)
- Peberdy MA (see Arena et al). 2006;151:851.e7-851.e13
- Pedersen SS, Ong ATL, Sonnenschein K, Serruys PW, Erdman RAM, van Domburg RT. Type D personality and diabetes predict the onset of depressive symptoms in patients after percutaneous coronary intervention. 2006;151:367.e1-367.e6
- Pellikka PA (see Arruda et al). 2006;151:744.e1-744.e6
- Pellikka PA (see Ling et al). 2006;151:882-9
- Pellikka PA (see Moller et al). 2006;151:419-25
- Pepine CJ (see Cooper-DeHoff et al). 2006;151:1072-9
- Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry Investigators (see Holper et al). 2006;151:69-75
- Perez A (see Daniels et al). 2006;151:999-1005
- Perez de Arenaza D (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
- Perez-Vizcayno MJ (see Alfonso et al). 2006;151:681.e1-681.e9
- Perna ER, Barbagelata A, Grinfeld L, Garcia Ben M, Cimbaro Canella JP, Bayol PA, Sosa Liprandi A. Overview of acute decompensated heart failure in Argentina: lessons learned from 5 registries during the last decade. 2006;151:84-91
- Perruchoud AP (see Mueller et al). 2006;151:471-7, 845-50, 1214.e1-1214.e7
- Perruchoud AP (see Staub et al). 2006;151:1223-30
- Perry K (see Gregory et al). 2006;151:1013-19
- Perseghin G (see Fragasso et al). 2006;151:1238.e1-1238.e8
- Pescatello LS (see Guidry et al). 2006;151:1322.e5-1322.e12
- Peschle C (see Briguori et al). 2006;151:674-80
- Petcherski S (see Goldberg et al). 2006;151:1265-70
- Peteiro J, Monserrat L, Piñeiro M, Calviño R, Vazquez JM, Mariñas J, Castro-Beiras A. Comparison of exercise echocardiography and the Duke treadmill score for risk stratification in patients with known or suspected coronary artery disease and normal resting electrocardiogram. 2006;151:1324.e1-1324.e10
- Peters J (see Eggebrecht et al). 2006;151:530-6
- Petersen LA (see Rumsfeld et al). 2006;151:32-8
- Peterson E (see Spertus et al). 2006;151:589-97 (Trial design)
- Peterson ED (see Kulkarni et al). 2006;151:185-91
- Peterson ED (see Roe et al). 2006;151:1205-13
- Peterson ED (see Rumsfeld et al). 2006;151:32-8
- Pettitt D (see Astor et al). 2006;151:492-500
- Pfeffer MA (see Lewis et al). 2006;151:699-705
- Pfeffer MA (see McMurray et al). 2006;151:985-91
- Pfisterer M (see Brunner-La Rocca et al). 2006;151:949-55 (Trial design)
- Pfisterer ME (see Jeger et al). 2006;151:508-13
- Pfisterer ME (see Staub et al). 2006;151:1223-30
- Phillips RC (see Goss et al). 2006;151:1033-42
- Picano E (see Rigo et al). 2006;151:124-30
- Picard MH (see Reynolds et al). 2006;151:890.e9-890.e15
- Picchio FM (see Giardini et al). 2006;151:922.e1-922.e5
- Pichler R (see Steinwender et al). 2006;151:1296.e7-1296.e13
- Pieper K (see Januzzi Jr et al). 2006;151:360-6
- Pilosof R (see Berdagué et al). 2006;151:690-8
- Pilote L (see Zhou et al). 2006;151:273-81 (Curriculum cardiol.)
- Piñeiro M (see Peteiro et al). 2006;151:1324.e1-1324.e10
- Pini D (see Mangiacavalli et al). 2006;151:477.e1-477.e6
- Pinsky DJ (see Cavusoglu et al). 2006;151:1101.e1-1101.e8

- Pinto DS, Southard M, Ciaglio L, Gibson CM. Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction. 2006;151:S27-9
- Pinto R (see Blackman et al). 2006;151:146-52
- Piot C (see Berdagué et al). 2006;151:690-3
- Pires LA, Abraham WT, Young JB, Johnson KM, MIRACLE and MIRACLE-ICD Investigators. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. 2006;151:837-43
- Plomondon ME (see Rumsfeld et al). 2006;151:32-8
- Podnar T (see Masura et al). 2006;151:755.e7-755.e10
- Poerner TC (see Kraleiv et al). 2006;151:153-7
- Pokov AN (see Serebruany et al). 2006;151:92-9
- Poldermans D (see Bountiokos et al). 2006;151:1323.e7-1323.e12
- Pollack CV Jr (see Roe et al). 2006;151:1205-13
- Pomè G (see Butera et al). 2006;151:228-34
- Popma JJ (see Halkin et al). 2006;151:915.e1-915.e7
- Porcellini A (see Briguori et al). 2006;151:674-80
- Porter TR (see Klein et al). 2006;151:380-9
- POST II Investigators (see Raj et al). 2006;151:1186.e11-1186.e17 (Trial design)
- Poutanen T, Tikanoja T, Jääskeläinen P, Jokinen E, Silvast A, Laakso M, Kuusisto J. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes. 2006;151:725.e1-725.e9
- Prandstraller D (see Giardini et al). 2006;151:922.e1-922.e5
- Prapavessis H (see Hammett et al). 2006;151:367.e7-367.e16
- Pregowski J, Tyczynski P, Mintz GS, Kim S-W, Witkowski A, Satler L, Kruk M, Waksman R, Machara A, Weissman NJ. Intravascular ultrasound assessment of the spatial distribution of ruptured coronary plaques in the left anterior descending coronary artery. 2006;151:898-901
- Prekates AA (see Zairis et al). 2006;151:892-7
- Preston KL (see Gorelick et al). 2006;151:754.e1-754.e5
- Pristipino C (see Pasceri et al). 2006;151:1215-22
- Pritchett ELC, Kowey P, Connolly S, Page RL, Kerr C, Wilkinson WE, A-COMET-1 Investigators. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. 2006;151:1043-9
- Probst C (see Jeger et al). 2006;151:508-13
- Pruitt JD, Bensimhon D, Kraus WE. Nutrition as a contributor and treatment option for overweight and obesity. 2006;151:628-32 (Meetings)
- R**
- Raco D (see Natarajan et al). 2006;151:175.e1-175.e6
- Radford MJ (see Bradley et al). 2006;151:1281-7
- Radford MJ (see Gage et al). 2006;151:713-19
- Rahme E (see Zhou et al). 2006;151:273-81 (Curriculum cardiol.)
- Raichlen JS (see Ballantyne et al). 2006;151:975.e1-975.e9
- Raitt MH, Volgman AS, Zoble RG, Charbonneau L, Padder FA, O'Hara GE, Kerr D, AFFIRM Investigators. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. 2006;151:390-6
- Raj SR, Rose S, Ritchie D, Sheldon RS, POST II Investigators. The Second Prevention of Syncope Trial (POST II)—a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: rationale and study design. 2006;151:1186.e11-1186.e17 (Trial design)
- Rajagopal V (see Karha et al). 2006;151:976.e7-976.e11
- Rakotoarivelo Z (see Remadi et al). 2006;151:198.e1-198.e7
- Ramaciotti C (see Lemler et al). 2006;151:928-33
- Raman SV, Shah M, McCarthy B, Garcia A, Ferketich AK. Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance. 2006;151:736-44
- Ramee S (see Halkin et al). 2006;151:915.e1-915.e7
- Rapace A (see Ong et al). 2006;151:1323.e1-1323.e6
- Rasoul S (see van't Hof et al). 2006;151:1255.e1-1255.e5
- Raviele A (see Rigo et al). 2006;151:124-30
- Ray W (see Butler et al). 2006;151:643-53
- REACH Registry Investigators (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
- Rector TS (see Hauptman et al). 2006;151:213-18
- Redfield MM (see Ammar et al). 2006;151:799-805
- Redheuil A (see Mansencal et al). 2006;151:1129.e1-1129.e6
- REDHOT Investigators (see Brenden et al). 2006;151:1006-11
- Reeder GS (see Moller et al). 2006;151:419-25
- Rega L (see Casolo et al). 2006;151:101-8
- Regar E (see Rodriguez-Granillo et al). 2006;151:1020-4, 1025.e1-1025.e6
- Regoli F (see Mangiacavacchi et al). 2006;151:477.e1-477.e6
- Rehling M (see Kaltoft et al). 2006;151:1108-14
- Reimers B (see Briguori et al). 2006;151:674-80
- Reisman M (see Goss et al). 2006;151:1033-42
- Remadi JP, Rakotoarivelo Z, Marticho P, Benamar A. Prospective randomized study comparing coronary artery bypass grafting with the new mini-extracorporeal circulation Jostra System or with a standard cardiopulmonary bypass. 2006;151:198.e1-198.e7
- Remaley AT (see Marshall et al). 2006;151:484-91
- Reny J-L (see Berdagué et al). 2006;151:690-8
- Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) Investigators (see Alfonso et al). 2006;151:681.e1-681.e9
- Restier L (see Chevalier et al). 2006;151:191.e1-191.e6
- Resynchronization for the Hemodynamic Treatment for Heart Failure Management II (RHYTHM II) investigators (see Boriani et al). 2006;151:1050-8
- REVERSE Study Group (see Linde et al). 2006;151:288-94 (Trial design)
- Reynolds HR, Anand SK, Fox JM, Harkness S, Dzavik V, White HD, Webb JG, Gin K, Hochman JS, Picard MH. Restrictive physiology in cardiogenic shock: observations from echocardiography. 2006;151:890.e9-890.e15
- Rhodes JF (see Latson et al). 2006;151:1129.e7-1129.e11
- Rich MW (see Gage et al). 2006;151:713-19
- Rich SS (see Burdon et al). 2006;151:706-11
- Richard A-J (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
- Richards AM (see Baggish et al). 2006;151:48-54
- Richichi G (see Pasceri et al). 2006;151:1215-22
- Richieri M (see Rigo et al). 2006;151:124-30
- Rickenbacher P (see Brunner-La Rocca et al). 2006;151:949-55 (Trial design)
- Riddle DL, Payton OD. Monitoring clinical changes in patients with heart failure: a comparison of methods. 2006;151:(6)e5 (Letter)
- Rifai N (see Lipshultz et al). 2006;151:916-22

- Rigo F, Cortigiani L, Pasanisi E, Richieri M, Cutaia V, Celestre M, Raviele A, Picano E. The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria. A transthoracic vasodilator stress echocardiography study. 2006;151:124-30
- Riksen NP, Smits P, Rongen RA. To the Editor. 2006;151:(5)e9 (Letter)
- Rimer D (see Goldberg et al). 2006;151:1265-70
- Ritchie D (see Raj et al). 2006;151:1186.e11-1186.e17 (Trial design)
- Robin NH (see Johnson et al). 2006;151:1012.e7-1012.e14
- Rodeheffer RJ (see Ammar et al). 2006;151:799-805
- Rodriguez A (see Coyle et al). 2006;151:1032.e9-1032.e12
- Rodriguez D (see Mueller et al). 2006;151:471-7
- Rodriguez-Granillo GA, Garcia-Garcia HM, Valgimigli M, Schaar JA, Pawar R, van der Giessen WJ, Regar E, van der Steen AFW, de Feyter TJ, Serruys PW. In vivo relationship between compositional and mechanical imaging of coronary arteries: insights from intravascular ultrasound radiofrequency data analysis. 2006;151:1025.e1-1025.e6
- Rodriguez-Granillo GA, Mc Fadden EP, Valgimigli M, van Mieghem CAG, Regar E, de Feyter TJ, Serruys PW. Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radiofrequency data analysis, is related to clinical presentation. 2006;151:1020-4
- Roe MT, Peterson ED, Newby LK, Chen AY, Pollack CV Jr, Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Braunwald E, Gibler WB, Ohman EM. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. 2006;151:1205-13
- Roe MT (see Galla et al). 2006;151:16-24
- Roecker EB (see Krum et al). 2006;151:55-61
- Roger VL (see Henkel et al). 2006;151:806-12
- Rogers C (see Halkin et al). 2006;151:915.e1-915.e7
- Roguin A (see Goldberg et al). 2006;151:1265-70
- Rohit M (see Singh et al). 2006;151:851.e1-851.e5
- Rojas Matas C (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
- Rolandi F (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
- Rollins S (see Armstrong et al). 2006;151:787-90
- Rollins S (see Benson et al). 2006;151:934-42
- Roman MJ (see Kizer et al). 2006;151:412-18
- Rongen RA (see Riksen et al). 2006;151:(5)e9 (Letter)
- Rosario S (see Atar et al). 2006;151:976.e1-976.e6
- Rosano GMC (see Mercurio et al). 2006;151:923-7
- Rose S (see Raj et al). 2006;151:1186.e11-1186.e17 (Trial design)
- Rosen BD (see Edvardsen et al). 2006;151:109-14
- Rosenson RR. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. 2006;151:556-63
- Rosneck J (see Hughes et al). 2006;151:1122.e1-1122.e6
- Ross JR (see Blackman et al). 2006;151:146-52
- Röther J (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
- Rougier P (see Mansencal et al). 2006;151:1129.e1-1129.e6
- Rouleau J-L (see Kauf et al). 2006;151:206-12
- Rouleau J-L (see Krum et al). 2006;151:55-61
- Rouleau J-L (see van Gilst et al). 2006;151:1240-6
- Rubinstein F (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
- Rumberger JA (see Hecht et al). 2006;151:1139-46 (Curriculum cardiol.)
- Rumsfeld JS, Magid DJ, Peterson ED, Plomondon ME, Petersen LA, Grunwald GK, Every NR, Sales AE. Outcomes after acute coronary syndrome admission to primary versus tertiary Veterans Affairs medical centers: the Veterans Affairs Access to Cardiology study. 2006;151:32-8
- Rumsfeld JS (see Spertus et al). 2006;151:589-97 (Trial design)
- Russell ME (see Ong et al). 2006;151:1194-204 (Trial design)
- Ruwende C (see Cavusoglu et al). 2006;151:1101.e1-1101.e8

S

- Saba S (see Hreybe et al). 2006;151:852-6
- Sabatine MS, Morrow DA, McCabe CH, Antman EM, Gibson CM, Cannon CP. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-segment elevation myocardial infarction. 2006;151:25-31
- Sabatine MS (see Januzzi Jr et al). 2006;151:360-6
- Saiu F (see Mercurio et al). 2006;151:923-7
- Salamé E (see Azar et al). 2006;151:521.e1-521.e4
- Salera P (see Mocini et al). 2006;151:192-7
- Sales AE (see Rumsfeld et al). 2006;151:32-8
- Sallabarger M (see Tonkin et al). 2006;151:1305-12
- Salomone L (see Giardini et al). 2006;151:922.e1-922.e5
- Saltzberg M (see Brenden et al). 2006;151:1006-11
- Sanborn TA (see Berger et al). 2006;151:1026-31
- Sand NP (see Kaltoft et al). 2006;151:1108-14
- Sane DC (see Serebruany et al). 2006;151:92-9
- Santini M (see Mocini et al). 2006;151:192-7
- Santoro GM (see Balzi et al). 2006;151:1094-100
- Sapp SK (see Galla et al). 2006;151:16-24
- Sarais C (see Briguori et al). 2006;151:674-80
- Sarmiento R (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
- Sarnak MJ (see Astor et al). 2006;151:492-500
- Satler L (see Pregowski et al). 2006;151:898-901
- Scally JP (see Marshall et al). 2006;151:484-91
- Scarano M (see Macchia et al). 2006;151:754.e7-754.e17
- Schaar JA (see Rodriguez-Granillo et al). 2006;151:1025.e1-1025.e6
- Schiele F, Legale P, Didier K, Meneveau N, Seronde MF, Caulfield F, Ducloux D, Bechetoille P, Magnin D, Faivre R, Bassand J-P. Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. 2006;151:661-7
- Schindler C (see Mueller et al). 2006;151:471-7
- Schindler R (see Brunner-La Rocca et al). 2006;151:949-55 (Trial design)
- Schinkel AFL (see Bountiokos et al). 2006;151:1323.e7-1323.e12
- Schirmer M (see Alber et al). 2006;151:139.e1-139.e7
- Schlegl M (see Butter et al). 2006;151:115-23
- Schmermund A (see Eggebrecht et al). 2006;151:530-6
- Schneider B (see Stöhlberger et al). 2006;151:(6)e1 (Letter)
- Schneider R (see Davidson et al). 2006;151:451-6
- Schoenbeck U (see Hammett et al). 2006;151:367.e7-367.e16
- Schoenhagen P, Stillman AE, Garcia MJ, Halliburton SS, Tuzcu EM, Nissen SE, Modic MT, Lytle BW, Topol EJ, White RD. Coronary artery imaging with multidetector computed tomography: a call for an evidence-based, multidisciplinary approach. 2006;151:945-8 (Editorial)
- Scholer A (see Mueller et al). 2006;151:471-7
- Schömig A (see Dibra et al). 2006;151:(5)e7 (Letter reply)
- Schömig A (see Schühlen et al). 2006;151:1248-54
- Schron E (see Lewis et al). 2006;151:699-705
- Schuchert A (see Boriani et al). 2006;151:1050-8
- Schühlen H, Kastrati A, Mehilli J, Hausleiter J, Dirschinger J, Dotzer F, Bollwein H, Schömig A. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the

- angiographic substudy of ISAR-REACT—a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. 2006;151:1248-54
- Schuijff JD, Bax JJ, Shaw LJ, de Roos A, Lamb HJ, van der Wall EE, Wijns W. Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. 2006;151:404-11
- Schulman KA (see Kauf et al). 2006;151:206-12
- Schulz-Menger J (see Taylor et al). 2006;151:891.e1-891.e7
- Schuster G (see Steinwender et al). 2006;151:1296.e7-1296.e13
- Schwamm LH (see Smith et al). 2006;151:338-44
- Scirica BM (see Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)
- Scott WA (see Lemler et al). 2006;151:928-33
- Seabra-Gomes R (see Alfonso et al). 2006;151:681.e1-681.e9
- Sedighian S (see Berdagué et al). 2006;151:690-8
- Sedrakyan A, Zhang H, Treasure T, Krumholz HM. Recursive partitioning-based preoperative risk stratification for atrial fibrillation after coronary artery bypass surgery. 2006;151:720-5
- Seeberger MD (see Jeger et al). 2006;151:508-13
- Seidlin PH (see Blackman et al). 2006;151:146-52
- Seidl KH (see Boriani et al). 2006;151:1050-8
- Seifert M (see Butter et al). 2006;151:115-23
- Seip RL (see Guidry et al). 2006;151:1322.e5-1322.e12
- Sekine T (see Kawata et al). 2006;151:798.e9-798.e15
- Selzer F (see Holper et al). 2006;151:69-75
- Seo J-B (see Park et al). 2006;151:864-9
- Sepic J (see Gogbashian et al). 2006;151:1325-33
- Sequist TD, Zaslavsky AM, Galloway JM, Ayanian JZ. Cardiac procedure use following acute myocardial infarction among American Indians. 2006;151:909-14
- Serebruany VL, Pokov AN, Malinin AI, O'Connor C, Bhatt DL, Tanguay J-F, Sane DC, Hennekens CH. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. 2006;151:92-9
- Seronde MF (see Schiele et al). 2006;151:661-7
- Serruys PW (see Agostoni et al). 2006;151:682-9
- Serruys PW (see Ong et al). 2006;151:1194-204 (Trial design)
- Serruys PW (see Pedersen et al). 2006;151:367.e1-367.e6
- Serruys PW (see Rodriguez-Granillo et al). 2006;151:1020-4, 1025.e1-1025.e6
- SESAMI Study Group (see Alter et al). 2006;151:323-31
- Seyfarth MT (see Ong et al). 2006;151:1323.e1-1323.e6
- Sgarbossa E (see Al-Faleh et al). 2006;151:10-5
- Shah M (see Raman et al). 2006;151:736-44
- Shaw L (see Boden et al). 2006;151:1173-9 (Trial design)
- Shaw LJ (see Schuijff et al). 2006;151:404-11
- Shaw LK (see Felker et al). 2006;151:457-62
- Sheldon RS (see Raj et al). 2006;151:1186.e11-1186.e17 (Trial design)
- Shellock FG, Fieno DS, Thomson LJ, Talavage TM, Berman DS. Cardiac pacemaker: in vitro assessment at 1.5T. 2006;151:436-43
- Sherman W (see Berger et al). 2006;151:1026-31
- Sherwood JB (see Benson et al). 2006;151:934-42
- Shub C (see Arruda et al). 2006;151:744.e1-744.e6
- Siebert U (see Baggish et al). 2006;151:48-54
- Sievers ML (see Jimenez-Corona et al). 2006;151:1080-6
- Siffert W (see Michalsen et al). 2006;151:870-7
- Silvast A (see Poutanen et al). 2006;151:725.e1-725.e9
- Silver MA (see McCullough et al). 2006;151:139.e9-139.e13
- Sim KH (see Ong et al). 2006;151:1323.e1-1323.e6
- Simbre VC II (see Lipshultz et al). 2006;151:916-22
- Simes J (see Tonkin et al). 2006;151:1305-12
- Simon-Lee A (see Coyle et al). 2006;151:1032.e9-1032.e12
- Simoons ML (see Galla et al). 2006;151:16-24
- Simsek D (see Uyarel et al). 2006;151:1239.e1-1239.e7
- Singh S (see Lewis et al). 2006;151:699-705
- Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. 2006;151:851.e1-851.e5
- Sinha S (see Edvardsen et al). 2006;151:109-14
- Skene A (see Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)
- Slingerland RJ (see Smit et al). 2006;151:1102-7
- Smalling RW. Role of fibrinolytic therapy in the current era of ST-segment elevation myocardial infarction management. 2006;151:S17-23
- Smit JJJ, Ernst NMSKJ, Slingerland RJ, Kolkman JJE, Suryapranata H, Hoortjje JCA, Dambrink JH, Ottervanger JP, Gosselink ATM, de Boer MJ, van't Hof AWJ, On-TIME study group. Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome. 2006;151:1102-7
- Smith A (see Detling et al). 2006;151:522-8
- Smith DA (see Galin and Smith). 2006;151:(5)e1 (Letter)
- Smith EE, Cannon CP, Murphy S, Feske SK, Schwamm LH. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes—Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 study. 2006;151:338-44
- Smith SC Jr (see Roe et al). 2006;151:1205-13
- Smits P (see Riksen et al). 2006;151:(5)e9 (Letter)
- Snead D (see Meier et al). 2006;151:1019.e1-1019.e7
- Soltész EG (see Gogbashian et al). 2006;151:1325-33
- Song G (see Gong et al). 2006;151:(5)e11-e12 (Letter reply)
- Sonnenschein K (see Pedersen et al). 2006;151:367.e1-367.e6
- Sorajja P, Chareonthaitawee P, Ommen SR, Miller TD, Hodge DO, Gibbons RJ. Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy. 2006;151:426-35
- Sordini P (see Mocini et al). 2006;151:192-7
- Sosa Liprandi A (see Perna et al). 2006;151:84-91
- Sousa E (see Meier et al). 2006;151:1019.e1-1019.e7
- Southard M (see Pinto et al). 2006;151:S27-9
- Spaeder JA, Najjar SS, Gerstenblith G, Heffter G, Kern L, Palmer JG, Gottlieb SH, Kasper EK. Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits. 2006;151:844.e1-844.e10
- Spencer F (see Goldberg et al). 2006;151:1297-304
- Spencer FA (see Botkin et al). 2006;151:199-205
- Sperling LS (see DeFilippis and Sperling). 2006;151:564-70 (Curriculum cardiol.)
- Speroff T (see Butler et al). 2006;151:643-53
- Spertus J (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Spertus JA. Monitoring clinical changes in patients with heart failure: a comparison of methods. 2006;151:(6)e7 (Letter reply)
- Spertus JA, Peterson E, Rumsfeld JS, Jones PG, Decker C, Krumholz H. Cardiovascular Outcomes Research Consortium. The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)—evaluating the impact of

- myocardial infarction on patient outcomes. 2006;151:589-97 (Trial design)
- Spertus JA (see Boden et al). 2006;151:1173-9 (Trial design)
- Spieker LE (see Sudano et al). 2006;151:1147-55 (Curriculum cardiol.)
- Sprecher DL (see Koro et al). 2006;151:755.e1-755.e6
- Staibano M (see Mocini et al). 2006;151:192-7
- Stanek HG (see Das et al). 2006;151:1087-93
- Stankowski JE (see Greenbaum et al). 2006;151:689.e1-689.e10
- Staub D, Nusbaumer C, Zellweger MJ, Jonas N, Wild D, Pfisterer ME, Mueller-Brand J, Perruchoud AP, Mueller C. Use of B-type natriuretic peptide in the detection of myocardial ischemia. 2006;151:1223-30
- Stecker EC, Fendrick AM, Knight BP, Aaronson KD. Prophylactic pacemaker use to allow β -blocker therapy in patients with chronic heart failure with bradycardia. 2006;151:820-8
- Steffensen R (see Kraglund et al). 2006;151:712.e1-712.e7
- Steg PG (see Daniels et al). 2006;151:999-1005
- Steg PG (see Goodman et al). 2006;151:654-60
- Steg PG (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
- Stein EA (see Ballantyne et al). 2006;151:975.e1-975.e9
- Steinwender C, Hofmann R, Kammiller J, Kypta A, Pichler R, Maschek W, Schuster G, Gabriel C, Leisch F. Effects of peripheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcatheter transplantation after primary stent implantation for acute myocardial infarction. 2006;151:1296.e7-1296.e13
- Stevenson K (see Berry et al). 2006;151:1313-21
- Stevenson WG (see Parkash et al). 2006;151:397-403
- Stewart MJ (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
- Stewart RAH (see Hammett et al). 2006;151:367.e7-367.e16
- Steyerberg EW (see Hernández et al). 2006;151:257-64 (Curriculum cardiol.)
- Stiles R (see Butler et al). 2006;151:643-53
- Stillman AE (see Schoenhagen et al). 2006;151:945-8 (Editorial)
- Stocker EM (see Alber et al). 2006;151:139.e1-139.e7
- Stoddard MF (see Klein et al). 2006;151:380-9
- Stöllberger C, Schneider B, Finsterer J. Benefits of left atrial appendage occlusion. 2006;151:6.e1 (Letter)
- Stone GW (see Brodie et al). 2006;151:1231-8
- Stone GW (see Halkin et al). 2006;151:915.e1-915.e7
- Stone GW (see Kandzari et al). 2006;151:1288-95
- Stone GW (see Nikolsky et al). 2006;151:168-75
- Storrow AB (see Daniels et al). 2006;151:999-1005
- Stough WG (see Felker et al). 2006;151:457-62
- Strande S (see Kraglund et al). 2006;151:712.e1-712.e7
- Stromberg D (see Lemler et al). 2006;151:928-33
- Stuckey T (see Kandzari et al). 2006;151:1288-95
- Stuckey T (see Nikolsky et al). 2006;151:168-75
- Stuckey TD (see Brodie et al). 2006;151:1231-8
- Stump TE (see Koro et al). 2006;151:755.e1-755.e6
- Sudano I, Spieker LE, Noll G, Corti R, Weber R, Lüscher TF. Cardiovascular disease in HIV infection. 2006;151:1147-55 (Curriculum cardiol.)
- Suessenbacher A (see Alber et al). 2006;151:139.e1-139.e7
- Sulla A (see Casolo et al). 2006;151:101-8
- Sulyok E (see Vannay et al). 2006;151:878-81
- Sun X (see Gong et al). 2006;151:62-8
- Suryapranata H (see De Luca et al). 2006;151:1256-9, 1296.e1-1296.e6
- Suryapranata H (see Elsmann et al). 2006;151:1239.e9-1239.12
- Suryapranata H (see Smit et al). 2006;151:1102-7
- Suryapranata H (see van't Hof et al). 2006;151:1255.e1-1255.e5
- Süselbeck T (see Krale et al). 2006;151:153-7
- Sutton A (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
- Suvan J (see D'Aiuto et al). 2006;151:977-84
- SVELTE Study Group (see Meier et al). 2006;151:1019.e1-1019.e7
- Svensson L, Aasa M, Dellborg M, Gibson CM, Kirtane A, Herlitz J, Ohlsson A, Karlsson T, Grip L. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. 2006;151:798.e1-798.e7
- Svilaas T, van der Horst ICC, Zijlstra F. Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)—study design. 2006;151:597.e1-597.e7 (Trial design)
- Svilaas T (see Bergstra et al). 2006;151:345-51
- Swedberg K (see McMurray et al). 2006;151:985-91
- Swieszkowski S (see Ferreiros et al). 2006;151:545-52
- Sztejman C (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7

T

- Takahashi T (see Kaneda et al). 2006;151:726-9
- Takeuchi K (see Hasegawa et al). 2006;151:332-7
- Talavage TM (see Shellock et al). 2006;151:436-43
- Talen A (see Meier et al). 2006;151:1019.e1-1019.e7
- Tan M (see Fitchett et al). 2006;151:373-9
- Tan M (see Goodman et al). 2006;151:791-7
- Tan M (see Yan et al). 2006;151:352-9
- Tanguay J-F (see Serebruany et al). 2006;151:92-9
- Tardif J-C (see Nigam et al). 2006;151:514-21
- Tartan Z (see Uyarel et al). 2006;151:1239.e1-1239.e7
- Tavazzi L (see Macchia et al). 2006;151:754.e7-754.e17
- Taylor AJ, Al-Saadi N, Abdel-Aty H, Schulz-Menger J, Messroghli DR, Gross M, Dietz R, Friedrich MG. Elective percutaneous coronary intervention immediately impairs resting microvascular perfusion assessed by cardiac magnetic resonance imaging. 2006;151:891.e1-891.e7
- Taylor AJ (see Coyle et al). 2006;151:1032.e9-1032.e12
- Taylor AJ (see Marshall et al). 2006;151:484-91
- Taylor AL (see Guidry et al). 2006;151:1322.e5-1322.e12
- Tcheng JE (see Brodie et al). 2006;151:1231-8
- Tcheng JE (see Kandzari et al). 2006;151:1288-95
- Tcheng JE (see Nikolsky et al). 2006;151:168-75
- te Riele H (see Meier et al). 2006;151:1019.e1-1019.e7
- Tendera M (see Krum et al). 2006;151:55-61
- Teo K (see Weintraub et al). 2006;151:1180-5 (Trial design)
- Teo KK (see Boden et al). 2006;151:1173-9 (Trial design)
- Teramoto K (see Kawata et al). 2006;151:798.e9-798.e15
- Terashima M (see Kaneda et al). 2006;151:726-9
- Tettamanzi A (see Navarro Estrada et al). 2006;151:1093.e1-1093.e7
- Theroux P (see Armstrong et al). 2006;151:787-90
- Theroux P (see Ballantyne et al). 2006;151:975.e1-975.e9
- Thomas KL (see Goyal et al). 2006;151:295-307 (Meetings), 1156-72 (Meetings)
- Thompson PD (see Guidry et al). 2006;151:1322.e5-1322.e12
- Thompson PL (see Bradshaw et al). 2006;151:537-44
- Thomson LJ (see Shellock et al). 2006;151:436-43
- Tierney WM (see Koro et al). 2006;151:755.e1-755.e6
- Tikanoja T (see Poutanen et al). 2006;151:725.e1-725.e9
- TIME-CHF-Investigators (see Brunner-La Rocca et al). 2006;151:949-55 (Trial design)
- Ting C-T (see Liu et al). 2006;151:235-41

- Tittel P (see Masura et al). 2006;151:755.e7-755.e10
 Todaro TG (see Armstrong et al). 2006;151:787-90
 Tognoni G (see Macchia et al). 2006;151:754.e7-754.e17
 Tonetti MS (see D'Aiuto et al). 2006;151:977-84
 Tonkin AM, Eckermann S, White H, Friedlander D, Glasziou P, Magnus P, Kirby A, Mulray S, Denton M, Sallaberger M, Hunt D, Simes J, LIPID Study Group. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. 2006;151:1305-12
 Topol EJ (see Chacko et al). 2006;151:1032.e1-1032.e7
 Topol EJ (see Galla et al). 2006;151:16-24
 Topol EJ (see Schoenhagen et al). 2006;151:945-8 (Editorial)
 Toprak N (see Iltumur et al). 2006;151:1115-22
 Towbin JA (see Johnson et al). 2006;151:1012.e7-1012.e14
 Toyoda T (see Kawata et al). 2006;151:798.e9-798.e15
 Traboulsi M (see Goodhart et al). 2006;151:529.e1-529.e6
 Trapp HJ (see Boriani et al). 2006;151:1050-8
 Treasure T (see Sedrakyan et al). 2006;151:720-5
 Trenk D (see Mueller et al). 2006;151:1214.e1-1214.e7
 Treszl A (see Vannay et al). 2006;151:878-81
 Tricoci P (see Goyal et al). 2006;151:295-307 (Meetings), 1156-72 (Meetings)
 Tsao L (see Lee et al). 2006;151:76-83
 Tsuchiya Y (see Chacko et al). 2006;151:1032.e1-1032.e7
 Tu JV (see Austin et al). 2006;151:969-75
 Tu JV (see Cantor et al). 2006;151:902-8
 Tubaro M (see Mocini et al). 2006;151:1231-8
 Tulassay T (see Vannay et al). 2006;151:878-81
 Tung R (see Baggish et al). 2006;151:48-54
 Turco M (see Brodie et al). 2006;151:1231-8
 Turco M (see Halkin et al). 2006;151:915.e1-915.e7
 Turco M (see Kandzari et al). 2006;151:1288-95
 Turco M (see Nikolsky et al). 2006;151:168-75
 Turner AT (see Goyal et al). 2006;151:295-307 (Meetings)
 Turi Z (see Fountain et al). 2006;151:956-61 (Trial design)
 Turpie AGG (see Natarajan et al). 2006;151:175.e1-175.e6
 Turri M (see Agostoni et al). 2006;151:682-9
 Tuzcu EM (see Schoenhagen et al). 2006;151:945-8 (Editorial)
 Tyczynski P (see Pregowski et al). 2006;151:898-901
 Tzanalaridou E (see Katrisis et al). 2006;151:1107.e1-1107.e7

U

- Uchida D (see Kawata et al). 2006;151:798.e9-798.e15
 Ueda M (see Hasegawa et al). 2006;151:332-7
 Uemura K (see Hirakawa et al). 2006;151:1271-5
 Uretsky BF (see Atar et al). 2006;151:976.e1-976.e6
 Uyarel H, Cam N, Okmen E, Kasikcioglu H, Tartan Z, Akgul O, Simsek D, Cetin M, Bozbeyoglu E, Buturak A, Uzunlar B. Level of Selvester QRS score is predictive of ST-segment resolution and 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. 2006;151:1239.e1-1239.e7
 Uzunlar B (see Uyarel et al). 2006;151:1239.e1-1239.e7

V

- Vacek JL (see Nath et al). 2006;151:730-5
 Vaeth PAC (see Das et al). 2006;151:1087-93
 Valagussa F (see Macchia et al). 2006;151:754.e7-754.e17
 Valgimigli M (see Agostoni et al). 2006;151:682-9

- Valgimigli M (see Rodriguez-Granillo et al). 2006;151:1020-4, 1025.e1-1025.e6
 Van de Werf F (see Al-Faleh et al). 2006;151:10-5
 Van de Werf F (see Kim et al). 2006;151:668-73
 Van de Werf F (see Patel et al). 2006;151:316-22
 van de Wetering H (see van't Hof et al). 2006;151:1255.e1-1255.e5
 van den Brand M (see Ong et al). 2006;151:1194-204 (Trial design)
 Van den Branden F (see Meier et al). 2006;151:1019.e1-1019.e7
 van den Heuvel AFM (see Bergstra et al). 2006;151:345-51
 van der Giessen WJ (see Rodriguez-Granillo et al). 2006;151:1025.e1-1025.e6
 van der Horst ICC (see Bergstra et al). 2006;151:345-51
 van der Horst ICC (see Svilaas et al). 2006;151:597.e1-597.e7 (Trial design)
 van der Steen AFW (see Rodriguez-Granillo et al). 2006;151:1025.e1-1025.e6
 van der Wall EE (see Schuijff et al). 2006;151:404-11
 van Domburg RT (see Pedersen et al). 2006;151:367.e1-367.e6
 van Es G-A (see Ong et al). 2006;151:1194-204 (Trial design)
 van Gilst WH, Warnica JW, Baillet R, Johnstone D, Calciu C-D, Block P, Myers MG, Chocron S, Rouleau J-L, IMAGINE Investigators. Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function: Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease. 2006;151:1240-6
 van Mieghem CAG (see Rodriguez-Granillo et al). 2006;151:1020-4
 van't Hof AWJ (see De Luca et al). 2006;151:1296.e1-1296.e6
 Van Tassel R (see Fountain et al). 2006;151:956-61 (Trial design)
 van Veldhuisen DJ (see Hogenhuis et al). 2006;151:1012.e1-1012.e5
 Vannay A, Väsárhelyi B, Környei M, Treszl A, Kozma G, Györfy B, Tulassay T, Sulyok E. Single-nucleotide polymorphisms of VEGF gene are associated with risk of congenital valvuloseptal heart defects. 2006;151:878-81
 van't Hof AWJ, Rasoul S, van de Wetering H, Ernst N, Suryapranata H, Hoorntje JCA, Dambrink J-HE, Gosselink M, Zijlstra F, Ottervanger JP, de Boer MJ, On-TIME study group. Feasibility and benefit of prehospital diagnosis, triage, and therapy by paramedics only in patients who are candidates for primary angioplasty for acute myocardial infarction. 2006;151:1255.e1-1255.e5
 van't Hof AWJ (see De Luca et al). 2006;151:1256-9
 van't Hof AWJ (see Elsmann et al). 2006;151:1239.e9-1239.12
 van't Hof AWJ (see Smit et al). 2006;151:1102-7
 Varini S (see Ferreiros et al). 2006;151:545-52
 Varo N (see Hammett et al). 2006;151:367.e7-367.e16
 Väsárhelyi B (see Vannay et al). 2006;151:878-81
 Vassanelli C (see Agostoni et al). 2006;151:682-9
 Vazquez JM (see Peteiro et al). 2006;151:1324.e1-1324.e10
 Velazquez EJ (see Kauf et al). 2006;151:206-12
 Veledar E (see Weintraub et al). 2006;151:1180-5 (Trial design)
 Velianou JL (see Natarajan et al). 2006;151:175.e1-175.e6
 Venkatesh V (see Alter et al). 2006;151:323-31
 Vergnes C (see Berdagué et al). 2006;151:690-8
 Vernalis MN (see Marshall et al). 2006;151:484-91
 Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA, Harcombe AA, Linker NJ, Stewart MJ, Davies A, de Belder MA. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial

- fibrillation for whom direct current cardioversion is planned. 2006;151:863.e1-863.e6
- Vijayvergiya R (see Singh et al). 2006;151:851.e1-851.e5
- Vinante O (see Briguori et al). 2006;151:674-80
- Vitale C (see Mercuro et al). 2006;151:923-7
- Vivekanathan D (see Gurm et al). 2006;151:1031.e1-1031.e6
- Vlachos H (see Holper et al). 2006;151:69-75
- Vliegen HW (see Oosterhof et al). 2006;151:265-72 (Curriculum cardiol.)
- Vogt J (see Boriani et al). 2006;151:1050-8
- Volgman AS (see Raitt et al). 2006;151:390-6
- Vollrath A (see Alter et al). 2006;151:829-36
- Voors AA (see Hogenhuis et al). 2006;151:1012.e1-1012.e5
- Voudris V (see Meier et al). 2006;151:1019.e1-1019.e7
- Vriend JWJ, de Groot E, de Waal TT, Zijta FM, Kastelein JJP, Mulder BJM. Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair. 2006;151:242-7
- ## W
- Wacchter D (see Hughes et al). 2006;151:1122.e1-1122.e6
- Wagenknecht LE (see Burdon et al). 2006;151:706-11
- Wagner G (see Al-Falch et al). 2006;151:10-5
- Wagner GS (see Davidson et al). 2006;151:451-6
- Wagner GS (see Welinder et al). 2006;151:1059-64
- Waitman LR (see Butler et al). 2006;151:643-53
- Waksman R (see Pregowski et al). 2006;151:898-901
- Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: There remains an unmet need. 2006;151:771-8 (Curriculum cardiol.)
- Walizer EM (see Marshall et al). 2006;151:484-91
- Wallentin L (see Al-Falch et al). 2006;151:10-5
- Wang K-Y (see Liu et al). 2006;151:235-41
- Wang Y (see Bradley et al). 2006;151:1281-7
- Warnica JW (see van Gilst et al). 2006;151:1240-6
- Waterman AD (see Gage et al). 2006;151:713-19
- WAVE Investigators. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. 2006;151:1-9 (Trial design)
- Weaver WD (see Armstrong et al). 2006;151:787-90
- Weaver WD (see Greenbaum et al). 2006;151:689.e1-689.e10
- Weaver WD (see Kauf et al). 2006;151:206-12
- Webb JG (see Reynolds et al). 2006;151:890.e9-890.e15
- Webb-Peploe MM (see Katrisis et al). 2006;151:1107.e1-1107.e7
- Weber MA (see White et al). 2006;151:176-84
- Weber R (see Sudano et al). 2006;151:1147-55 (Curriculum cardiol.)
- Weidinger F (see Alber et al). 2006;151:139.e1-139.e7
- Weintraub WS, Barnett P, Chen S, Hartigan P, Casperson P, O'Rourke R, Boden WE, Lewis C, Veledar E, Becker E, Culler S, Kolm P, Mahoney EM, Dunbar SB, Deaton C, O'Brien B, Goeree R, Blackhouse G, Nease R, Spertus J, Kaufman S, Teo K. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. 2006;151:1180-5 (Trial design)
- Weintraub WS (see Boden et al). 2006;151:1173-9 (Trial design)
- Weintraub WS (see Mahoney et al). 2006;151:219-27
- Weiss R (see Ballantyne et al). 2006;151:975.e1-975.e9
- Weissman NJ (see Pregowski et al). 2006;151:898-901
- Welinder A, Feild DQ, Liebman J, Maynard C, Wagner GS, Wettrell G, Pahlm O. Diagnostic conclusions from the EASI-derived 12-lead electrocardiogram as compared with the standard 12-lead electrocardiogram in children. 2006;151:1059-64
- Wellnhofer E (see Butter et al). 2006;151:115-23
- Wentworth D (see Hauptman et al). 2006;151:213-18
- Westheim A (see Daniels et al). 2006;151:999-1005
- Weston SA (see Henkel et al). 2006;151:806-12
- Wettrell G (see Welinder et al). 2006;151:1059-64
- White H (see Patel et al). 2006;151:316-22
- White H (see Tonkin et al). 2006;151:1305-12
- White HD (see Galla et al). 2006;151:16-24
- White HD (see Hammett et al). 2006;151:367.e7-367.e16
- White HD (see Kauf et al). 2006;151:206-12
- White HD (see Reynolds et al). 2006;151:890.e9-890.e15
- White RD (see Schoenhagen et al). 2006;151:945-8 (Editorial)
- White WB, Giles T, Bakris GL, Neutel JM, Davidai G, Weber MA. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. 2006;151:176-84
- Whitlow PL (see Gurm et al). 2006;151:1031.e1-1031.e6
- Whittaker VJ (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
- Whitten RW (COAP) (see Goss et al). 2006;151:1033-42
- Wijns W (see Schuijff et al). 2006;151:404-11
- Wild D (see Staub et al). 2006;151:1223-30
- Wilensky RL (see Holper et al). 2006;151:69-75
- Wilhelm FH (see Michalsen et al). 2006;151:870-7
- Wilkinson WE (see Pritchett et al). 2006;151:1043-9
- Williams DO (see Holper et al). 2006;151:69-75
- Wilson PWF (see Ohman et al). 2006;151:786.e1-786.e10 (Trial design)
- Wilson PWF (see Patel et al). 2006;151:633-42 (Meetings)
- Wimmer-Greinecker G (see Doss et al). 2006;151:943.e1-943.e4
- Windecker S (see Meier et al). 2006;151:1019.e1-1019.e7
- Witkowski A (see Pregowski et al). 2006;151:898-901
- Witt BJ (see Henkel et al). 2006;151:806-12
- Witteveen JCM (see Brouwer et al). 2006;151:857-62
- Wolpert C (see Kralek et al). 2006;151:153-7
- Wolski KE (see Chacko et al). 2006;151:1032.e1-1032.e7
- Wong JCL (see Lipshultz et al). 2006;151:916-22
- Wong SC (see Minutello et al). 2006;151:164-7
- Wood JP (see Doss et al). 2006;151:943.e1-943.e4
- Wright RA (see Vijayalakshmi et al). 2006;151:863.e1-863.e6
- Wu AHB (see Daniels et al). 2006;151:999-1005
- Wu T-J (see Liu et al). 2006;151:235-41
- Wu YX, Jin R, Grunkemeier GL. Validating the Clinical Outcomes Assessment Program risk model for percutaneous coronary intervention. 2006;151:1276-80
- ## Y
- Yamagishi H (see Hasegawa et al). 2006;151:332-7
- Yamamoto K (see Kawata et al). 2006;151:798.e9-798.e15
- Yamashita H (see Hasegawa et al). 2006;151:332-7
- Yan AT (see Yan et al). 2006;151:352-9
- Yan J (see Gong et al). 2006;151:62-8
- Yan RT, Yan AT, Tan M, Chow C-M, Fitchett DH, Ervin FL, Cha JYM, Langer A, Goodman SG, Canadian Acute Coronary Syndromes (ACS) Registry Investigators. Age-related differences in the management and outcome of patients with acute coronary syndromes. 2006;151:352-9
- Yan Y (see Gage et al). 2006;151:713-19
- Yanamadala S (see Cavusoglu et al). 2006;151:1101.e1-1101.e8
- Yarzebski J (see Botkin et al). 2006;151:199-205
- Yarzebski J (see Goldberg et al). 2006;151:1297-304

Yeh RW, Jang I-K. Argatroban: update. 2006;151:1131-8 (Curriculum cardiol.)

Yen MH (see Chacko et al). 2006;151:1032.e1-1032.e7

Yen MH (see Gurm et al). 2006;151:1031.e1-1031.e6

Yock PG (see Kaneda et al). 2006;151:726-9

Yoshida K (see Kawata et al). 2006;151:798.e9-798.e15

Yoshikawa J (see Hasegawa et al). 2006;151:332-7

Yoshinaga K, Beanlands RSB, deKemp RA, Lortie M, Morin J, Aung M, McKelvie R, Davies RF. Effect of exercise training on myocardial blood flow in patients with stable coronary artery disease. 2006;151:1324.e11-1324.e18

Yoshiyama M (see Hasegawa et al). 2006;151:332-7

Young JB (see McMurray et al). 2006;151:985-91

Young JB (see Pires et al). 2006;151:837-43

Young W (see Detling et al). 2006;151:522-8

Youssef R (see Butera et al). 2006;151:228-34

Yuan Y (see Mahoney et al). 2006;151:219-27

Yusuf S (see Mahoney et al). 2006;151:219-27

Yusuf S (see McMurray et al). 2006;151:985-91

Z

Zacharski LR (see Lee et al). 2006;151:1247.e1-1247.e7

Zagler A, Azadpour M, Mercado C, Hennekens CH. N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. 2006;151:140-5

Zahn E (see Latson et al). 2006;151:1129.e7-1129.e11

Zairis MN, Manousakis SJ, Adamopoulou EN, Makrygiannis SS, Glyptis MP, Beldekos DJ, Patsourakos NG, Olympios CD, Prekates AA, Foussas SG. Continuous 12-lead electrocardio-

graphic ST monitoring and long-term prognosis after successful coronary stenting. 2006;151:892-7

Zanco P (see Briguori et al). 2006;151:674-80

Zareba KM (see Lipshultz et al). 2006;151:916-22

Zaslavsky AM (see Sequist et al). 2006;151:909-14

Zehelein J (see Korosoglou et al). 2006;151:131-8

Zeller T (see Mueller et al). 2006;151:1214.e1-1214.e7

Zellweger MJ (see Staub et al). 2006;151:1223-30

Zhang H (see Sedrakyan et al). 2006;151:720-5

Zhang S (see Johnson et al). 2006;151:1012.e7-1012.e14

Zhang S-Y (see Park et al). 2006;151:864-9

Zhang X (see Gong et al). 2006;151:62-8

Zhang Z (see Gong et al). 2006;151:5.e11-e12 (Letter reply), 62-8
Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. 2006;151:273-81 (Curriculum cardiol.)

Ziada KM (see Gurm et al). 2006;151:1031.e1-1031.e6

Zijlstra F (see Bergstra et al). 2006;151:345-51

Zijlstra F (see Elsmann et al). 2006;151:1239.e9-1239.12

Zijlstra F (see Kaltoft et al). 2006;151:1108-14

Zijlstra F (see Svilaas et al). 2006;151:597.e1-597.e7 (Trial design)

Zijlstra F (see van't Hof et al). 2006;151:1255.e1-1255.e5

Zijta FM (see Vriend et al). 2006;151:242-7

Zimetbaum P (see Kandzari et al). 2006;151:1288-95

Zoble RG (see Raitt et al). 2006;151:390-6

Zock PL (see Brouwer et al). 2006;151:857-62

Zoghbi A (see Azar et al). 2006;151:521.e1-521.e4

Zueco J (see Alfonso et al). 2006;151:681.e1-681.e9

Zugck C (see Korosoglou et al). 2006;151:131-8

Subject Index*

A

Abciximab

- Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT—a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel (Schühlen et al). 2006;151:1247-53
- Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial (Svensson et al). 2006;151:798.e1-798.e7
- Initial experience with an intravenous P2Y₁₂ platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial (Greenbaum et al). 2006;151:689.e1-689.e10

ACE inhibitors; see Angiotensin-converting enzyme inhibitors

Acetylcysteine

- N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials (Zagler et al). 2006;151:140-5
- Acetylcysteine in Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics (Coyle et al). 2006;151:1032.e9-1032.e12

Acute coronary syndromes; see Angina, unstable; Myocardial infarction; Myocardial ischemia

Adenosine

- To the Editor (Riksen et al). 2006;151:(5)e9 (Letter)
- What mediated the beneficial roles of methotrexate in chronic heart failure? (Riksen et al) (Letter); (Gong et al) (Reply). 2006;151:(5)e9, e11-e12

Adenosine monophosphate

- Initial experience with an intravenous P2Y₁₂ platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial (Greenbaum et al). 2006;151:689.e1-689.e10

Adipose tissue

- Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk (Hammett et al). 2006;151:367.e7-367.e16

Adrenergic beta-antagonists

- Are β -blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study (Krum et al). 2006;151:55-61
- Long-term adherence with cardiovascular drug regimens (Kulkarni et al). 2006;151:185-91

Adrenergic beta-antagonists (continued)

- Multifaceted intervention to promote β -blocker use in heart failure (LaPointe et al). 2006;151:992-8
- Prophylactic pacemaker use to allow β -blocker therapy in patients with chronic heart failure with bradycardia (Stecker et al). 2006;151:820-8

Age factors

- Age-related differences in the management and outcome of patients with acute coronary syndromes (Yan et al). 2006;151:352-9

Aged

- The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST) (Lewis et al). 2006;151:699-705
- Clinical significance of calcification of the fibrous skeleton of the heart and atherosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS) (Barasch et al). 2006;151:39-47
- Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study (Tonkin et al). 2006;151:1304-11
- Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS) (Kizer et al). 2006;151:412-18
- Life expectancy of elderly and very elderly patients with chronic heart failure (Owen). 2006;151:1321.e1-1321.e4
- Management of elderly patients with congestive heart failure—design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) (Brunner-La Rocca et al). 2006;151:949-55 (Trial design)
- Operative and long-term survival of elderly is significantly improved by mitral valve repair (Gogbashian et al). 2006;151:1324-32
- Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients (Berdagué et al). 2006;151:690-8

Alcohol drinking

- Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts (Mukamal et al). 2006;151:368-72

Ambulatory blood pressure monitoring; see Blood pressure monitoring, ambulatory

Ambulatory care

- Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits (Spaeder et al). 2006;151:844.e1-844.e10

American College of Cardiology

- Highlights from the 55th Annual Scientific Sessions of the American College of Cardiology: March 11 to 14, 2006, Atlanta, Georgia (Goyal et al). 2006;151:1156-1172 (Meetings)
- Highlights from the American Heart Association Scientific Sessions, November 13 to 16, 2005, Dallas, TX (Goyal et al). 2006;151:295-307 (Meetings)

Amiodarone

- A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned (Vijayalakshmi et al). 2006;151:863.e1-863.e6

*January, pp. 1-248; February, pp. 249-552; March, pp. 553-756; April, pp. 757-944; May, pp. 945-1130; June, pp. 1131-1386.

Amplatzer duct occluders

Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders (Masura et al). 2006;151:755.e7-755.e10

Anemia

Anemia in patients with heart failure and preserved systolic function (Felker et al). 2006;151:457-62
Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study (Astor et al). 2006;151:492-500
The prevalence, nature, and importance of hematologic abnormalities in heart failure (Berry et al). 2006;151:1312-20

Angina, unstable

Bare metal stent restenosis is not a benign clinical entity (Chen et al). 2006;151:1259-63
Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-segment elevation myocardial infarction (Sabatine et al). 2006;151:25-31
Comparison of long-term mortality across the spectrum of acute coronary syndromes (Allen et al). 2006;151:1065-71
Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial (Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)
External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes (Hubacek et al). 2006;151:308-15
The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction (Mueller et al). 2006;151:1214.e1-1214.e7
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Aggarwal) (Letter); (Dibra et al) (Reply). 2006;151:(5)e5, e7
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes (Roe et al). 2006;151:1205-13
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation (Mahoney et al). 2006;151:219-27
Outcomes after acute coronary syndrome admission to primary versus tertiary Veterans Affairs medical centers: the Veterans Affairs Access to Cardiology study (Rumsfeld et al). 2006;151:32-8

Angina pectoris

Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defects (D'Antonio et al). 2006;151:813-19
Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina (Briguori et al). 2006;151:674-80
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy (Goodman et al). 2006;151:791-7
Impact of body mass index on outcomes of enhanced external counterpulsation therapy (McCullough et al). 2006;151:139.e9-139.e13

Angina pectoris (continued)

Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina (Goldberg et al). 2006;151:1264-9

Angina pectoris, variant

Common adrenergic receptor polymorphisms as novel risk factors for vasospastic angina (Park et al). 2006;151:864-9

Angiography

Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT—a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel (Schühlen et al). 2006;151:1247-53
N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials (Zagler et al). 2006;151:140-5
Coronary artery imaging with multidetector computed tomography: a call for an evidence-based, multidisciplinary approach (Schoenhagen et al). 2006;151:945-8 (Editorial)
Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography (Schuijff et al). 2006;151:404-11
Side branch occlusion after coronary stent implantation in patients presenting with ST-elevation myocardial infarction: clinical impact and angiographic predictors (Kraleiv et al). 2006;151:153-7

Angioplasty

Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT—a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel (Schühlen et al). 2006;151:1247-53
Argatroban: update (Yeh and Jang). 2006;151:1131-8 (Curriculum cardioid.)
Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial (Svensson et al). 2006;151:798.e1-798.e7
Contemporary challenges in the management of acute myocardial infarction: ST-elevation myocardial infarction guidelines (Henry). 2006;151:S11-16
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424 (Boden et al). 2006;151:1173-9 (Trial design)
Differences in in-hospital mortality between men and women with acute myocardial infarction undergoing percutaneous coronary intervention in Japan: Tokai Acute Myocardial Infarction Study (TAMIS) (Hirakawa et al). 2006;151:1270-4
Do operator volumes relate to clinical outcomes after percutaneous coronary intervention in the Canadian health care system? (Cantor et al). 2006;151:902-8
Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction (Pinto et al). 2006;151:S27-9

Angioplasty (continued)

- Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial (Weintraub et al). 2006;151:1180-5 (Trial design)
- Effects of a statewide physician-led quality-improvement program on the quality of cardiac care (Goss et al). 2006;151:1033-42
- Elective percutaneous coronary intervention immediately impairs resting microvascular perfusion assessed by cardiac magnetic resonance imaging (Taylor et al). 2006;151:891.e1-891.e7
- External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes (Hubacek et al). 2006;151:308-15
- Feasibility and benefit of prehospital diagnosis, triage, and therapy by paramedics only in patients who are candidates for primary angioplasty for acute myocardial infarction (van't Hof et al). 2006;151:1254.e1-1254.e5
- Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction (Nikolsky et al). 2006;151:168-75
- The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry (Holper et al). 2006;151:69-75
- Impact of infarct location on left ventricular ejection fraction after correction for enzymatic infarct size in acute myocardial infarction treated with primary coronary intervention (Elsman et al). 2006;151:1239.e9-1239.12
- Impact of race and ethnicity on in-hospital outcomes after percutaneous coronary intervention (report from the 2000-2001 New York State Angioplasty Registry) (Minutello et al). 2006;151:164-7
- Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (De Luca et al). 2006;151:1295.e1-1295.e6
- Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial (Brodie et al). 2006;151:1231-8
- Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention (Berger et al). 2006;151:1026-31
- Initial experience with an intravenous P2Y₁₂ platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial (Greenbaum et al). 2006;151:689.e1-689.e10
- Introduction (Herrmann). 2006;151:S3
- Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Chacko et al). 2006;151:1032.e1-1032.e7
- Level of Selvester QRS score is predictive of ST-segment resolution and 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention (Uyarel et al). 2006;151:1239.e1-1239.e7

Angioplasty (continued)

- Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome (Smit et al). 2006;151:1102-7
- Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction (De Luca et al). 2006;151:1255-8
- A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions (Natarajan et al). 2006;151:175.e1-175.e6
- Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction (Kandzari et al). 2006;151:1287-94
- Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? (Holmes Jr et al). 2006;151:779-85
- (Curriculum cardiol.)
- Sestamibi single photon emission computed tomography immediately after primary percutaneous coronary intervention identifies patients at risk for large infarcts (Kaltoft et al). 2006;151:1108-14
- Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial (Halkin et al). 2006;151:915.e1-915.e7
- The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase (Ong et al). 2006;151:1194-1204 (Trial design)
- Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)—study design (Svilaas et al). 2006;151:597.e1-597.e7 (Trial design)
- Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation (Herrmann). 2006;151:S30-9
- Validating the Clinical Outcomes Assessment Program risk model for percutaneous coronary intervention (Wu et al). 2006;151:1275-9
- Angioplasty, balloon**
- Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era (Agostoni et al). 2006;151:682-9
- Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis: insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial (Alfonso et al). 2006;151:681.e1-681.e9
- Angiotensin-converting enzyme inhibitors**
- Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function: Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease (van Gilst et al). 2006;151:1240-6
- Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist (Kawata et al). 2006;151:798.e9-798.e15

Angiotensin-converting enzyme inhibitors (continued)

- Long-term adherence with cardiovascular drug regimens (Kulkarni et al). 2006;151:185-91
- Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial (McMurray et al). 2006;151:985-91

Angiotensin II type 1 receptor blockers

- Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist (Kawata et al). 2006;151:798.e9-798.e15

Anti-arrhythmia agents

- A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need (Waldo). 2006;151:771-8 (Curriculum cardiolo.)

Antibodies, monoclonal

- Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction (Armstrong et al). 2006;151:787-90

Anticoagulants

- The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials (WAVE Investigators). 2006;151:1-9 (Trial design)

Antigens, bacterial

- Virulent strains of *Helicobacter pylori* and vascular diseases: a meta-analysis (Pasceri et al). 2006;151:1215-22

Antigens, CD40

- Variants of the *CD40* gene but not of the *CD40L* gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS) (Burdon et al). 2006;151:706-11

Antihypertensive agents

- Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting (White et al). 2006;151:176-84

Antioxidants

- Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study (Engelhard et al). 2006;151:100.e1-100.e6

Aortic coarctation

- Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair (Vriend et al). 2006;151:242-7

Aortic diseases

- Endovascular stent-graft treatment of penetrating aortic ulcer: results over a median follow-up of 27 months (Eggebrecht et al). 2006;151:530-6

Aortic valve

- Clinical significance of calcification of the fibrous skeleton of the heart and atherosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS) (Barasch et al). 2006;151:39-47

Apolipoproteins

- The role of exercise in modulating the impact of an ultra-low-fat diet on serum lipids and apolipoproteins in patients with or at risk for coronary artery disease (Marshall et al). 2006;151:484-91

Apolipoproteins B

- Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II (Ballantyne et al). 2006;151:975.e1-975.e9

Argatroban; see Pipecolic acids

Argentina

- Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina-2 (EIRA-2) Study (Ferreiros et al). 2006;151:545-52
- Overview of acute decompensated heart failure in Argentina: lessons learned from 5 registries during the last decade (Perna et al). 2006;151:84-91

Arrhythmia; see also Atrial fibrillation

- Immediate and late outcomes of patients undergoing transseptal left-sided heart catheterization for symptomatic valvular and arrhythmic diseases (Liu et al). 2006;151:235-41
- Prevention of implantable defibrillator shocks by cognitive behavioral therapy: a pilot trial (Chevalier et al). 2006;151:191.e1-191.e6
- Ventricular arrhythmias after acute myocardial infarction: a 20-year community study (Henkel et al). 2006;151:806-12

Arrhythmia, sinus

- Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm (Pritchett et al). 2006;151:1043-9

Arterial remodeling

- Acute myocardial infarction: clinical characteristics and plaque morphology between expansive remodeling and constrictive remodeling by intravascular ultrasound (Hasegawa et al). 2006;151:332-7

Arteriosclerosis

- Clinical significance of calcification of the fibrous skeleton of the heart and atherosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS) (Barasch et al). 2006;151:39-47
- The REDuction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events—study design (Ohman et al). 2006;151:786.e1-786.e10 (Trial design)

Aspirin

- Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers (Karha et al). 2006;151:976.e7-976.e11
- Long-term adherence with cardiovascular drug regimens (Kulkarni et al). 2006;151:185-91
- Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial (Fitchett et al). 2006;151:373-9
- Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (Connolly and the ACTIVE Steering Committee). 2006;151:1187-93 (Trial design)

Atherectomy, coronary

- Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy—a propensity-adjusted analysis (Gurm et al). 2006;151:1031.e1-1031.e6

Atheroma; see Atherosclerosis

Atherosclerosis

- Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts (Mukamal et al). 2006;151:368-72

Atherosclerosis (continued)

- Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function: Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease (van Gilst et al). 2006;151:1240-6
- Increased cardiovascular risk associated with diabetes in Dallas County (Das et al). 2006;151:1087-93
- Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function (Isbel et al). 2006;151:745-53
- Insights into the pathophysiology of ST-elevation myocardial infarction (Brenner). 2006;151:54-10
- Introduction (Herrmann). 2006;151:53
- Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging—the Multi-Ethnic Study of Atherosclerosis (MESA) (Edvardson et al). 2006;151:109-14

Atorvastatin

- Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention (Zhou et al). 2006;151:273-81 (Curriculum cardiol.)
- Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—a randomized, placebo-controlled study (Alber et al). 2006;151:139.e1-139.e7
- To the Editor (Galin et al). 2006;151:5.e1 (Letter)

Atrial appendage

- Benefits of left atrial appendage occlusion (Stöhlberger et al) (Letter); (Healey et al) (Reply). 2006;151:6.e1, e3

Atrial fibrillation

- Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm (Pritchett et al). 2006;151:1043-9
- Benefits of left atrial appendage occlusion Stöhlberger et al) (Letter); (Healey et al) (Reply). 2006;151:6.e1, e3
- Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) (Gage et al). 2006;151:713-19
- Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial (Klein et al). 2006;151:380-9
- Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study (Brouwer et al). 2006;151:857-62
- A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need (Waldo). 2006;151:771-8 (Curriculum cardiol.)
- Potential mechanisms between atrial dilatation and atrial fibrillation (Liu and Li) (Letter); (Parkash and Green) (Reply). 2006;151:2.e1, e3
- Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study (Raitt et al). 2006;151:390-6
- The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTION in Patients with Atrial Fibrillation) Trial (Fountain et al). 2006;151:956-61 (Trial design)
- A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned (Vijayalakshmi et al). 2006;151:863.e1-863.e6

Atrial fibrillation (continued)

- Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (Connolly and the ACTIVE Steering Committee). 2006;151:1187-93 (Trial design)
- Recursive partitioning-based preoperative risk stratification for atrial fibrillation after coronary artery bypass surgery (Sedrakyan et al). 2006;151:720-5
- Atrial septal defect; see Heart septal defects, atrial**
- Autologous transplantation; see Transplantation, autologous**
- Azimilide; see Imidazolidines; Piperazines**

B**B-type natriuretic peptide; see Natriuretic peptide, brain****Bacterial proteins**

- Virulent strains of *Helicobacter pylori* and vascular diseases: a meta-analysis (Pasceri et al). 2006;151:1215-22

Behavior therapy

- The behavioral approach for treating obesity (Foster). 2006;151:625-7 (Meetings)

beta-Blockers; see Adrenergic beta-antagonists**beta-Myosin heavy chain; see Myosin heavy chains****Biopsy**

- Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors (Magnani et al). 2006;151:463-70

Bivalirudin

- Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Chacko et al). 2006;151:1032.e1-1032.e7
- The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Aggarwal). 2006;151:5.e3 (Letter)

Blood pressure

- The association between blood pressure and mortality in patients with heart failure (Lee et al). 2006;151:76-83
- Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST) (Cooper-DeHoff et al). 2006;151:1072-9
- The influence of short and long duration on the blood pressure response to an acute bout of dynamic exercise (Guidry et al). 2006;151:1321.e5-1321.e12
- Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study (Engelhard et al). 2006;151:100.e1-100.e6

Blood pressure monitoring, ambulatory

- 24-hour ambulatory blood pressure monitoring (O'Shea and Califf). 2006;151:962-8 (Meetings)
- Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting (White et al). 2006;151:176-84

BNP; see Natriuretic peptide, brain**Body mass index**

- Excess body weight, clinical profile, management practices, and hospital prognosis in men and women after acute myocardial infarction (Goldberg et al). 2006;151:1296-1303

Body mass index (continued)

- How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study (Daniels et al). 2006;151:999-1005
- Impact of body mass index on outcomes of enhanced external counterpulsation therapy (McCullough et al). 2006;151:139.e9-139.e13
- Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction (Nikolsky et al). 2006;151:168-75

Bone marrow transplantation

- Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting (Mocini et al). 2006;151:192-7
- Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina (Briguori et al). 2006;151:674-80

Bradycardia

- Prophylactic pacemaker use to allow β -blocker therapy in patients with chronic heart failure with bradycardia (Stecker et al). 2006;151:820-8

Bundle-branch block

- Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials (Al-Faleh et al). 2006;151:10-5

C

C-reactive protein

- Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease (Azar et al). 2006;151:521.e1-521.e4
- Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk (Hammett et al). 2006;151:367.e7-367.e16
- Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Aggarwal) (Letter); (Dibra et al) (Reply). 2006;151(5):e5, e7
- Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina (Goldberg et al). 2006;151:1264-9
- To the Editor (Galin et al). 2006;151(5):e1 (Letter)

CagA protein; see Antigens, bacterial; Bacterial proteins

Calcinosis

- Accuracy of 64-row multidetector computed tomography in detecting coronary artery disease in 134 symptomatic patients: influence of calcification (Ong et al). 2006;151:1322.e1-1322.e6

Calcium

- Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment (Hecht et al). 2006;151:1139-46 (Curriculum cardiol.)

Canada

- Do operator volumes relate to clinical outcomes after percutaneous coronary intervention in the Canadian health care system? (Cantor et al). 2006;151:902-8
- Interpretation of subgroup results in clinical trial publications: insights from a survey of medical specialists in Ontario, Canada (Parker and Naylor). 2006;151:580-8 (Curriculum cardiol.)

Candesartan

- Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial (McMurray et al). 2006;151:7985-91

Cangrelor; see Adenosine monophosphate

Carcinoid heart disease

- Assessment of patent foramen ovale in carcinoid heart disease (Mansencal et al). 2006;151:1129.e1-1129.e6

Cardiac catheterization; see Heart catheterization

Cardiac pacing, artificial

- Time course of left ventricular volumes in severe congestive heart failure patients treated by optimized AV sequential left ventricular pacing alone—a 3-dimensional echocardiographic study (Butter et al). 2006;151:115-23

Cardiac rehabilitation

- Determinants of referral to cardiac rehabilitation programs in patients with coronary artery disease: a systematic review (Cortés and Arthur). 2006;151:249-56 (Curriculum cardiol.)

Cardiac resynchronization

- Cardiac resynchronization therapy: a regulatory perspective (Laskey and Maisel). 2006;151:757-61 (Editorial)
- Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure (Mangiavacchi et al). 2006;151:477.e1-477.e6
- Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials (Pires et al). 2006;151:837-43
- Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy: the Resynchronization for the Hemodynamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study (Boriani et al). 2006;151:1050-8
- Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure—the RESynchronization reVerses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study (Linde et al). 2006;151:288-94 (Trial design)

Cardiac surgical procedures

- Cardiac procedure use following acute myocardial infarction among American Indians (Sequist et al). 2006;151:909-14
- Operative and long-term survival of elderly is significantly improved by mitral valve repair (Gogbashian et al). 2006;151:1324-32
- Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications (Butera et al). 2006;151:228-34
- The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase (Ong et al). 2006;151:1194-1204 (Trial design)

Cardiac tamponade

- Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction (Patel et al). 2006;151:316-22

Cardiologists

Psychophysiologic responses of invasive cardiologists in an academic catheterization laboratory (Detling et al). 2006;151:522-8

Cardiology

Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? (Hernández et al). 2006;151:257-64 (Curriculum cardiol.)

Cardiomegaly

Heart rate variability in patients with cardiac hypertrophy—relation to left ventricular mass and etiology (Alter et al). 2006;151:829-36

Cardiomyopathy, hypertrophic

Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy—causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes (Poutanen et al). 2006;151:725.e1-725.e9

Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy (Sorajja et al). 2006;151:426-35

Cardiopulmonary bypass

Prospective randomized study comparing coronary artery bypass grafting with the new mini-extracorporeal circulation Jostra System or with a standard cardiopulmonary bypass (Remadi et al). 2006;151:198.e1-198.e7

Cardiovascular diseases

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention (Zhou et al). 2006;151:273-81 (Curriculum cardiol.)

Argatroban: update (Yeh and Jang). 2006;151:1131-8 (Curriculum cardiol.)

Cardiovascular disease in HIV infection (Sudano et al). 2006;151:1147-55 (Curriculum cardiol.)

Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes (Jimenez-Corona et al). 2006;151:1080-6

Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials (B-Vitamin Treatment Trialists' Collaboration). 2006;151:282-7 (Trial design)

Increased cardiovascular risk associated with diabetes in Dallas County (Das et al). 2006;151:1087-93

Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy (Rosenson). 2006;151:556-63

Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (Connolly and the ACTIVE Steering Committee). 2006;151:1187-93 (Trial design)

Schizophrenia and increased risk of cardiovascular disease (Mackin and McAllister-Williams). 2006;151:5e13 (Letter)

Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study (Ammar et al). 2006;151:799-805

Cardioversion; see Electric countershock**Cardioverter defibrillator; see Defibrillators, implantable****Carotid artery**

Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair (Vriend et al). 2006;151:242-7

Carrier proteins

Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy—causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes (Poutanen et al). 2006;151:725.e1-725.e9

Carvedilol

Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits (Spaeder et al). 2006;151:844.e1-844.e10

CD40 ligand

Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—a randomized, placebo-controlled study (Alber et al). 2006;151:139.e1-139.e7

Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease (Azar et al). 2006;151:521.e1-521.e4

Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk (Hammett et al). 2006;151:367.e7-367.e16

Variants of the *CD40* gene but not of the *CD40L* gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS) (Burdon et al). 2006;151:706-11

Cerebrovascular accident

Benefits of left atrial appendage occlusion (Stöllerberger et al) (Letter); (Healey et al) (Reply). 2006;151:6e1, e3

Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke (Iltumur et al). 2006;151:1115-22

Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes—Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 study (Smith et al). 2006;151:338-44

Chest pain; see Angina pectoris**Child**

Diagnostic conclusions from the EASI-derived 12-lead electrocardiogram as compared with the standard 12-lead electrocardiogram in children (Welinder et al). 2006;151:1059-64

Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy—causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes (Poutanen et al). 2006;151:725.e1-725.e9

Frequency of clinically unsuspected myocardial injury at a children's hospital (Lipshultz et al). 2006;151:916-22

Clinical Outcome Assessment Program

Effects of a statewide physician-led quality-improvement program on the quality of cardiac care (Goss et al). 2006;151:1033-42

Validating the Clinical Outcomes Assessment Program risk model for percutaneous coronary intervention (Wu et al). 2006;151:1275-9

Clinical trials

Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function: Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease (van Gilst et al). 2006;151:1240-6

Clinical trials (continued)

A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research (Davidson et al). 2006;151:451-6
Highlights from the 55th Annual Scientific Sessions of the American College of Cardiology: March 11 to 14, 2006, Atlanta, Georgia (Goyal et al). 2006;151:1156-1172 (Meetings)
Interpretation of subgroup results in clinical trial publications: insights from a survey of medical specialists in Ontario, Canada (Parker and Naylor). 2006;151:580-8 (Curriculum cardiol.)
Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? (Hernández et al). 2006;151:257-64 (Curriculum cardiol.)

Clopidogrel

Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT—a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel (Schühlen et al). 2006;151:1247-53
Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease (Azar et al). 2006;151:521.e1-521.e4
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation (Mahoney et al). 2006;151:219-27
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (Connolly and the ACTIVE Steering Committee). 2006;151:1187-93 (Trial design)

Cognitive therapy

Prevention of implantable defibrillator shocks by cognitive behavioral therapy: a pilot trial (Chevalier et al). 2006;151:191.e1-191.e6

Comorbidity

Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction (Balzi et al). 2006;151:1094-1100

Computed tomography; see Tomography, x-ray computed

Congenital heart disease; see Heart defects, congenital

Congestive heart failure; see Heart failure, congestive

Contrast media

N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials (Zagler et al). 2006;151:140-5
Acetylcysteine in Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics (Coyle et al). 2006;151:1032.e9-1032.e12
To the Editor (Fricke) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:1.e1, e3
To the Editor (Hoher) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:1.e5, e7

Coronary angiography

Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? (Kragelund et al). 2006;151:712.e1-712.e7
Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome (Smit et al). 2006;151:1102-7

Coronary angiography (continued)

Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis: insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial (Alfonso et al). 2006;151:681.e1-681.e9

Coronary arteriosclerosis

Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radiofrequency data analysis, is related to clinical presentation (Rodríguez-Granillo et al). 2006;151:1020-4
Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina—the role of GNB3 C825T polymorphism (Michalsen et al). 2006;151:870-7
Intravascular ultrasound assessment of the spatial distribution of ruptured coronary plaques in the left anterior descending coronary artery (Pregowski et al). 2006;151:898-901
Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? (Kragelund et al). 2006;151:712.e1-712.e7
Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS) (Burdon et al). 2006;151:706-11

Coronary artery bypass

Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts (Mukamal et al). 2006;151:368-72
Asymptomatic long-term survivors of coronary artery bypass surgery enjoy a quality of life equal to the general population (Bradshaw et al). 2006;151:537-44
Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting (Mocini et al). 2006;151:192-7
Benefits of left atrial appendage occlusion (Stöhlberger et al) (Letter); (Healey et al) (Reply). 2006;151:6.e1, e3
Effects of a statewide physician-led quality-improvement program on the quality of cardiac care (Goss et al). 2006;151:1033-42
From efficacy to safety concerns: a STEP forward or a step back for clinical research and intercessory prayer?: the Study of Therapeutic Effects of Intercessory Prayer (STEP) (Krucoff et al). 2006;151:762-4 (Editorial)
Prospective randomized study comparing coronary artery bypass grafting with the new mini-extracorporeal circulation Jostra System or with a standard cardiopulmonary bypass (Remadi et al). 2006;151:198.e1-198.e7
Recursive partitioning-based preoperative risk stratification for atrial fibrillation after coronary artery bypass surgery (Sedrakyan et al). 2006;151:720-5
Study of the therapeutic effects of intercessory prayer (STEP) in cardiac bypass patients: a multicenter randomized trial of uncertainty and certainty of receiving intercessory prayer (Benson et al). 2006;151:934-42
The SYNergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase (Ong et al). 2006;151:1194-1204 (Trial design)

Coronary artery calcification; see Coronary arteriosclerosis

Coronary circulation

The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria. A transthoracic vasodilator stress echocardiography study (Rigo et al). 2006;151:124-30

Coronary circulation (continued)

Effect of exercise training on myocardial blood flow in patients with stable coronary artery disease (Yoshinaga et al). 2006;151:1323.e11-1323.e18

Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist (Kawata et al). 2006;151:798.e9-798.e15

Handgrip-enhanced myocardial fractional flow reserve for assessment of coronary artery stenoses (Katrakis et al). 2006;151:1107.e1-1107.e7

Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction (Kandzari et al). 2006;151:1287-94

Coronary disease

Accuracy of 64-row multidetector computed tomography in detecting coronary artery disease in 134 symptomatic patients: influence of calcification (Ong et al). 2006;151:1322.e1-1322.e6

The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition (Fragasso et al). 2006;151:1238.e1-1238.e8

Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE) (Froehlich et al). 2006;151:1123-8

Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST) (Cooper-DeHoff et al). 2006;151:1072-9

Comparison of exercise echocardiography and the Duke treadmill score for risk stratification in patients with known or suspected coronary artery disease and normal resting electrocardiogram (Peteiro et al). 2006;151:1323.e1-1323.e10

Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study (Tonkin et al). 2006;151:1304-11

Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424 (Boden et al). 2006;151:1173-9 (Trial design)

Determinants of referral to cardiac rehabilitation programs in patients with coronary artery disease: a systematic review (Cortés and Arthur). 2006;151:249-56 (Curriculum cardiol.)

Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial (Weintraub et al). 2006;151:1180-5 (Trial design)

Effect of exercise training on myocardial blood flow in patients with stable coronary artery disease (Yoshinaga et al). 2006;151:1323.e11-1323.e18

The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events (Koro et al). 2006;151:755.e1-755.e6

Insights into the pathophysiology of ST-elevation myocardial infarction (Brenner). 2006;151:S4-10

Introduction (Herrmann). 2006;151:S3

Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study (Astor et al). 2006;151:492-500

The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease (Nigam et al). 2006;151:514-21

Coronary disease (continued)

NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes (Estrada et al). 2006;151:1093.e1-1093.e7

Schizophrenia and increased risk of cardiovascular disease (Mackin and McAllister-Williams). 2006;151:(5)e13 (Letter)

Side branch occlusion after coronary stent implantation in patients presenting with ST-elevation myocardial infarction: clinical impact and angiographic predictors (Krale et al). 2006;151:153-7

The SYNergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase (Ong et al). 2006;151:1194-1204 (Trial design)

Trends in community mortality due to coronary heart disease (Goldberg et al). 2006;151:501-7

What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? (Kim et al). 2006;151:668-73

Coronary disease, diagnosis

Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defects (D'Antonio et al). 2006;151:813-19

Coronary artery imaging with multidetector computed tomography: a call for an evidence-based, multidisciplinary approach (Schoenhagen et al). 2006;151:945-8 (Editorial)

Diagnostic conclusions from the EASI-derived 12-lead electrocardiogram as compared with the standard 12-lead electrocardiogram in children (Welinder et al). 2006;151:1059-64

Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography (Schuijff et al). 2006;151:404-11

Real-time myocardial perfusion imaging for pharmacologic stress testing: added value to single photon emission computed tomography (Korosoglou et al). 2006;151:131-8

Coronary disease, drug therapy

Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—a randomized, placebo-controlled study (Alber et al). 2006;151:139.e1-139.e7

Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease (Azar et al). 2006;151:521.e1-521.e4

Long-term adherence with cardiovascular drug regimens (Kulkarni et al). 2006;151:185-91

Coronary disease, prognosis

Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease (Jeger et al). 2006;151:508-13

Prognostic significance of ST-segment elevation during dobutamine stress echocardiography (Arruda et al). 2006;151:744.e1-744.e6

Coronary disease, therapy

Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era (Agostoni et al). 2006;151:682-9

Effect of percutaneous coronary intervention of nonacute total coronary artery occlusions on QT dispersion (Goodhart et al). 2006;151:529.e1-529.e6

Coronary disease, therapy (continued)

Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention (Berger et al). 2006;151:1026-31

The role of exercise in modulating the impact of an ultralow-fat diet on serum lipids and apolipoproteins in patients with or at risk for coronary artery disease (Marshall et al). 2006;151:484-91

Coronary occlusion; see Coronary disease

Coronary reperfusion; see Myocardial reperfusion

Coronary restenosis

Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT—a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel (Schühlen et al). 2006;151:1247-53

Bare metal stent restenosis is not a benign clinical entity (Chen et al). 2006;151:1259-63

Incidence and predictors of late recurrence after β -radiation therapy with a ^{188}Re -MAG₃-filled balloon for diffuse in-stent restenosis (Lee et al). 2006;151:158-63

Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Aggarwal) (Letter); (Dibra et al) (Reply). 2006;151:5)e5, e7

Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis: insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial (Alfonso et al). 2006;151:681.e1-681.e9

Coronary stenosis

Handgrip-enhanced myocardial fractional flow reserve for assessment of coronary artery stenoses (Katrisis et al). 2006;151:1107.e1-1107.e7

Coronary vessels

Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment (Hecht et al). 2006;151:1139-46 (Curriculum cardioli.)

In vivo relationship between compositional and mechanical imaging of coronary arteries: insights from intravascular ultrasound radiofrequency data analysis (Rodriguez-Granillo et al). 2006;151:1025.e1-1025.e6

Sirolimus-eluting coronary stents in small vessels (Meier et al). 2006;151:1019.e1-1019.e7

Corrections

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial (Bhatt et al) (2005;150:401.e1-401.e7). 2006;151:247.e1-247.e3

Correspondence; see Letters to the Editor

Cortisol; see Hydrocortisone

Counterpulsation

Impact of body mass index on outcomes of enhanced external counterpulsation therapy (McCullough et al). 2006;151:139.e9-139.e13

COURAGE trial

Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424 (Boden et al). 2006;151:1173-9 (Trial design)

Creatine kinase

Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials (Galla et al). 2006;151:16-24

D

Dalteparin

A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions (Natarajan et al). 2006;151:175.e1-175.e6

Death; see Mortality

Decompensated heart failure; see Heart failure, congestive

Defibrillators, implantable

Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection (Parkash et al). 2006;151:397-403

Prevention of implantable defibrillator shocks by cognitive behavioral therapy: a pilot trial (Chevalier et al). 2006;151:191.e1-191.e6

Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy: the Resynchronization or the Hemodynamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study (Boriani et al). 2006;151:1050-8

Renal insufficiency predicts the time to first appropriate defibrillator shock (Hreybe et al). 2006;151:852-6

Depression

Depression symptoms predict heart rate recovery after treadmill stress testing (Hughes et al). 2006;151:1122.e1-1122.e6

Type D personality and diabetes predict the onset of depressive symptoms in patients after percutaneous coronary intervention (Pedersen et al). 2006;151:367.e7-367.e16

Diabetes mellitus

Acetylcysteine in Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics (Coyle et al). 2006;151:1032.e9-1032.e12

A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring (Macchia et al). 2006;151:754.e7-754.e17

Increased cardiovascular risk associated with diabetes in Dallas County (Das et al). 2006;151:1087-93

Type D personality and diabetes predict the onset of depressive symptoms in patients after percutaneous coronary intervention (Pedersen et al). 2006;151:367.e1-367.e6

An unexpected inverse relationship between HbA_{1c} levels and mortality in patients with diabetes and advanced systolic heart failure (Eshaghian et al). 2006;151:91.e1-91.e6

Diabetes mellitus, type 2

Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist (Kawata et al). 2006;151:798.e9-798.e15

Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes (Jimenez-Corona et al). 2006;151:1080-6

Diet, fat-restricted

The role of exercise in modulating the impact of an ultralow-fat diet on serum lipids and apolipoproteins in patients with or at risk for coronary artery disease (Marshall et al). 2006;151:484-91

Dilatation

A dilated inferior vena cava is a marker of poor survival (Nath et al). 2006;151:730-5
Potential mechanisms between atrial dilatation and atrial fibrillation (Liu and Li) (Letter); (Parkash and Green) (Reply). 2006;151:(2)e1, e3

Dobutamine stress echocardiography; see**Echocardiography, stress****Ductus arteriosus, patent**

Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders (Masura et al). 2006;151:755.e7-755.e10

Dyspnea

Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease (Mueller et al). 2006;151:471-7
Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients (Berdagué et al). 2006;151:690-8
A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score (Baggish et al). 2006;151:48-54

E**Echocardiography**

Assessment of patent foramen ovale in carcinoid heart disease (Mansencal et al). 2006;151:1129.e1-1129.e6
Comparison of exercise echocardiography and the Duke treadmill score for risk stratification in patients with known or suspected coronary artery disease and normal resting electrocardiogram (Peteiro et al). 2006;151:1323.e1-1323.e10
Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography (Ling et al). 2006;151:882-9
Restrictive physiology in cardiogenic shock: observations from echocardiography (Reynolds et al). 2006;151:890.e9-890.e15
Time course of left ventricular volumes in severe congestive heart failure patients treated by optimized AV sequential left ventricular pacing alone—a 3-dimensional echocardiographic study (Butter et al). 2006;151:115-23

Echocardiography, Doppler

The impact of hypertension on systolic and diastolic left ventricular function. A tissue Doppler echocardiographic study (Bountiokos et al). 2006;151:1322.e7-1322.e12

Echocardiography, stress

The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria. A transthoracic vasodilator stress echocardiography study (Rigo et al). 2006;151:124-30
Prognostic significance of ST-segment elevation during dobutamine stress echocardiography (Arruda et al). 2006;151:744.e1-744.e6

Echocardiography, stress (continued)

Real-time myocardial perfusion imaging for pharmacologic stress testing: added value to single photon emission computed tomography (Korosoglou et al). 2006;151:131-8

Echocardiography, transesophageal

Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial (Klein et al). 2006;151:380-9

Editorials

Cardiac resynchronization therapy: a regulatory perspective (Laskey and Maisel). 2006;151:757-61
The clinically unrecognized Q-wave myocardial infarction: what does it mean and what should we do? (Aguilar). 2006;151:768-70
Coronary artery imaging with multidetector computed tomography: a call for an evidence-based, multidisciplinary approach (Schoenhagen et al). 2006;151:945-8
From efficacy to safety concerns: a STEP forward or a step back for clinical research and intercessory prayer?: the Study of Therapeutic Effects of Intercessory Prayer (STEP) (Krucoff et al). 2006;151:762-4
A salty salute: progenitor cell therapies and no-option heart disease (Patterson). 2006;151:553-5
Unraveling the pathophysiology of acute heart failure: an inflammatory proposal (Felker and Cotter). 2006;151:765-7

Ejection fraction; see Stroke volume**Elderly; see Aged****Electric countershock**

Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial (Klein et al). 2006;151:380-9
Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study (Raitt et al). 2006;151:390-6
Prevention of implantable defibrillator shocks by cognitive behavioral therapy: a pilot trial (Chevalier et al). 2006;151:191.e1-191.e6
A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned (Vijayalakshmi et al). 2006;151:863.e1-863.e6

Electrocardiography

Continuous 12-lead electrocardiographic ST monitoring and long-term prognosis after successful coronary stenting (Zairis et al). 2006;151:892-7
Diagnostic conclusions from the EASI-derived 12-lead electrocardiogram as compared with the standard 12-lead electrocardiogram in children (Welinder et al). 2006;151:1059-64
Effect of percutaneous coronary intervention of nonacute total coronary artery occlusions on QT dispersion (Goodhart et al). 2006;151:529.e1-529.e6
Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes (Jimenez-Corona et al). 2006;151:1080-6
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy (Goodman et al). 2006;151:791-7
Level of Selvester QRS score is predictive of ST-segment resolution and 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention (Üyarel et al). 2006;151:1239.e1-1239.e7

Electrocardiography (continued)

- Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease (Jeger et al). 2006;151:508-13
- Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study (Ammar et al). 2006;151:799-805
- Use of B-type natriuretic peptide in the detection of myocardial ischemia (Staub et al). 2006;151:1223-30

Embolism; see Thromboembolism

Endocarditis

- Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina-2 (EIRA-2) Study (Ferreiros et al). 2006;151:545-52

Endothelium, vascular

- The effects of periodontal therapy on vascular endothelial function: a pilot trial (Elter et al). 2006;151:47.e1-47.e6
- The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Aggarwal). 2006;151:(5)e3 (Letter)

Enoxaparin

- The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy (Goodman et al). 2006;151:791-7
- Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial (Fitchett et al). 2006;151:373-9
- The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Aggarwal). 2006;151:(5)e3 (Letter)

Eptifibatide

- Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial (Fitchett et al). 2006;151:373-9

Ethnic groups

- Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST) (Cooper-DeHoff et al). 2006;151:1072-9
- Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes (Jimenez-Corona et al). 2006;151:1080-6
- Impact of race and ethnicity on in-hospital outcomes after percutaneous coronary intervention (report from the 2000-2001 New York State Angioplasty Registry) (Minutello et al). 2006;151:164-7

Exercise

- Effect of exercise training on myocardial blood flow in patients with stable coronary artery disease (Yoshinaga et al). 2006;151:1323.e11-1323.e18
- Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk (Hammett et al). 2006;151:367.e7-367.e16
- Handgrip-enhanced myocardial fractional flow reserve for assessment of coronary artery stenoses (Katrisis et al). 2006;151:1107.e1-1107.e7
- The influence of short and long duration on the blood pressure response to an acute bout of dynamic exercise (Guidry et al). 2006;151:1321.e5-1321.e12
- Obesity and physical activity: a review (Bensimhon et al). 2006;151:598-603 (Meetings)
- The role of exercise in modulating the impact of an ultra-low-fat diet on serum lipids and apolipoproteins in patients with or at risk for coronary artery disease (Marshall et al). 2006;151:484-91

Exercise test

- Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defects (D'Antonio et al). 2006;151:813-19
- Comparison of exercise echocardiography and the Duke treadmill score for risk stratification in patients with known or suspected coronary artery disease and normal resting electrocardiogram (Peteiro et al). 2006;151:1323.e1-1323.e10
- Depression symptoms predict heart rate recovery after treadmill stress testing (Hughes et al). 2006;151:1122.e1-1122.e6
- Evaluation of a specific activity questionnaire to predict mortality in men referred for exercise testing (McAuley et al). 2006;151:890.e1-890.e7
- Impairment of physical exercise capacity in healthy postmenopausal women (Mercuro et al). 2006;151:923-7
- Monitoring clinical changes in patients with heart failure: a comparison of methods (Riddle and Payton) (Letter); (Spertus) (Reply). 2006;151:(6)e5, e7
- Real-time myocardial perfusion imaging for pharmacologic stress testing: added value to single photon emission computed tomography (Korossoglou et al). 2006;151:131-8
- Use of B-type natriuretic peptide in the detection of myocardial ischemia (Staub et al). 2006;151:1223-30

Extracorporeal circulation

- Prospective randomized study comparing coronary artery bypass grafting with the new mini-extracorporeal circulation Jostra System or with a standard cardiopulmonary bypass (Remadi et al). 2006;151:198.e1-198.e7

Ezetimibe

- To the Editor (Galin et al). 2006;151:(5)e1 (Letter)

F

Faith healing

- From efficacy to safety concerns: a STEP forward or a step back for clinical research and intercessory prayer?: the Study of Therapeutic Effects of Intercessory Prayer (STEP) (Krucoff et al). 2006;151:762-4 (Editorial)
- Study of the Therapeutic Effects of Intercessory Prayer (STEP) in cardiac bypass patients: a multicenter randomized trial of uncertainty and certainty of receiving intercessory prayer (Benson et al). 2006;151:934-42

Fatty acids, omega-3

- Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study (Brouwer et al). 2006;151:857-62

Fatty acids, omega-3 (continued)

Understanding omega-3's (DeFilippis and Sperling).
2006;151:564-70 (Curriculum cardiol.)

Femoral artery

Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair (Vriend et al). 2006;151:242-7

Ferritin

Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes (Lee et al). 2006;151:1247.e1-1247.e7

Fibrinogen

Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk (Hammett et al). 2006;
151:367.e7-367.e16

Fibrinolytic therapy; see Thrombolytic therapy**FilterWire EX device**

Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial (Halkin et al). 2006;
151:915.e1-915.e7

Fludrocortisone

The Second Prevention of Syncope Trial (POST II)—a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: rationale and study design (Raj et al). 2006;151:1186.e11-1186.e17 (Trial design)

Fontan procedure

The extracardiac lateral tunnel Fontan, constructed with bovine pericardium: comparison with the extracardiac conduit Fontan (Lemler et al). 2006;151:928-33

G**Gadolinium**

Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement (Casolo et al). 2006;151:101-8

Gastrointestinal hemorrhage

Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis in Myocardial Infarction 16 (OPUS-TIMI 16) trial (Atar et al). 2006;151:976.e1-976.e6

Genetics

Common adrenergic receptor polymorphisms as novel risk factors for vasospastic angina (Park et al). 2006;151:864-9
Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes (Poutanen et al). 2006;151:725.e1-725.e9

Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina—the role of GNB3 C825T polymorphism (Michalsen et al). 2006;151:870-7

Intrafamilial variability of noncompaction of the ventricular myocardium (Johnson et al). 2006;151:1012.e7-1012.e14

Single-nucleotide polymorphisms of VEGF gene are associated with risk of congenital valvuloseptal heart defects (Vannay et al). 2006;151:878-81

Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS) (Burdon et al). 2006;151:706-11

Glucose

Glucose-insulin-potassium infusion in acute myocardial infarction: a hemodynamic study (Bergstra et al). 2006;151:345-51

Glycoprotein IIb/IIIa inhibitors; see Platelet aggregation inhibitors**Graft occlusion, vascular**

Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts (Mukamal et al). 2006;151:368-72

Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: an intravascular ultrasound study (Kaneda et al). 2006;151:726-9

Granulocyte colony-stimulating factor

Effects of peripheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcatheter transplantation after primary stent implantation for acute myocardial infarction (Steinwender et al). 2006;151:1295.e7-1295.e13

GuardWire device

Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial (Halkin et al). 2006;151:915.e1-915.e7

H**HbA_{1c}; see Hemoglobin A, glycosylated****Heart atria**

Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS) (Kizer et al). 2006;151:412-18

Heart catheterization

Immediate and late outcomes of patients undergoing transeptal left-sided heart catheterization for symptomatic valvular and arrhythmic diseases (Liu et al). 2006;151:235-41
Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders (Masura et al). 2006;151:755.e7-755.e10

Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting (Giardini et al). 2006;151:922.e1-922.e5

Heart defects, congenital

Single-nucleotide polymorphisms of VEGF gene are associated with risk of congenital valvuloseptal heart defects (Vannay et al). 2006;151:878-81

Heart diseases

Frequency of clinically unsuspected myocardial injury at a children's hospital (Lipshultz et al). 2006;151:916-22
A salty salute: progenitor cell therapies and no-option heart disease (Patterson). 2006;151:553-5 (Editorial)

Heart failure, congestive

Anemia in patients with heart failure and preserved systolic function (Felker et al). 2006;151:457-62
The association between blood pressure and mortality in patients with heart failure (Lee et al). 2006;151:76-83

The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST) (Lewis et al). 2006;151:699-705

Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function (Ahmed et al). 2006;
151:444-50

Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial (Gregory et al). 2006;151:1013-19

Inflammation and long-term mortality in acute congestive heart failure (Mueller et al). 2006;151:845-50

Heart failure, congestive (continued)

- Life expectancy of elderly and very elderly patients with chronic heart failure (Owen). 2006;151:1321.e1-1321.e4
- Low prevalence of B-type natriuretic peptide levels <100 pg/mL in patients with heart failure at hospital discharge (Hogenhuis et al). 2006;151:1012.e1-1012.e5
- Management of elderly patients with congestive heart failure—design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) (Brunner-La Rocca et al). 2006;151:949-55 (Trial design)
- Monitoring clinical changes in patients with heart failure: a comparison of methods (Riddle and Payton) (Letter); (Spertus) (Reply). 2006;151:(6)e5, e7
- Optimizing outcomes in the patient with acute decompensated heart failure (Mehra). 2006;151:571-9 (Curriculum cardi.)
- Overview of acute decompensated heart failure in Argentina: lessons learned from 5 registries during the last decade (Perna et al). 2006;151:84-91
- The prevalence, nature, and importance of hematologic abnormalities in heart failure (Berry et al). 2006;151:1312-20
- Quality of life in advanced heart failure: role of mitral regurgitation (Hauptman et al). 2006;151:213-18
- An unexpected inverse relationship between HbA_{1c} levels and mortality in patients with diabetes and advanced systolic heart failure (Eshaghian et al). 2006;151:91.e1-91.e6
- Unraveling the pathophysiology of acute heart failure: an inflammatory proposal (Felker and Cotter). 2006;151:765-7 (Editorial)

Heart failure, congestive, diagnosis

- Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study (Brenden et al). 2006;151:1006-11
- How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study (Daniels et al). 2006;151:999-1005
- Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement (Casolo et al). 2006;151:101-8
- A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score (Baggish et al). 2006;151:48-54

Heart failure, congestive, drug therapy

- Are β -blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study (Krum et al). 2006;151:55-61
- Multifaceted intervention to promote β -blocker use in heart failure (LaPointe et al). 2006;151:992-8
- The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure (Gong et al). 2006;151:62-8
- Prophylactic pacemaker use to allow β -blocker therapy in patients with chronic heart failure with bradycardia (Stecker et al). 2006;151:820-8
- Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits (Spaeder et al). 2006;151:844.e1-844.e10
- Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial (McMurray et al). 2006;151:985-91

Heart failure, congestive, drug therapy (continued)

- To the Editor (Riksen et al). 2006;151:(5)e9 (Letter)
- Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease (Mueller et al). 2006;151:471-7
- What mediated the beneficial roles of methotrexate in chronic heart failure? (Riksen et al) (Letter); (Gong et al) (Reply). 2006;151:(5)e9, e11-e12
- Heart failure, congestive, prognosis**
- Prognostic value of heart rate recovery in patients with heart failure (Arena et al). 2006;151:851.e7-851.e13
- Heart failure, congestive, therapy**
- Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure (Mangiavacchi et al). 2006;151:477.e1-477.e6
- Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials (Pires et al). 2006;151:837-43
- The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry (Holper et al). 2006;151:69-75
- Mortality benefit of a comprehensive heart failure disease management program in indigent patients (Hebert et al). 2006;151:478-83
- Prophylactic pacemaker use to allow β -blocker therapy in patients with chronic heart failure with bradycardia (Stecker et al). 2006;151:820-8
- Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy: the Resynchronization for the Hemodynamic Treatment of Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study (Boriani et al). 2006;151:1050-8
- Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure—the RESynchronization reVERses Remodeling in Systolic left ventricular dysfunction (REVERSE) study (Linde et al). 2006;151:288-94 (Trial design)
- Time course of left ventricular volumes in severe congestive heart failure patients treated by optimized AV sequential left ventricular pacing alone—a 3-dimensional echocardiographic study (Butter et al). 2006;151:115-23
- Heart rate**
- Depression symptoms predict heart rate recovery after treadmill stress testing (Hughes et al). 2006;151:1122.e1-1122.e6
- Heart rate variability in patients with cardiac hypertrophy—relation to left ventricular mass and etiology (Alter et al). 2006;151:829-36
- Prognostic value of heart rate recovery in patients with heart failure (Arena et al). 2006;151:851.e7-851.e13
- Heart septal defects, atrial**
- Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder (Latson et al). 2006;151:1129.e7-1129.e11

Heart septal defects, atrial (continued)

- Assessment of patent foramen ovale in carcinoid heart disease (Mansencal et al). 2006;151:1129.e1-1129.e6
- Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications (Butera et al). 2006;151:228-34
- Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting (Giardini et al). 2006;151:922.e1-922.e5

Heart valve diseases

- Immediate and late outcomes of patients undergoing transseptal left-sided heart catheterization for symptomatic valvular and arrhythmic diseases (Liu et al). 2006;151:235-41

Heart ventricles

- Heart rate variability in patients with cardiac hypertrophy—relation to left ventricular mass and etiology (Alter et al). 2006;151:829-36
- Intrafamilial variability of noncompaction of the ventricular myocardium (Johnson et al). 2006;151:1012.e7-1012.e14

HELEX septal occluder

- Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder (Latson et al). 2006;151:1129.e7-1129.e11

Helicobacter pylori

- Virulent strains of *Helicobacter pylori* and vascular diseases: a meta-analysis (Pasceri et al). 2006;151:1215-22

Hemoglobin A_{1c}, glycosylated

- An unexpected inverse relationship between HbA_{1c} levels and mortality in patients with diabetes and advanced systolic heart failure (Eshaghian et al). 2006;151:91.e1-91.e6

Hemorrhage

- Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) (Gage et al). 2006;151:713-19
- Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Chacko et al). 2006;151:1032.e1-1032.e7

Heparin

- The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy (Goodman et al). 2006;151:791-7
- Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Chacko et al). 2006;151:1032.e1-1032.e7
- Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial (Fitchett et al). 2006;151:373-9
- A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions (Natarajan et al). 2006;151:175.e1-175.e6

Heparin (continued)

- The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Aggarwal). 2006;151:5.e3 (Letter)

HIV

- Cardiovascular disease in HIV infection (Sudano et al). 2006;151:1147-55 (Curriculum cardiol.)

Homocysteine

- Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials (B-Vitamin Treatment Trialists' Collaboration). 2006;151:282-7 (Trial design)

Hospital mortality

- Differences in in-hospital mortality between men and women with acute myocardial infarction undergoing percutaneous coronary intervention in Japan: Tokai Acute Myocardial Infarction Study (TAMIS) (Hirakawa et al). 2006;151:1270-4
- Impact of race and ethnicity on in-hospital outcomes after percutaneous coronary intervention (report from the 2000-2001 New York State Angioplasty Registry) (Minutello et al). 2006;151:164-7
- The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes (Roe et al). 2006;151:1205-13
- Validating the Clinical Outcomes Assessment Program risk model for percutaneous coronary intervention (Wu et al). 2006;151:1275-9

Hydroxymethylglutaryl-CoA reductase inhibitors

- Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy—a propensity-adjusted analysis (Gurm et al). 2006;151:1031.e1-1031.e6
- Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis in Myocardial Infarction 16 (OPUS-TIMI 16) trial (Atar et al). 2006;151:976.e1-976.e6
- Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention (Zhou et al). 2006;151:273-81 (Curriculum cardiol.)
- Long-term adherence with cardiovascular drug regimens (Kulkarni et al). 2006;151:185-91
- Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy (Rosenson). 2006;151:556-63
- Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality (Austin et al). 2006;151:969-75

Hypertension

- 24-hour ambulatory blood pressure monitoring (O'Shea and Califf). 2006;151:962-8 (Meetings)
- Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST) (Cooper-DeHoff et al). 2006;151:1072-9
- The impact of hypertension on systolic and diastolic left ventricular function. A tissue Doppler echocardiographic study (Bountiukos et al). 2006;151:1322.e7-1322.e12
- Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting (White et al). 2006;151:176-84

Hypertension (continued)

Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study (Engelhard et al). 2006;151:100.e1-100.e6

Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial (Serebruany et al). 2006;151:92-9

Hypertension, pulmonary

A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension (Singh et al). 2006;151:851.e1-851.e5

Hypertrophic cardiomyopathy; *see* Cardiomyopathy, hypertrophic

Hypertrophy, left ventricular

Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy—causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes (Poutanen et al). 2006;151:725.e1-725.e9

Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging—the Multi-Ethnic Study of Atherosclerosis (MESA) (Edvardsen et al). 2006;151:109-14

Hypotension

The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers (Gorelick et al). 2006;151:754.e1-754.e5

I

Imidazolidines

Antiarrhythmic efficacy of azimilide in patients with trial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm (Pritchett et al). 2006;151:1043-9

Implantable defibrillators; *see* Defibrillators, implantable

Indoles

Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST) (Cooper-DeHoff et al). 2006;151:1072-9

Infective endocarditis; *see* Endocarditis, bacterial

Inflammation

Inflammation and long-term mortality in acute congestive heart failure (Mueller et al). 2006;151:845-50

Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Aggarwal) (Letter); (Dibra et al) (Reply). 2006;151:(5)e5, e7

Insights into the pathophysiology of ST-elevation myocardial infarction (Brenner). 2006;151:S4-10

Introduction (Herrmann). 2006;151:S3

Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized controlled clinical trial (D'Aiuto et al). 2006;151:977-84

To the Editor (Riksen et al). 2006;151:(5)e9 (Letter)

Unraveling the pathophysiology of acute heart failure: an inflammatory proposal (Felker and Cotter). 2006;151:765-7 (Editorial)

What mediated the beneficial roles of methotrexate in chronic heart failure? (Riksen et al) (Letter); (Gong et al) (Reply). 2006;151:(5)e9, e11-e12

Insulin

Glucose-insulin-potassium infusion in acute myocardial infarction: a hemodynamic study (Bergstra et al). 2006;151:345-51

Intercellular adhesion molecule 1

Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk (Hammett et al). 2006;151:367.e7-367.e16

Intravascular ultrasound; *see* Ultrasonography, interventional

Iodixanol

To the Editor (Fricke) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:(1)e1, e3

To the Editor (Hoher) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:(1)e5, e7

Iohexol

To the Editor (Fricke) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:(1)e1, e3

To the Editor (Hoher) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:(1)e5, e7

Irbesartan

Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (Connolly and the ACTIVE Steering Committee). 2006;151:1187-93 (Trial design)

Iron

Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes (Lee et al). 2006;151:1247.e1-1247.e7

Ischemic heart disease; *see* Myocardial ischemia

K

Kidney

Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study (Astor et al). 2006;151:492-500

Kidney diseases

N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials (Zagler et al). 2006;151:140-5

Acetylcysteine in Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics (Coyle et al). 2006;151:1032.e9-1032.e12

Impact of renal dysfunction on 1-year mortality after acute myocardial infarction (Schiele et al). 2006;151:661-7

Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention (Blackman et al). 2006;151:146-52

Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function (Isbel et al). 2006;151:745-53

Renal insufficiency predicts the time to first appropriate defibrillator shock (Hreybe et al). 2006;151:852-6

To the Editor (Fricke) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:(1)e1, e3

To the Editor (Hoher) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:(1)e5, e7

L

Left ventricular dysfunction; *see* Ventricular dysfunction, left

Left ventricular hypertrophy; *see* Hypertrophy, left ventricular

Letters to the Editor

- Benefits of left atrial appendage occlusion (Stöcklberger et al) (Letter); (Healey et al) (Reply). 2006;151:(6)e1, e3
- Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Aggarwal) (Letter); (Dibra et al) (Reply). 2006;151:(5)e5, e7
- Is nesiritide really that good or that bad? (Cheng) (Letter); (Fitzgerald et al) (Reply). 2006;151:(4)e1, e3
- Monitoring clinical changes in patients with heart failure: a comparison of methods (Riddle and Payton) (Letter); (Spertus) (Reply). 2006;151:(6)e5, e7
- Potential mechanisms between atrial dilatation and atrial fibrillation (Liu and Li) (Letter); (Parkash and Green) (Reply). 2006;151:(2)e1, e3
- Schizophrenia and increased risk of cardiovascular disease (Mackin and McAllister-Williams). 2006;151:(5)e13
- To the Editor (Fricke) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:(1)e1, e3
- To the Editor (Galin et al). 2006;151:(5)e1
- To the Editor (Hoher) (Letter); (Aspelin and Lundkvist) (Reply). 2006;151:(1)e5, e7
- To the Editor (Rixsen et al). 2006;151:(5)e9
- The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Aggarwal). 2006;151:(5)e3
- What mediated the beneficial roles of methotrexate in chronic heart failure? (Rixsen et al) (Letter); (Gong et al) (Reply). 2006;151:(5)e9, e11-e12

Leukocyte count

- Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk (Hammett et al). 2006;151:367.e7-367.e16

Life expectancy

- Life expectancy of elderly and very elderly patients with chronic heart failure (Owen). 2006;151:1321.e1-1321.e4

Life style

- Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina—the role of GNB3 C825T polymorphism (Michalsen et al). 2006;151:870-7

Lipids

- Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized controlled clinical trial (D'Aiuto et al). 2006;151:977-84
- The role of exercise in modulating the impact of an ultra-low-fat diet on serum lipids and apolipoproteins in patients with or at risk for coronary artery disease (Marshall et al). 2006;151:484-91

Lipoproteins, HDL cholesterol

- The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events (Koro et al). 2006;151:755.e1-755.e6
- Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy (Rosenson). 2006;151:556-63

Lipoproteins, LDL cholesterol

- Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II (Ballantyne et al). 2006;151:975.e1-975.e9

Lipoproteins, LDL cholesterol (continued)

- To the Editor (Galin et al). 2006;151:(5)e1 (Letter)

Lipoproteins, non-HDL cholesterol

- Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II (Ballantyne et al). 2006;151:975.e1-975.e9

Lung diseases

- Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study (Ammar et al). 2006;151:799-805
- Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease (Mueller et al). 2006;151:471-7

Lycopersicon esculentum

- Natural antioxidants from tomato extract reduce blood pressure in patients with grade 1 hypertension: a double-blind, placebo-controlled pilot study (Engelhard et al). 2006;151:100.e1-100.e6

M**Magnetic resonance imaging**

- Cardiovascular magnetic resonance in the follow-up of patients with corrected tetralogy of Fallot: a review (Oosterhof et al). 2006;151:265-72 (Curriculum cardiol.)
- Elective percutaneous coronary intervention immediately impairs resting microvascular perfusion assessed by cardiac magnetic resonance imaging (Taylor et al). 2006;151:891.e1-891.e7
- Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement (Casolo et al). 2006;151:101-8
- Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography (Schuijff et al). 2006;151:404-11
- Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance (Raman et al). 2006;151:736-44
- Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging—the Multi-Ethnic Study of Atherosclerosis (MESA) (Edvardsen et al). 2006;151:109-14

Marijuana smoking

- The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers (Gorelick et al). 2006;151:754.e1-754.e5

Medical order entry systems

- Improved compliance with quality measures at hospital discharge with a computerized physician order entry system (Butler et al). 2006;151:643-53

Men; see also Sex factors

- Evaluation of a specific activity questionnaire to predict mortality in men referred for exercise testing (McAuley et al). 2006;151:890.e1-890.e7

Menopause

- Impairment of physical exercise capacity in healthy postmenopausal women (Mercurio et al). 2006;151:923-7

Mercaptoacetyltriglycine

Incidence and predictors of late recurrence after β -radiation therapy with a ^{189}Re -MAG₃-filled balloon for diffuse in-stent restenosis (Lee et al). 2006;151:158-63

Metabolic syndrome X

A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring (Macchia et al). 2006;151:754.e7-754.e17

The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease (Nigam et al). 2006;151:514-21

Methotrexate

The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure (Gong et al). 2006;151:62-8

To the Editor (Riksen et al). 2006;151:(5)e9 (Letter)

What mediated the beneficial roles of methotrexate in chronic heart failure? (Riksen et al) (Letter); (Gong et al) (Reply). 2006;151:(5)e9, e11-e12

Microcirculation

Introduction (Herrmann). 2006;151:S3

Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation (Herrmann). 2006;151:S30-9

Migraine with aura

Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting (Giardini et al). 2006;151:922.e1-922.e5

Mitral regurgitation; see Mitral valve insufficiency

Mitral valve

Clinical significance of calcification of the fibrous skeleton of the heart and atherosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS) (Barasch et al). 2006;151:39-47

Operative and long-term survival of elderly is significantly improved by mitral valve repair (Gogbashian et al). 2006;151:1324-32

Mitral valve insufficiency

Quality of life in advanced heart failure: role of mitral regurgitation (Hauptman et al). 2006;151:213-18

Mortality; see also Hospital mortality

The association between blood pressure and mortality in patients with heart failure (Lee et al). 2006;151:76-83

The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST) (Lewis et al). 2006;151:699-705

Comparison of long-term mortality across the spectrum of acute coronary syndromes (Allen et al). 2006;151:1065-71

Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424 (Boden et al). 2006;151:1173-9 (Trial design)

Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction (Balzi et al). 2006;151:1094-1100

Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes (Jimenez-Corona et al). 2006;151:1080-6

Mortality; see also Hospital mortality (continued)

Evaluating the performance of the Global Registry of Acute Coronary Events risk-adjustment index across socioeconomic strata among patients discharged from the hospital after acute myocardial infarction (Alter et al). 2006;151:323-31

Evaluation of a specific activity questionnaire to predict mortality in men referred for exercise testing (McAuley et al). 2006;151:890.e1-890.e7

External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes (Hubacek et al). 2006;151:308-15

Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function (Ahmed et al). 2006;151:444-50

The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction (Mueller et al). 2006;151:1214.e1-1214.e7

Impact of renal dysfunction on 1-year mortality after acute myocardial infarction (Schiele et al). 2006;151:661-7

Inflammation and long-term mortality in acute congestive heart failure (Mueller et al). 2006;151:845-50

Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention (Berger et al). 2006;151:1026-31

Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study (Astor et al). 2006;151:492-500

The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease (Nigam et al). 2006;151:514-21

Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality (Austin et al). 2006;151:969-75

Mortality benefit of a comprehensive heart failure disease management program in indigent patients (Hebert et al). 2006;151:478-83

Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection (Parkash et al). 2006;151:397-403

Schizophrenia and increased risk of cardiovascular disease (Mackin and McAllister-Williams). 2006;151:(5)e13 (Letter)

Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction (Cavusoglu et al). 2006;151:1101.e1-1101.e8

Trends in community mortality due to coronary heart disease (Goldberg et al). 2006;151:501-7

An unexpected inverse relationship between HbA_{1c} levels and mortality in patients with diabetes and advanced systolic heart failure (Eshaghian et al). 2006;151:91.e1-91.e6

Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study (Ammar et al). 2006;151:799-805

Myocardial infarction

Age-related differences in the management and outcome of patients with acute coronary syndromes (Yan et al). 2006;151:352-9

Bare metal stent restenosis is not a benign clinical entity (Chen et al). 2006;151:1259-63

Myocardial infarction (continued)

- A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring (Macchia et al). 2006;151:754.e7-754.e17
- The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry (Kauf et al). 2006;151:206-12
- Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424 (Boden et al). 2006;151:1173-9 (Trial design)
- The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction (Mueller et al). 2006;151:1214.e1-1214.e7
- Impact of renal dysfunction on 1-year mortality after acute myocardial infarction (Schiele et al). 2006;151:661-7
- The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events (Koro et al). 2006;151:755.e1-755.e6
- The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes (Roe et al). 2006;151:1205-13
- Insights into the pathophysiology of ST-elevation myocardial infarction (Brenner). 2006;151:S4-10
- Introduction (Herrmann). 2006;151:S3
- Level of Selvester QRS score is predictive of ST-segment resolution and 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention (Uyarel et al). 2006;151:1239.e1-1239.e7
- Outcomes after acute coronary syndrome admission to primary versus tertiary Veterans Affairs medical centers: the Veterans Affairs Access to Cardiology study (Rumsfeld et al). 2006;151:32-8
- The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)—evaluating the impact of myocardial infarction on patient outcomes (Spertus et al). 2006;151:589-97 (Trial design)
- Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction (Kandari et al). 2006;151:1287-94
- Sestamibi single photon emission computed tomography immediately after primary percutaneous coronary intervention identifies patients at risk for large infarcts (Kaltoft et al). 2006;151:1108-14
- Ventricular arrhythmias after acute myocardial infarction: a 20-year community study (Henkel et al). 2006;151:806-12

Myocardial infarction, diagnosis

- The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE) (Goodman et al). 2006;151:654-60
- Feasibility and benefit of prehospital diagnosis, triage, and therapy by paramedics only in patients who are candidates for primary angioplasty for acute myocardial infarction (van't Hof et al). 2006;151:1254.e1-1254.e5
- Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study (Ammar et al). 2006;151:799-805

Myocardial infarction, drug therapy

- Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial (Svensson et al). 2006;151:798.e1-798.e7
- Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction (Armstrong et al). 2006;151:787-90
- Contemporary challenges in the management of acute myocardial infarction: ST-elevation myocardial infarction guidelines (Henry). 2006;151:S11-16
- Glucose-insulin-potassium infusion in acute myocardial infarction: a hemodynamic study (Bergstra et al). 2006;151:345-51
- The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy (Goodman et al). 2006;151:791-7
- Introduction (Herrmann). 2006;151:S3
- Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality (Austin et al). 2006;151:969-75
- Optimizing reperfusion outcomes in ST-elevation myocardial infarction (Henry and Herrmann). 2006;151:S1-2
- Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome (Smit et al). 2006;151:1102-7
- Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial (Fitchett et al). 2006;151:373-9
- Role of fibrinolytic therapy in the current era of ST-segment elevation myocardial infarction management (Smalling). 2006;151:S17-23
- Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials (Al-Faleh et al). 2006;151:10-5
- Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation (Herrmann). 2006;151:S30-9
- What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? (Kim et al). 2006;151:668-73
- Myocardial infarction, prognosis**
- Acute myocardial infarction: clinical characteristics and plaque morphology between expansive remodeling and constrictive remodeling by intravascular ultrasound (Hasegawa et al). 2006;151:332-7
- Changing trends in the long-term prognosis of patients with acute myocardial infarction: a population-based perspective (Botkin et al). 2006;151:199-205
- The clinically unrecognized Q-wave myocardial infarction: what does it mean and what should we do? (Aguilar). 2006;151:768-70 (Editorial)

Myocardial infarction, prognosis (continued)

- Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-segment elevation myocardial infarction (Sabatine et al). 2006;151:25-31
- Comparison of long-term mortality across the spectrum of acute coronary syndromes (Allen et al). 2006;151:1065-71
- The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE) (Goodman et al). 2006;151:654-60
- Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials (Galla et al). 2006;151:16-24
- Evaluating the performance of the Global Registry of Acute Coronary Events risk-adjustment index across socioeconomic strata among patients discharged from the hospital after acute myocardial infarction (Alter et al). 2006;151:323-31
- Excess body weight, clinical profile, management practices, and hospital prognosis in men and women after acute myocardial infarction (Goldberg et al). 2006;151:1296-1303
- Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies (Januzzi Jr et al). 2006;151:360-6
- Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction (Cavusoglu et al). 2006;151:1101.e1-1101.e8
- Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction (Møller et al). 2006;151:419-25

Myocardial infarction, surgery

- Cardiac procedure use following acute myocardial infarction among American Indians (Sequist et al). 2006;151:909-14
- Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction (Balzi et al). 2006;151:1094-1100

Myocardial infarction, therapy

- Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction (Patel et al). 2006;151:316-22
- Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial (Svensson et al). 2006;151:798.e1-798.e7
- Contemporary challenges in the management of acute myocardial infarction: ST-elevation myocardial infarction guidelines (Henry). 2006;151:S11-16
- Differences in in-hospital mortality between men and women with acute myocardial infarction undergoing percutaneous coronary intervention in Japan: Tokai Acute Myocardial Infarction Study (TAMIS) (Hirakawa et al). 2006;151:1270-4
- Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction (Pinto et al). 2006;151:S27-9

Myocardial infarction, therapy (continued)

- Door-to-drug and door-to-balloon times: where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI) (Bradley et al). 2006;151:1280-6
- Effects of peripheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcatheter transplantation after primary stent implantation for acute myocardial infarction (Steinwender et al). 2006;151:1295.e7-1295.e13
- External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes (Hubacek et al). 2006;151:308-15
- Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction (Nikolsky et al). 2006;151:168-75
- Impact of infarct location on left ventricular ejection fraction after correction for enzymatic infarct size in acute myocardial infarction treated with primary coronary intervention (Elsman et al). 2006;151:1239.e9-1239.12
- Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (De Luca et al). 2006;151:1295.e1-1295.e6
- Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial (Brodie et al). 2006;151:1231-8
- Introduction (Herrmann). 2006;151:S3
- Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation (Mahoney et al). 2006;151:219-27
- Optimizing reperfusion outcomes in ST-elevation myocardial infarction (Henry and Herrmann). 2006;151:S1-2
- Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome (Smit et al). 2006;151:1102-7
- Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction (De Luca et al). 2006;151:1255-8
- Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? (Holmes Jr et al). 2006;151:779-85 (Curriculum cardiol.)
- Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 study (Smith et al). 2006;151:338-44
- Side branch occlusion after coronary stent implantation in patients presenting with ST-elevation myocardial infarction: clinical impact and angiographic predictors (Kralek et al). 2006;151:153-7
- Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)—study design (Svilaas et al). 2006;151:597.e1-597.e7 (Trial design)
- Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation (Herrmann). 2006;151:S30-9

Myocardial ischemia

- Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defects (D'Antonio et al). 2006;151:813-19

Myocardial ischemia (continued)

- The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition (Fragasso et al). 2006;151:1238.e1-1238.e8
- Comparison of long-term mortality across the spectrum of acute coronary syndromes (Allen et al). 2006;151:1065-71
- Continuous 12-lead electrocardiographic ST monitoring and long-term prognosis after successful coronary stenting (Zairis et al). 2006;151:892-7
- Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radiofrequency data analysis, is related to clinical presentation (Rodríguez-Granillo et al). 2006;151:1020-4
- Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 210 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography (Ling et al). 2006;151:882-9
- Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes (Jimenez-Corona et al). 2006;151:1080-6
- Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial (Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)
- Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement (Casolo et al). 2006;151:101-8
- Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Chacko et al). 2006;151:1032.e1-1032.e7
- Use of B-type natriuretic peptide in the detection of myocardial ischemia (Staub et al). 2006;151:1223-30

Myocardial reperfusion

- Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction (Balzi et al). 2006;151:1094-1100
- Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (De Luca et al). 2006;151:1295.e1-1295.e6
- Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction (Kandzari et al). 2006;151:1287-94

Myocardial revascularization

- Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424 (Boden et al). 2006;151:1173-9 (Trial design)
- Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial (Weintraub et al). 2006;151:1180-5 (Trial design)
- Effect of percutaneous coronary intervention of nonacute total coronary artery occlusions on QT dispersion (Goodhart et al). 2006;151:529.e1-529.e6

Myocardial revascularization (continued)

- Effects of a statewide physician-led quality-improvement program on the quality of cardiac care (Goss et al). 2006;151:1033-42

Myocarditis

- Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors (Magnani et al). 2006;151:463-70

Myosin-binding protein C; see Carrier proteins**Myosin heavy chains**

- Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy—causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes (Poutanen et al). 2006;151:725.e1-725.e9

N**N-terminal prohormone brain natriuretic peptide; see Natriuretic peptide, brain; Peptide fragments**
Natriuretic peptide, brain

- Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke (Iltumur et al). 2006;151:1115-22
- Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study (Brenden et al). 2006;151:1006-11
- How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study (Daniels et al). 2006;151:999-1005
- Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? (Kragelund et al). 2006;151:712.e1-712.e7
- Low prevalence of B-type natriuretic peptide levels <100 pg/mL in patients with heart failure at hospital discharge (Hogenhuis et al). 2006;151:1012.e1-1012.e5
- NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes (Estrada et al). 2006;151:1093.e1-1093.e7
- Use of B-type natriuretic peptide in the detection of myocardial ischemia (Staub et al). 2006;151:1223-30
- Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease (Mueller et al). 2006;151:471-7
- Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients (Berdagué et al). 2006;151:690-8
- A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score (Baggish et al). 2006;151:48-54

Necrosis

- Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (De Luca et al). 2006;151:1295.e1-1295.e6
- Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy—a propensity-adjusted analysis (Gurm et al). 2006;151:1031.e1-1031.e6

Nesiritide

- Is nesiritide really that good or that bad? (Cheng) (Letter); (Fitzgerald et al) (Reply). 2006;151:4e1, e3

NT-proBNP; see Natriuretic peptide, brain; Peptide fragments
Nutrition

Nutrition as a contributor and treatment option for overweight and obesity (Pruitt et al). 2006;151:628-32 (Meetings)

O

Obesity

The behavioral approach for treating obesity (Foster). 2006;151:625-7 (Meetings)

Excess body weight, clinical profile, management practices, and hospital prognosis in men and women after acute myocardial infarction (Goldberg et al). 2006;151:1296-1303

How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study (Daniels et al). 2006;151:999-1005

Nutrition as a contributor and treatment option for overweight and obesity (Pruitt et al). 2006;151:628-32 (Meetings)

Obesity and physical activity: a review (Bensimhon et al). 2006;151:598-603 (Meetings)

Pharmacological and surgical treatments for obesity (DeWald et al). 2006;151:604-24 (Meetings)

Orbifiban

Risk factors for stroke after acute coronary syndromes in the Orbifiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 study (Smith et al). 2006;151:338-44

Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbifiban in Patients with Unstable coronary Syndromes-Thrombolysis in Myocardial Infarction 16 (OPUS-TIMI 16) trial (Atar et al). 2006;151:976.e1-976.e6

Outpatient care; see Ambulatory care

Overweight; see Obesity

Oxidative stress

Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes (Lee et al). 2006;151:1247.e1-1247.e7

P

Pacemaker, artificial

Cardiac pacemaker: in vitro assessment at 1.5T (Shellock et al). 2006;151:436-43

Prophylactic pacemaker use to allow β -blocker therapy in patients with chronic heart failure with bradycardia (Stecker et al). 2006;151:820-8

Patent foramen ovale; see Heart septal defects, atrial

Pediatric patients; see Child

Peptide fragments

Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? (Kragelund et al). 2006;151:712.e1-712.e7

Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients (Berdagué et al). 2006;151:690-8

Percutaneous coronary intervention; see

Angioplasty; Myocardial revascularization; Stents

Periodontitis

The effects of periodontal therapy on vascular endothelial function: a pilot trial (Elter et al). 2006;151:47.e1-47.e6

Periodontitis (continued)

Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized controlled clinical trial (D'Aiuto et al). 2006;151:977-84

Peripheral arterial disease

Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE) (Froehlich et al). 2006;151:1123-8
The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials (WAVE Investigators). 2006;151:1-9 (Trial design)

Peripheral blood stem cell transplantation

Effects of peripheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcatheter transplantation after primary stent implantation for acute myocardial infarction (Steinwender et al). 2006;151:1295.e7-1295.e13

Personality

Type D personality and diabetes predict the onset of depressive symptoms in patients after percutaneous coronary intervention (Pedersen et al). 2006;151:367.e1-367.e6

Pexelizumab; see Antibodies, monoclonal

Pipelicolic acids

Argatroban: update (Yeh and Jang). 2006;151:1131-8 (Curriculum cardioid.)

Piperazines

Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm (Pritchett et al). 2006;151:1043-9

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial (Morrow et al). 2006;151:1186.e1-1186.e9 (Trial design)

A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension (Singh et al). 2006;151:851.e1-851.e5

Piperidines

The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers (Gorelick et al). 2006;151:754.e1-754.e5

Platelet aggregation

Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers (Karha et al). 2006;151:976.e7-976.e11

Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome (Smit et al). 2006;151:1102-7

Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial (Serebruany et al). 2006;151:92-9

Platelet aggregation inhibitors

The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Aggarwal). 2006;151:5.e3 (Letter)

Platelet count

The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction (Mueller et al). 2006;151:1214.e1-1214.e7

Potassium

Glucose-insulin-potassium infusion in acute myocardial infarction: a hemodynamic study (Bergstra et al). 2006;151:345-51

Pravastatin

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention (Zhou et al). 2006;151:273-81 (Curriculum cardi.)

Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study (Tonkin et al). 2006;151:1304-11

Prognosis

The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria. A transthoracic vasodilator stress echocardiography study (Rigo et al). 2006;151:124-30

Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts (Mukamal et al). 2006;151:368-72

Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS) (Kizer et al). 2006;151:412-18

Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy (Sorajja et al). 2006;151:426-35

Pulmonary diseases; see Lung diseases**Pyrazoles**

The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers (Gorelick et al). 2006;151:754.e1-754.e5

Q**Quality of life**

Asymptomatic long-term survivors of coronary artery bypass surgery enjoy a quality of life equal to the general population (Bradshaw et al). 2006;151:537-44

Quality of life in advanced heart failure: role of mitral regurgitation (Hauptman et al). 2006;151:213-18

Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy: the Resynchronization for the Hemodynamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study (Boriani et al). 2006;151:1050-8

Quattro stentless mitral valve prosthesis; see St. Jude Quattro stentless mitral valve prosthesis**R****Race; see Ethnic groups****Radiotherapy**

Incidence and predictors of late recurrence after β -radiation therapy with a ^{188}Re -MAG₃-filled balloon for diffuse in-stent restenosis (Lee et al). 2006;151:158-63

Ranolazine; see Piperazines**Receptors, adrenergic**

Common adrenergic receptor polymorphisms as novel risk factors for vasospastic angina (Park et al). 2006;151:864-9

Renal insufficiency; see Kidney diseases**Rhenium**

Incidence and predictors of late recurrence after β -radiation therapy with a ^{188}Re -MAG₃-filled balloon for diffuse in-stent restenosis (Lee et al). 2006;151:158-63

Rimonabant; see Piperidines; Pyrazoles**Risk assessment**

Comparison of exercise echocardiography and the Duke treadmill score for risk stratification in patients with known or suspected coronary artery disease and normal resting electrocardiogram (Peteiro et al). 2006;151:1323.e1-1323.e10

Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment (Hecht et al). 2006;151:1139-46 (Curriculum cardi.)

Evaluating the performance of the Global Registry of Acute Coronary Events risk-adjustment index across socioeconomic strata among patients discharged from the hospital after acute myocardial infarction (Alter et al). 2006;151:323-31

The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes (Roe et al). 2006;151:1205-13

Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study (Astor et al). 2006;151:492-500

The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease (Nigam et al). 2006;151:514-21

Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies (Januzzi Jr et al). 2006;151:360-6

Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection (Parkash et al). 2006;151:397-403

Recursive partitioning-based preoperative risk stratification for atrial fibrillation after coronary artery bypass surgery (Sedrakyan et al). 2006;151:720-5

Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 study (Smith et al). 2006;151:338-44

Schizophrenia and increased risk of cardiovascular disease (Mackin and McAllister-Williams). 2006;151:(5)e13 (Letter)

Risk management

Increased cardiovascular risk associated with diabetes in Dallas County (Das et al). 2006;151:1087-93

Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy (Rosenson). 2006;151:556-63

Rosuvastatin

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II (Ballantyne et al). 2006;151:975.e1-975.e9

Rotational atherectomy; see Atherectomy, coronary**S****Saphenous vein**

Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: an intravascular ultrasound study (Kaneda et al). 2006;151:726-9

Saphenous vein (continued)

Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial (Halkin et al). 2006;151:915.e1-915.e7

Schizophrenia

Schizophrenia and increased risk of cardiovascular disease (Mackin and McAllister-Williams). 2006;151(5):e13 (Letter)

Sex factors; see also Men; Women

Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defects (D'Antonio et al). 2006;151:813-19

Differences in in-hospital mortality between men and women with acute myocardial infarction undergoing percutaneous coronary intervention in Japan: Tokai Acute Myocardial Infarction Study (TAMIS) (Hirakawa et al). 2006;151:1270-4

Excess body weight, clinical profile, management practices, and hospital prognosis in men and women after acute myocardial infarction (Goldberg et al). 2006;151:1296-1303

Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention (Berger et al). 2006;151:1026-31

Shock, cardiogenic

Introduction (Herrmann). 2006;151:S3

Restrictive physiology in cardiogenic shock: observations from echocardiography (Reynolds et al). 2006;151:890.e9-890.e15

Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation (Herrmann). 2006;151:S30-9

Sildenafil; see Piperazines

Simvastatin

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention (Zhou et al). 2006;151:273-81 (Curriculum cardiol.)

To the Editor (Galini et al). 2006;151(5):e1 (Letter)

Single photon emission computed tomography; see Tomography, emission-computed, single-photon

Sinus rhythm

Sinus rhythm; see Arrhythmia, sinus

Sirolimus

Sirolimus-eluting coronary stents in small vessels (Meier et al). 2006;151:1019.e1-1019.e7

Sotalol

A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned (Vijayalakshmi et al). 2006;151:863.e1-863.e6

Spironolactone

Are β -blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study (Krum et al). 2006;151:55-61

St. Jude Quattro stentless mitral valve prosthesis

Left ventricular remodeling impacts the function of the Quattro stentless mitral valve bioprosthesis (a 4-year experience) (Doss et al). 2006;151:943.e1-943.e4

Statins; see Hydroxymethylglutaryl-CoA reductase inhibitors

Stem cell transplantation

A salty salute: progenitor cell therapies and no-option heart disease (Patterson). 2006;151:553-5 (Editorial)

Stents

Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT—a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel (Schühlen et al). 2006;151:1247-53

Bare metal stent restenosis is not a benign clinical entity (Chen et al). 2006;151:1259-63

Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era (Agostoni et al). 2006;151:682-9

Continuous 12-lead electrocardiographic ST monitoring and long-term prognosis after successful coronary stenting (Zairis et al). 2006;151:892-7

Effects of peripheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcatheter transplantation after primary stent implantation for acute myocardial infarction (Steinwender et al). 2006;151:1295.e7-1295.e13

Endovascular stent-graft treatment of penetrating aortic ulcer: results over a median follow-up of 27 months (Eggebrecht et al). 2006;151:530-6

External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes (Hubacek et al). 2006;151:308-15

Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention (Blackman et al). 2006;151:146-52

Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (De Luca et al). 2006;151:1295.e1-1295.e6

Incidence and predictors of late recurrence after β -radiation therapy with a ^{188}Re -MAG₃-filled balloon for diffuse in-stent restenosis (Lee et al). 2006;151:158-63

Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Aggarwal) (Letter); (Dibra et al) (Reply). 2006;151(5):e5, e7

Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina (Goldberg et al). 2006;151:1264-9

A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions (Natarajan et al). 2006;151:175.e1-175.e6

Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? (Holmes Jr et al). 2006;151:779-85 (Curriculum cardiol.)

Side branch occlusion after coronary stent implantation in patients presenting with ST-elevation myocardial infarction: clinical impact and angiographic predictors (Kralek et al). 2006;151:153-7

Sirolimus-eluting coronary stents in small vessels (Meier et al). 2006;151:1019.e1-1019.e7

The SYNergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase (Ong et al). 2006;151:1194-1204 (Trial design)

Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)—study design (Svilaas et al). 2006;151:597.e1-597.e7 (Trial design)

Stents (continued)

Type D personality and diabetes predict the onset of depressive symptoms in patients after percutaneous coronary intervention (Pedersen et al). 2006;151:367.e1-367.e6

Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis: insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial (Alfonso et al). 2006;151:681.e1-681.e9

Stress, psychological

Psychophysiological responses of invasive cardiologists in an academic catheterization laboratory (Detling et al). 2006;151:522-8

Stress echocardiography; see Echocardiography, stress**Stress test; see Echocardiography, stress; Exercise test****Stroke; see Cerebrovascular accident****Stroke volume**

The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry (Holper et al). 2006;151:69-75

Stroke volume

Impact of infarct location on left ventricular ejection fraction after correction for enzymatic infarct size in acute myocardial infarction treated with primary coronary intervention (Elsman et al). 2006;151:1239.e9-1239.12

Time course of left ventricular volumes in severe congestive heart failure patients treated by optimized AV sequential left ventricular pacing alone—a 3-dimensional echocardiographic study (Butter et al). 2006;151:115-23

Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction (Møller et al). 2006;151:419-25

Syncope, vasovagal

The Second Prevention of Syncope Trial (POST II)—a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: rationale and study design (Raj et al). 2006;151:1186.e11-1186.e17 (Trial design)

T**T-lymphocyte subsets**

Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—a randomized, placebo-controlled study (Alber et al). 2006;151:139.e1-139.e7

Tablets, enteric-coated

Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers (Karha et al). 2006;151:976.e7-976.e11

Technetium Tc 99m sestamibi

Sestamibi single photon emission computed tomography immediately after primary percutaneous coronary intervention identifies patients at risk for large infarcts (Kaltoft et al). 2006;151:1108-14

Telemedicine

Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits (Spaeder et al). 2006;151:844.e1-844.e10

Tetralogy of Fallot

Cardiovascular magnetic resonance in the follow-up of patients with corrected tetralogy of Fallot: a review (Oosterhof et al). 2006;151:265-72 (Curriculum cardiol.)

Thrombectomy

Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)—study design (Svilaas et al). 2006;151:597.e1-597.e7 (Trial design)

Thromboembolism

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTION in Patients with Atrial Fibrillation) Trial (Fountain et al). 2006;151:956-61 (Trial design)

Thrombolytic therapy

Cardiac tamponade in the fibrinolytic era: analysis of >100000 patients with ST-segment elevation myocardial infarction (Patel et al). 2006;151:316-22

Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial (Svensson et al). 2006;151:798.e1-798.e7

Contemporary challenges in the management of acute myocardial infarction: ST-elevation myocardial infarction guidelines (Henry). 2006;151:S11-16

Introduction (Herrmann). 2006;151:S3

Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? (Holmes Jr et al). 2006;151:779-85 (Curriculum cardiol.)

Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes—Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 study (Smith et al). 2006;151:338-44

Role of fibrinolytic therapy in the current era of ST-segment elevation myocardial infarction management (Smalling). 2006;151:S17-23

Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation (Herrmann). 2006;151:S30-9

What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? (Kim et al). 2006;151:668-73

Thrombosis

Insights into the pathophysiology of ST-elevation myocardial infarction (Brenner). 2006;151:S4-10

Introduction (Herrmann). 2006;151:S3

The REDuction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events—study design (Ohman et al). 2006;151:786.e1-786.e10 (Trial design)

The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Aggarwal). 2006;151:(5):e3 (Letter)

Tirofiban

Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome (Smit et al). 2006;151:1102-7

Tissue Doppler imaging; see Echocardiography, Doppler
Tissue inhibitor of metalloproteinase-1

Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction Cavusoglu et al. 2006;151:1101.e1-1101.e8

Tomato; see Lycopersicon esculentum

Tomography, emission-computed, single-photon

Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 210 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography (Ling et al). 2006;151:882-9

Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy (Sorajja et al). 2006;151:426-35

Real-time myocardial perfusion imaging for pharmacologic stress testing: added value to single photon emission computed tomography (Korosoglou et al). 2006;151:131-8

Sestamibi single photon emission computed tomography immediately after primary percutaneous coronary intervention identifies patients at risk for large infarcts (Kaltoft et al). 2006;151:1108-14

Tomography, x-ray computed

Accuracy of 64-row multidetector computed tomography in detecting coronary artery disease in 134 symptomatic patients: influence of calcification (Ong et al). 2006;151:1322.e1-1322.e6

Coronary artery imaging with multidetector computed tomography: a call for an evidence-based, multidisciplinary approach (Schoenhagen et al). 2006;151:945-8 (Editorial)

Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography (Schuijff et al). 2006;151:404-11

Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance (Raman et al). 2006;151:736-44

Trandolapril; see Indoles

Transesophageal echocardiography; see Echocardiography, transesophageal

Transferrin

Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes (Lee et al). 2006;151:1247.e1-1247.e7

Transient ischemic attack; see Ischemic attack, transient
Transplantation, autologous

Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting (Mocini et al). 2006;151:192-7

Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina (Briguori et al). 2006;151:674-80

Triage

Feasibility and benefit of prehospital diagnosis, triage, and therapy by paramedics only in patients who are candidates for primary angioplasty for acute myocardial infarction (van't Hof et al). 2006;151:1254.e1-1254.e5

Trimetazidine

The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition (Fragasso et al). 2006;151:1238.e1-1238.e8

Tropomyosin

Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy—causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes (Poutanen et al). 2006;151:725.e1-725.e9

Troponin

Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-segment elevation myocardial infarction (Sabatine et al). 2006;151:25-31

Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies (Januzzi Jr et al). 2006;151:360-6

Troponin T

Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina (Goldberg et al). 2006;151:1264-9

U

Ultrasonography

Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radiofrequency data analysis, is related to clinical presentation (Rodriguez-Granillo et al). 2006;151:1020-4

In vivo relationship between compositional and mechanical imaging of coronary arteries: insights from intravascular ultrasound radiofrequency data analysis (Rodriguez-Granillo et al). 2006;151:1025.e1-1025.e6

Ultrasonography, interventional

Acute myocardial infarction: clinical characteristics and plaque morphology between expansive remodeling and constrictive remodeling by intravascular ultrasound (Hasegawa et al). 2006;151:332-7

Intravascular ultrasound assessment of the spatial distribution of ruptured coronary plaques in the left anterior descending coronary artery (Pregowski et al). 2006;151:898-901

Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: an intravascular ultrasound study (Kaneda et al). 2006;151:726-9

Unstable angina; see Angina, unstable

V

Valsartan

Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial (Serebruany et al). 2006;151:92-9

Vascular diseases

Virulent strains of *Helicobacter pylori* and vascular diseases: a meta-analysis (Pasceri et al). 2006;151:1215-22

Vascular endothelial growth factors

Single-nucleotide polymorphisms of *VEGF* gene are associated with risk of congenital valvuloseptal heart defects (Vannay et al). 2006;151:878-81

Vascular patency

Introduction (Herrmann). 2006;151:S3

Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation (Herrmann). 2006;151:S30-9

Vena cava, inferior

A dilated inferior vena cava is a marker of poor survival (Nath et al). 2006;151:730-5

Ventricular arrhythmias; see Arrhythmia**Ventricular dysfunction, left**

Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 210 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography (Ling et al). 2006;151:882-9

Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy—causing mutations in the β -myosin heavy chain, α -tropomyosin, and myosin-binding protein C genes (Poutanen et al). 2006;151:725.e1-725.e9

Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure—the REsynchronization REVerses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study (Linde et al). 2006;151:288-94 (Trial design)

Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging—the Multi-Ethnic Study of Atherosclerosis (MESA) (Edwards et al). 2006;151:109-14

Ventricular function

Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance (Raman et al). 2006;151:736-44

Ventricular function, left

Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function: Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease (van Gilst et al). 2006;151:1240-6

The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition (Fragasso et al). 2006;151:1238.e1-1238.e8

Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure (Mangiavacchi et al). 2006;151:477.e1-477.e6

Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function (Ahmed et al). 2006;151:444-50

The impact of hypertension on systolic and diastolic left ventricular function. A tissue Doppler echocardiographic study (Bountiokos et al). 2006;151:1322.e7-1322.e12

Impact of infarct location on left ventricular ejection fraction after correction for enzymatic infarct size in acute myocardial infarction treated with primary coronary intervention (Elsman et al). 2006;151:1239.e9-1239.12

Ventricular function, left (continued)

NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes (Estrada et al). 2006;151:1093.e1-1093.e7

Time course of left ventricular volumes in severe congestive heart failure patients treated by optimized AV sequential left ventricular pacing alone—a 3-dimensional echocardiographic study (Butter et al). 2006;151:115-23

Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction (Moller et al). 2006;151:419-25

Ventricular remodeling

Left ventricular remodeling impacts the function of the Quattro stentless mitral valve bioprosthesis (a 4-year experience) (Doss et al). 2006;151:943.e1-943.e4

Verapamil

Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST) (Cooper-DeHoff et al). 2006;151:1072-9

Vitamin B complex

Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials (B-Vitamin Treatment Trialists' Collaboration). 2006;151:282-7 (Trial design)

Vytorin

To the Editor (Galin et al). 2006;151:(5)e1 (Letter)

W**Warfarin**

The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials (WAVE Investigators). 2006;151:1-9 (Trial design)

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTION in Patients with Atrial Fibrillation) Trial (Fountain et al). 2006;151:956-61 (Trial design)

WATCHMAN Left Atrial Appendage System

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTION in Patients with Atrial Fibrillation) Trial (Fountain et al). 2006;151:956-61 (Trial design)

Weight loss

Clinical trial issues in weight-loss therapy (Patel et al). 2006;151:633-42 (Meetings)

White blood cell count; see Leukocyte count**Women; see also Sex factors**

Impairment of physical exercise capacity in healthy postmenopausal women (Mercuro et al). 2006;151:923-7

Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Chacko et al). 2006;151:1032.e1-1032.e7

